Methods and composition for producing a heterologous protein

Abstract

Described herein are methods and compositions for producing heterologous proteins. Heterologous proteins can include sweet proteins and sweet polypeptides. For examples, described herein are expression cassettes, including, for example, promoters and signal peptides, for recombinantly expressing a recombinant sweet protein in a host cell.

Description

Attorney Docket No. 54282-0011WO1METHODS AND COMPOSITION FOR PRODUCING A HETEROLOGOUS PROTEINCLAIM OF PRIORITY

[0001] This application claims the benefit of U. S. Provisional Application Serial No. 63 / 725,855, filed on November 27, 2024. The entire contents of the foregoing are incorporated herein by reference.SEQUENCE LISTING

[0002] This application contains a Sequence Listing that has been submitted electronically as an XML file named "54282-0011WO1_ST26.XML". The XML file, created on November 25, 2025, is 274,251 bytes in size. The material in the XML file is hereby incorporated by reference in its entirety.TECHNICAL FIELD

[0003] This disclosure relates to methods and compositions for producing heterologous proteins. In particular, provided herein are expression cassettes and components thereof (e.g., promoters and signal peptides) that are useful in the production of heterologous proteins, including the production of recombinant sweet proteins.BACKGROUND

[0004] Recombinant expression provides an alternative production means for proteins, for example, proteins used for food and nutrition. In some cases, recombinant proteins can provide healthy diet alternatives. In one such example, various sweeteners are available, including naturally occurring carbohydrates, such as those obtainable from plants, and artificial sweeteners. However, high levels of sugar consumption have been linked to obesity and associated health problems, including an increased risk of high blood pressure, high cholesterol, Type 2 diabetes, and cardiovascular disease. Yet, sweet food products are favored by a large proportion of the population. Therefore, there is a need to provide and produce adequate amounts of healthy sweetener alternatives that deliver similar or improved qualities to currently available sugar and sugar alternatives, such as by expressing sweet proteins.Attorney Docket No. 54282-0011WO1SUMMARY

[0005] Producing proteins through recombinant expression can provide alternative sources for food, flavorings, and nutrition. However, there remains a challenge to produce proteins in sufficient quantities in a cost-efficient manner to make the recombinant protein production economically viable and to provide such proteins in sufficient quantity and quality to be compatible with the existing food supply chain. Such challenges can include both the amount of protein expressed in the selected host organism for recombinant expression, as well as the amount that can be extracted and purified away from unwanted host cell components. There remains a need for tools for recombinant expression, particularly for proteins that appear to be poorly expressed and / or secreted when placed in a heterologous host cell. Accordingly, provided herein are promoters comprising a first nucleotide sequence comprising a first nucleotide sequence set forth in any one of SEQ ID NOs:3-8, 10-13, 18, 26-32, 34, 56, 58, or 65.

[0006] Also disclosed herein are expression cassettes including a promoter operably linked to a coding sequence of a heterologous protein, where the promoter includes a first nucleotide sequence selected from anyone of SEQ ID NOs: 3-8, 10-13, 18, 26-32, 34, 56, 58, or 65. in some cases, the expression cassette also includes a second nucleotide sequence encoding a signal peptide linked to the coding sequence of the heterologous protein. In some cases, the heterologous protein includes a sweet protein selected from the group consisting of brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, or mycodulcein protein or a functional fragment thereof. In some cases, the signal peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 66-71, 79, 81, 82, 85, 97, 100, 106, 107, 109, 113-116, 119, 120, 122, 125, 127, 134, 144, 145, 149, 150, 155, 158, 159, 166, 174, and 203.

[0007] Also disclosed herein are expression cassettes including a promoter operably linked to a coding sequence of a heterologous protein that is a sweet protein selected from the group consisting of brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, mycodulcein or a functional fragment thereof, wherein the promoter comprises a first nucleotide sequence selected from any one of SEQ ID NOs: 1-34 or 65. In some cases, the expression cassette also includes a second nucleotide sequence encoding a signal peptide linked to the coding sequence of the sweet protein. In some cases, the first nucleotide sequence is selected from the group consisting of SEQ ID NOs: 3, 4, 5, 6, 7, 8, 9, 18, 19, 21, 25, 33, 34, and 65. in some cases, the second nucleotide sequence encodes an amino acid sequence selected from the group consisting of SEQ ID NOs: 66, 81, 82, 97, 144, 145, 149, 150, 155, 159, 166, 174, and 189-200. in some cases, the amino acid sequence is selected from the group consisting of SEQ ID NOs: 81, 82, 97, 144, 155, 190, and 195. In some cases, the heterologous protein comprises brazzein, brazzein 53, brazzein-54 or aAttorney Docket No. 54282-0011WO1functional fragment thereof. In some cases, the second nucleotide sequence encodes an amino acid sequence selected from the group consisting of SEQ ID NOs: 100, 106, 107, 109, 113-116, 119, 120, 122, 125, 127, 149, 155, 158, and 203. In some cases, the amino acid sequence is selected from the group consisting of SEQ ID NOs: 100, 109, 115, 119, 120, 149, and 158. In some cases, the heterologous protein comprises monellin or a functional fragment thereof. In some cases, the second nucleotide sequence encodes an amino acid sequence selected from the group consisting of SEQ ID NOs: 67-71, 79, 81, 85, 116, 134, and 150. In some cases, the amino acid sequence is selected from the group consisting of SEQ ID NOs: 69, 79, 81, and 85. In some cases, the heterologous protein comprises thaumatin, thaumatin I, thaumatin II or a functional fragment thereof.

[0008] Also disclosed herein are signal peptides including the amino acid sequence set forth in any one of SEQ ID NOs: 99-107, 109-158, or 203-206.

[0009] Also disclosed herein are protein coding sequences including a nucleic acid encoding any of the signal peptides described herein or a signal peptide with an amino acid sequence set forth in any one of SEQ ID NOS: 67, 75, 77, 81, or 88 fused in frame to a coding sequence for a heterologous protein. In some cases, the signal peptide is 5' to the heterologous protein. In some cases, the signal peptide is 3' to the heterologous protein. In some cases, the heterologous protein is a sweet protein selected from the group consisting of brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, mycodulcein or a functional fragment thereof.

[0010] Also disclosed herein are protein coding sequences including a nucleic acid encoding a signal peptide comprising the amino acid sequence set forth in any one of SEQ ID NOS: 66-206 fused in frame to a coding sequence for a heterologous protein that is a sweet protein selected from the group consisting of a brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, or mycodulcein protein or a functional fragment thereof.

[0011] Also disclosed herein are fusion protein comprising a signal peptide having an amino acid sequence set forth in any one of SEQ ID NOS: 66-206 operatively linked to a heterologous protein.

[0012] Also disclosed herein are expression cassettes including any of the protein coding sequences described herein. In some cases, the expression cassette also includes a promoter, where the promoter comprises a first nucleotide sequence set forth in any one of SEQ ID NOS: 1-34 or 65.

[0013] Also disclosed herein are vectors including any of the promoters disclosed herein, any of the expression cassettes disclosed herein, any of the signal peptides disclosed herein, and / or any of theAttorney Docket No. 54282-0011WO1protein coding sequences disclosed herein, optionally operably linked to any of the promoters disclosed herein and / or any of the signal peptides disclosed herein.

[0014] Also disclosed herein are expression vectors including any one of the promoter-signal sequence combinations set forth in Table 9, optionally, wherein the expression vectors include a heterologous protein. In some cases, the heterologous protein is selected from the group consisting of a brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, or mycodulcein protein or a functional fragment thereof.

[0015] Also disclosed herein are cells including any of the promoters disclosed herein, any of the expression cassettes disclosed herein, any of the signal peptides disclosed herein, and / or any of the protein coding sequences disclosed herein, optionally operably linked to any of the promoters disclosed herein and / or any of the signal peptides disclosed herein. In some cases, the cell is a eukaryotic cell. In some cases, the cell a yeast cell or a filamentous fungal cell. In some cases, the cell is Komagataella sp., optionally Komagataella phaffii.

[0016] Also disclosed herein are methods of producing a heterologous protein, the method including inserting any of the expression cassettes disclosed herein into an expression system whereby the heterologous protein is produced. In some cases, the expression system is a cell. In some cases, the expression system is a eukaryotic cell. In some cases, the cell a yeast cell or a filamentous fungal cell. In some cases, the cell is Komagataella sp., optionally Komagataella phaffii. In some cases, the heterologous protein is secreted into a culture medium. In some cases, the method also includes collecting the culture medium. In some cases, the method also includes isolating the heterologous protein from the culture medium. In some cases, the heterologous protein is a sweet protein selected from the group consisting of a brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, or mycodulcein protein or a functional fragment thereof.

[0017] The details of one or more embodiments of the invention are set forth in the accompanying description below. Other features, objects, and advantages of the invention will be apparent from the description, and from the claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the present invention; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences,Attorney Docket No. 54282-0011WO1database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.DETAILED DESCRIPTION

[0018] Described herein are promoter sequences that drive gene expression of heterologous proteins. Also described herein are signal peptide sequences for secretion of heterologous proteins and nucleotide sequences encoding such signal peptide sequences. Also described herein are cells, expression cassettes, and vectors that include the promoters, the signal peptides, and combinations thereof, for recombinantly expressing a heterologous protein in a host cell. In some particular cases, the expressed heterologous protein is a sweet protein.I. Compositions for Producing Heterologous Proteins or Heterologous Peptides

[0019] Provided herein are compositions for producing and secreting heterologous proteins, such as sweet proteins. Compositions for producing heterologous proteins (e.g., sweet proteins; also called sweet polypeptides) include expression elements, such as promoters, signal peptides, and terminators. These elements can be incorporated into expression cassettes. Such expression cassettes are described and provided herein. Expression cassettes can be incorporated into vectors (also called expression vectors). Expression cassettes and / or vectors can also be incorporated into host cells to facilitate production of a heterologous peptide (e.g., a sweet polypeptide). Expression systems are also provided for producing the heterologous protein. Such expression systems can be a cell, such as a host cell that includes one or more expression cassettes or vectors. Host cells can include eukaryotic cells, such as yeast cells or filamentous fungal cells. Exemplary yeast cells include cells of Komagataella sp. (also known as Pichia sp.), such as Komagataella phaffii.Engineered Promoters

[0020] A promoter is a nucleic acid sequence that, when operably linked to another nucleic acid sequence such as a nucleic acid sequence encoding a polypeptide (e.g., a recombinant peptide, such as a recombinant sweet polypeptide), is sufficient to direct transcription of the linked nucleic acid sequence. In some cases, the activity of a promoter can be measured indirectly, such as by assessing the amount of protein produced, where such protein is encoded by the linked nucleic acid (e.g., a gene of interest encoding the heterologous protein).Attorney Docket No. 54282-0011WO1

[0021] Promoters are generally located upstream (5') to the nucleic acid sequence to be transcribed. In some cases, a promoter can be in its native configuration, e.g., operatively linked to a nucleic acid sequence as such linkage is found in nature, e.g., in a native organism. In other cases, such as described herein, a promoter is operatively linked to a heterologous nucleic acid sequence. In some embodiments, a promoter is linked to a heterologous nucleic acid sequence derived from a different organism. For example, a promoter derived from a yeast species is operatively linked to a gene sequence derived from a plant species. In some cases, a promoter derived from one species, such as a promoter derived from one species of filamentous fungi can be used for expression in a different species of filamentous fungi.

[0022] In any of the embodiments provided herein, the promoter can be a constitutive promoter, an inducible promoter, or a hybrid promoter. A hybrid promoter combines a portion of each of at least two different promoters of any kind. In some cases, a promoter is constitutive. In other cases, a promoter is inducible. In some cases, a promoter is a repressible promoter. Exemplary inducible promoters include promoters that are responsive to ethanol, methanol, copper, lactose, or other induction elements. Exemplary repressible promoters include promoters that are responsive to phosphate, glucose, or other repression elements. Promoters are well known in the art and are contemplated by the present application. See, for example, Veeresh, and Wu. ChemBioChem 19.1 (2018), pp. 7-21. Non-limiting examples of promoters are described herein.

[0023] Provided herein are engineered promoters for driving expression of a heterologous protein (e.g., a sweet protein) in a host cell. An engineered promoter (also referred to herein as synthetic promoter) is a non-naturally occurring nucleotide sequence that serves as a promoter for expression of a heterologous gene such as a gene encoding a polypeptide (e.g., a sweet protein). Engineered promoters can include some or all of the nucleotide sequence of one or more naturally occurring promoters. Engineered promoters can also include one or more mutations (e.g., one, two, three, four, five, six, seven, eight, nine, ten, twenty, thirty, forty, fifty, sixty, seventy, eighty, ninety, one hundred, or more mutations) compared to a non-engineered promoter. Engineered promoters also can include combinations of natural promoters or portions thereof and / or engineered promoters or portions thereof to drive expression of a heterologous protein. A mutation can include a base change, a deletion, and / or an insertion of one or more nucleotides compared to any of the promoters described herein. For example, a base change of one or more nucleotides compared to any of the promoters described herein can include a base change of one, two, three, four, five, six, seven, eight, nine, ten, twenty, thirty, forty, fifty, sixty, seventy, eighty, ninety, one hundred, or more bases compared to any of the promoters described herein. A deletion ofAttorney Docket No. 54282-0011WO1one or more nucleotides compared to any of the promoters described herein can include a deletion of one, two, three, four, five, six, seven, eight, nine, ten, twenty, thirty, forty, fifty, sixty, seventy, eighty, ninety, one hundred or more bases compared to any of the promoters described herein. An insertion of one or more nucleotides compared to any of the promoters described herein can include an insertion of one, two, three, four, five, six, seven, eight, nine, ten, twenty, thirty, forty, fifty, sixty, seventy, eighty, ninety, one hundred, or more bases compared to any of the promoters described herein. An engineered promoter can also include the repetition, such as a duplication, of all or a part of a promoter or addition of all or a part of a sequences from a second (different) promoter.

[0024] In some embodiments, an engineered promoter is any promoter set forth in any one of SEQ ID NOs: 3-8, 10-13, 18, 26-32, 34, 56, 58, or 65 (Table 2). In some embodiments, an engineered promoter is a promoter with at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more than 99% sequence identity to any one of SEQ ID NOs: 3-8, 10-13, 18, 26-32, 34, 56, 58, or 65. An engineered promoter set forth in any one of SEQ ID NOs: 3-8, 10-13, 18, 26-32, 34, 56, 58, or 65 can include one or more mutations (e.g., one, two, three, four, five, six, seven, eight, nine, ten, twenty, thirty, forty, fifty, sixty, seventy, eighty, ninety, one hundred, or more mutations).

[0025] The provided engineered promoters are recognized by transcription factors and / or RNA polymerase of a host cell and are compatible with expression (e.g., transcription) pathways of a host cell to drive RNA expression that in turn provides production of a heterologous protein, such as a sweet protein. In some cases, the provided engineered promotes are compatible with expression in a fungal cell. In some cases, the provided engineered promotes are compatible with expression in a yeast cell. In some cases, the provided engineered promoters are compatible with a transcription pathway of Komagataella sp. (also known as Pichia sp.), optionally a transcription pathway of Komagataella phaffii cells. In some embodiments, the engineered promoters described herein increase the production of a heterologous protein to which the engineered promoter is operably linked, such as a heterologous sweet protein (e.g,, a brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, or mycodulcein protein or a functional fragment thereof) in a host cell, such as in a yeast cell such as Komagataella sp. (also known as Pichia sp.), optionally Komagataella phaffii. In some cases, the provided engineered promoters increase the production of a heterologous peptide to which it is operably linked compared to a reference promoter or a natural promoter. Such improved production of the heterologous protein increases protein yield upon purification or manufacture.Attorney Docket No. 54282-0011WO1Engineered Signal Peptide

[0026] A signal peptide (also called a secretion signal peptide, a signal sequence, a targeting signal, a localization signal, a localization sequence, a transit peptide, a leader sequence, or a leader peptide) is a peptide sequence present on a newly synthesized polypeptide that is recognized by the secretion pathway of the host cell, ultimately directingthe polypeptide across or into a cell membrane of the cell (the plasma membrane in prokaryotes or the endoplasmic reticulum membrane in eukaryotes). Use of signal peptides can help obtain high yields of heterologous proteins, especially secreted heterologous proteins.

[0027] A signal peptide may be present at the N-terminal end of the newly synthesized polypeptide, but in some cases is found elsewhere such as at the C-terminal end or within a polypeptide sequence. In some cases, a signal peptide may contain at least a positively charged N-terminus of 1-5 residues (n-region), a central hydrophobic core of 6-16 amino acids (h-region), and a polar region of 3-7 amino acids that is a recognition site for a signal peptidase (c-region). A signal peptide is typically 15 to 100 amino acids in length. In some cases, a signal peptide is 60 to 80 amino acids in length (e.g., 65 to 85 amino acids). In some cases, the signal peptide is specific to the type of host cell, i.e., promotes secretion only in a subset of host cells.

[0028] All or part of the signal peptide may be cleaved off from the rest of the protein by a signal peptidase, for example, during translocation or shortly after completion of translocation. A signal peptide can be removed (e.g., cleaved by a protease) from the protein such that the mature form of the protein lacks all or a part of the signal peptide. The signal peptide can direct the polypeptide encoding a heterologous protein into a cell's secretory pathway and result in extracellular secretion of the heterologous protein, such as secretion of a heterologous sweet protein. In some cases, a signal peptide can direct a polypeptide into a cell's secretory pathway and result in incorporation of the heterologous protein into the cell's membrane. See, for example, Damascene and Batt. (2012). Appl Microbiol Biotechnol 93, pp. 31-39, which is incorporated in its entirety herein.

[0029] Extracellular secretion of a recombinantly expressed protein from a host cell can facilitate protein purification. For example, recovery of a recombinant protein from a cell culture supernatant can be preferable to lysing host cells to release a complex mixture of proteins and other substances, including intracellular proteins, carbohydrates and metabolites of the host cell. Secretion, in some cases, can reduce deleterious effects that intracellular overexpression of a heterologous protein can have on a host cell suchAttorney Docket No. 54282-0011WO1as toxicity or decreased growth rate. Secretion, in some cases, can allow increased protein production compared to intracellular expression in a host cell of limited volume to store the synthesized proteins. Further, secretory production of a protein, in some cases, can facilitate post-translational modification or processing (e.g., protein folding, formation of disulfide bonds, and glycosylation).

[0030] A signal peptide may be derived from a precursor (e.g., prepropeptide, preprotein) of a known secreted protein. In some cases, the signal peptide is derived from a prepropeptide or preprotein of the host cell. In some cases, the signal peptide is derived from a prepropeptide or preprotein of another type of cell (i.e., not from the host cell). In some cases, the signal peptide is an engineered or synthetic (not naturally occurring) sequence.

[0031] Provided herein are engineered signal peptides and nucleotide sequences encoding the same. In some embodiments, provided herein is a signal peptide set forth in any one of SEQ ID NOs: 66-206. In some embodiments, provided herein is a signal peptide having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more than 99% sequence identity with a signal peptide set forth in any one of SEQ ID NOs: 66-206.

[0032] Engineered signal peptides are non-naturally occurring amino acid sequences that are recognized by the secretory pathway of the host cell and facilitate translocation of a heterologous protein into the secretory pathway and ultimately to extracellular secretion of the heterologous protein. In some cases, the provided engineered signal peptides are compatible with the secretory pathway of a filamentous fungal cell. In some cases, the provided engineered signal peptides are compatible with the secretory pathway of Komagataella sp. cells, optionally Komagataella phaffii cells. In some cases, the provided engineered signal peptides facilitate secretion of the heterologous protein (e.g., sweet protein) into culture medium in which the host cell is grown, fermented, or propagated.

[0033] Engineered signal peptides can include one or more mutations (e.g., one, two, three, four, five, six, seven, eight, nine, ten, fifteen, twenty, twenty-five, thirty, thirty-five, forty, forty-five, fifty or more mutations) compared to any of the signal peptides that are naturally occurring or otherwise known. A mutation can include an amino acid substitution, a deletion, and / or an insertion of one or more amino acids. Engineered signal peptides also can include combinations of one or more natural signal peptide(s) or fragment(s) thereof and / or one or more engineered signal peptide(s) or fragment(s) thereof.

[0034] In some cases, a signal peptide can include a truncated signal peptide or a fragment of a known signal peptide. In some cases, truncated signal peptides have maintained their secretory function. For example, a truncated signal peptide can be 15 to 25 amino acids long and includes a functional portion ofAttorney Docket No. 54282-0011WO1the non-truncated signal peptide. An insertion of one or more amino acids compared to any of the signal peptides described herein can include an insertion of one, two, three, four, five, six, seven, eight, nine, ten, fifteen, twenty, twenty-five, thirty, thirty-five, forty, forty-five, fifty or more amino acids compared to any of the signal peptides described herein. An engineered signal peptide can also include insertion of all or a part of a duplicate signal peptide or insertion of all or a part of one or more additional signal peptides (e.g., a second signal peptide) before, within, or after a signal peptide described.

[0035] For example, a substitution of one or more amino acids compared to any of the signal peptides described herein can include an amino acid change of one, two, three, four, five, six, seven, eight, nine, ten, fifteen, twenty, twenty-five, thirty, thirty-five, forty, forty-five, fifty or more amino acids compared to any of the signal peptides described herein. A deletion of one or more amino acids compared to any of the signal peptides described herein can include a deletion of one, two, three, four, five, six, seven, eight, nine, ten, fifteen, twenty, twenty-five, thirty, thirty-five, forty, forty-five, fifty or more amino acids compared to any of the signal peptides described herein. In some embodiments, provided herein is an engineered signal peptide as set forth in any one of SEQ ID NOs: 67, 75, 77, 81, 88, 99-107, 109-200, or 203-206. In some embodiments, provided herein is an engineered signal peptide having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more than 99% sequence identity with a signal peptide set forth in any one of SEQ ID NOs: 67, 75, 77, 81, 88, 99-107, 109-200, or 203-206.

[0036] The signal peptides described herein, including the engineered signal peptides described herein, can be fused to a heterologous protein, such as a sweet protein to promote extracellular secretion of the mature heterologous protein, such as a sweet protein. In some embodiments, a nucleotide sequence encoding a signal peptide is fused in frame to the 5' end of a heterologous protein, such as a sweet protein (e.g., a brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, or mycodulcein protein or a functional fragment thereof).

[0037] In some embodiments, the engineered signal peptides described herein increase the extracellular secretion of a heterologous protein, such as a sweet protein (e.g., a brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, or mycodulcein protein or a functional fragment thereof). In some cases, the engineered signal peptides increase the efficiency of the extracellular secretion of the heterologous protein, such as a sweet protein. In some cases, the provided signal peptides increase the secretion or efficiency of the secretion of a heterologous peptide compared to a reference signal peptide. In some cases, the provided signal peptide facilitates the entry of the heterologous protein into the secretoryAttorney Docket No. 54282-0011WO1pathway of the host cell. Such improved secretion increases protein yield upon production of the heterologous protein.Expression Cassettes

[0038] Expression cassettes can include expression elements (e.g., promoters, signal peptides, and transcription terminators) that are combined with the coding sequence of a heterologous protein to express, and optionally secrete, a heterologous protein, such as a sweet protein. For example, an expression cassette can include a first nucleotide sequence encoding any promoter described herein operably linked to a coding sequence of any heterologous protein (e.g., a sweet polypeptide), or any combination of promoters described herein operably linked to a coding sequence of any heterologous protein (e.g., a sweet polypeptide). Exemplary promoters that can be included in the expression cassettes described herein include, but are not limited to, an ACO1, acu-5, adhl+, alcohol dehydrogenase (ADH1, ADH2, ADH3, ADH4), AHSB4m, AINV, alcA, a-amylase, ALD4, alternative oxidase (AOD), alcohol oxidase 1 (AOX1), alcohol oxidase 2 (AOX2), ATO, ATP fragment (e.g., ATP1 or ATP2), AXDH, B2, CaMV, cellobiohydrolase 1 (cbhl), CBOI, ccg-1, cDNAl, cellularfilament polypeptide (cfp), CIT, cpc-2, CTA1, ctr4+, CUP1, dihydroxyacetone synthase (DAS), enolase (ENO, ENO1), EPX1, EXG1-1000, FDH1, formaldehyde dehydrogenase (FLD1), FMD, formate dehydrogenase (FMDH), Gl, G6, GAA, GALI, GAL2, GAL3, GAL4, GAL5, GAL6, GAL7, GAL8, GAL9, GAL10, GAP, GCW14, gdhA, gla-1, a-glucoamylase (glaA), glyceraldehyde-3- phosphate dehydrogenase (gpdA, GAP, GAPDH), phosphoglycerate mutase (GPM1), GTH1, glycerol kinase (GUT1), heat shock protein (e.g., HSP10, HSP12, HSP82), invl, isocitrate lyase (ICL1), acetohydroxy acid isomeroreductase (ILV5), KAR2, KCAP, KEX2, KKUR, KP1113, KPAS, b-galactosidase (Iac4), LEET2, melO, MET3, MLS1, methanol oxidase (MOX), nmtl, NSP, 0LE1, OPOL, PCK1, PDC1, PDI1, pcbC, PET9, peroxin 8 (PEX8), phosphoglycerate kinase (PGK, PGK1), phol, PHO5, PHO89, phosphatidylinositol synthase (PIS1), PIR1, PKUD, PYK1, pyruvate kinase (pkil), PMEM, PORI, QCR7, RGI2, RPS7, SCW10, sorbitol dehydrogenase (SDH), SD001, 3-phospho serine aminotransferase (SERI), SINS, SSA3, SSA4, SV40, TDH3, TEF, translation elongation factor 1 alpha (TEF1), THI11, homoserine kinase (THR1), TMA10, tpi, TPS1, triose phosphate isomerase (TPI1), XRP2, or YPT1 promoter, or functional fragments thereof, or any combination of the full-length promoters and / or fragments thereof.

[0039] In some cases, the promoter in the expression cassette is any one of SEQ ID NOs: 1-65. In some cases, the promoter is any one of the promoters set forth in Table 2. In some cases, a promoter is any promoter set forth in Table 3. In some cases, a promoter is any promoter set forth in Table 4. In someAttorney Docket No. 54282-0011WO1cases, the promoter in the expression cassette is any promoter set forth in any one of SEQ ID NOs: 1-34 or 65.

[0040] In some cases, the promoter in the expression cassette is an engineered promoter described herein. In some cases, the promoter in the expression cassette is any promoter set forth in any one of SEQ ID NOs: 3, 4, 5, 6, 7, 8, 9, 18, 19, 21, 25, 33, 34, and 65. In some cases, the promoter in the expression cassette is an engineered promoter with at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more than 99% sequence identity to any one of SEQ ID NOs: 3-8, 10-13, 18, 26-32, 34, 56, 58, or 65.

[0041] In some cases, an expression cassette can include a first nucleotide sequence encoding any promoter set forth in any one of SEQ ID NOs: 1-65 operably linked to a coding sequence of a heterologous protein (e.g., a sweet protein). In some cases, an expression cassette can include a first nucleotide sequence encoding any promoter set forth in Tables 2, 3, or 4 operably linked to a coding sequence of a heterologous protein (e.g., a sweet protein). In some cases, an expression cassette can include a first nucleotide sequence encoding any promoter set forth in any one of SEQ ID NOs: 1-34, or 65 operably linked to a coding sequence of a heterologous protein (e.g., a sweet protein). In some cases, an expression cassette can include a first nucleotide sequence that is a promoter (e.g., an engineered promoter) set forth in anyone of SEQ ID NOS: 3-8, 10-13, 18, 26-32, 34, 56, 58, or 65 operably linked to a coding sequence of a heterologous protein (e.g., a sweet protein).

[0042] Expression cassettes can further include a second nucleotide sequence encoding any signal peptide described herein or combination of signal peptides described herein. In some cases, a second nucleotide sequence encoding a signal peptide can be linked in-frame to a coding sequence of a heterologous protein (e.g., a coding sequence of a sweet protein or a coding sequence of a sweet protein fragment or peptide). A signal peptide can be in any appropriate location such that the associated polypeptide sequence is secreted from a host cell. In some cases, a second nucleotide sequence encoding a signal peptide can be upstream of a coding sequence of a heterologous protein (e.g., a coding sequence of a sweet protein). In some cases, a second nucleotide sequence encoding a signal peptide can be downstream of a promoter sequence and upstream of a coding sequence of a heterologous protein (e.g., a coding sequence of a sweet protein). In some cases, a second nucleotide sequence encoding a signal peptide can be 5' to a heterologous protein coding sequence (e.g., a coding sequence of a sweet polypeptide). In some cases, a second nucleotide sequence encoding a signal peptide can be 3' to the coding sequence of the heterologous protein (e.g., a coding sequence of a sweet protein). In some cases,Attorney Docket No. 54282-0011WO1a second nucleotide sequence encoding a signal peptide can be 5' and / or 3' to the coding sequence of the heterologous protein described herein (e.g., a coding sequence of a sweet protein or fragment).

[0043] In some cases, an expression vector includes a combination of a promoter and a signal peptide, particularly any of the combination of promoter and signal peptides listed in Table 11. In such cases, the promoter is operably linked to the coding sequence of a heterologous protein, such as a sweet protein. The signal peptide is encoded by a nucleic acid in-frame with the coding sequence of the heterologous protein (e.g., the sweet protein), such that when expressed, the signal peptide is operably linked to the heterologous protein, and then may be cleaved after expression. In some aspects, the sweet protein is any one of brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, or mycodulcein protein or a functional fragment thereof. In some aspects, the sweet protein has an amino acid sequence of any one of SEQ ID Nos: 208, 211-229.

[0044] Expression cassettes including a second nucleotide sequence encoding any signal peptide described herein can be linked to a coding sequence of a heterologous protein, such as the coding sequence of a sweet protein. In some cases, an expression cassette can include a second nucleotide sequence encoding a signal peptide upstream of (and in-frame with) a coding sequence of a heterologous protein (e.g., a coding sequence of a sweet protein, such as a sweet protein selected from the group consisting of brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, or mycodulcein protein or a functional fragment thereof). In some cases, an expression cassette can include a second nucleotide sequence encoding a signal peptide downstream (and in-frame with) of a coding sequence of a heterologous protein (e.g., a coding sequence of a sweet protein, such as brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, or mycodulcein protein or a functional fragment thereof). In some cases, an expression cassette can include a second nucleotide sequence encoding a signal peptide downstream of any promoter sequence described herein and upstream of a coding sequence encoding a heterologous protein (e.g., a coding sequence of a sweet protein). In some cases, an expression cassette can include a second nucleotide sequence encoding a signal peptide downstream of any promoter sequence described herein and downstream of a coding sequence encoding a heterologous protein (e.g., a coding sequence of a sweet protein). In some cases, an expression cassette can include a second nucleic acid sequence encoding any signal peptide described herein fused in frame to a coding sequence for a heterologous protein (e.g., a coding sequence of a sweet protein).

[0045] In some cases, an expression cassette can include a second nucleic acid sequence encoding any signal peptide set forth in any one of SEQ ID NOS: 66-206 or set forth in Tables 2, or 5-8 can be fused inAttorney Docket No. 54282-0011WO1frame to a coding sequence for a heterologous protein, such as a sweet protein. In some cases, an expression cassette can include a second nucleotide sequence encoding any signal peptide set forth in any one of SEQ ID NOS: 66-206 can be upstream of a heterologous protein, such as a sweet protein. In some cases, an expression cassette can include a second nucleotide sequence encoding any signal peptide set forth in any one of SEQ ID NOs: 66, 81, 82, 97, 144, 145, 149, 150, 155, 159, 166, 174, and 189-200 can be upstream of a heterologous protein, such as a sweet protein. In some cases, an expression cassette can include a second nucleotide sequence encoding any signal peptide set forth in any one of SEQ ID NOs: 81, 82, 97, 144, 155, 190, and 195 can be upstream of a heterologous protein, such as a sweet protein. In some cases, an expression cassette can include a second nucleotide sequence encoding any signal peptide set forth in any one of SEQ ID NOs: 100, 106, 107, 109, 113-116, 119, 120, 122, 125, 127, 149, 155, 158, and 203 can be upstream of a heterologous protein, such as a sweet protein. In some cases, an expression cassette can include a second nucleotide sequence encoding any signal peptide set forth in any one of SEQ ID NOs: 100, 109, 115, 119, 120, 149, and 158 can be upstream of a heterologous protein, such as a sweet protein. In some cases, an expression cassette can include a second nucleotide sequence encoding any signal peptide set forth in any one of SEQ ID NOs: 67-71, 79, 81, 85, 116, 134, and 150 can be upstream of a heterologous protein, such as a sweet protein. In some cases, an expression cassette can include a second nucleotide sequence encoding any signal peptide set forth in any one of SEQ ID NOs: 69, 79, 81, and 85 can be upstream of a heterologous protein, such as a sweet protein. In some cases, an expression cassette can include a second nucleotide sequence encoding any signal peptide set forth in any one of SEQ ID NOs: 67, 75, 77, 81, 88, 99-107, 109-200, or 203-206 can be upstream of a heterologous protein, such as a sweet protein.

[0046] In some cases, an expression cassette can include a second nucleotide sequence encoding any signal peptide set forth in any one of SEQ ID NOs: 66-206 can be downstream of a first nucleotide sequence encoding any promoter set forth in any one of SEQ ID NOs: 1-65 and upstream of a coding sequence encoding a heterologous protein, such as a sweet protein (e.g., a coding sequence of a sweet polypeptide). In some cases, an expression cassette can include a second nucleotide sequence encoding any signal peptide set forth in any one of SEQ ID NOs: 66-206 can be downstream of a first nucleotide sequence encoding any promoter described herein (e.g., an engineered promoter, such as a promoter set forth in any one of SEQ ID NOS: 3-8, 10-13, 18, 26-32, 34, 56, 58, or 65) and upstream of a coding sequence encoding a heterologous protein (e.g., a coding sequence of a sweet protein or functional fragment thereof).Attorney Docket No. 54282-0011WO1

[0047] In some cases, an expression cassette can include a second nucleotide sequence encoding a signal peptide can be downstream of any promoter (e.g., an engineered promoter) set forth in any one of SEQ ID NOS: 3-8, 10-13, 18, 26-32, 34, 56, 58, or 65 and upstream of a coding sequence encoding a heterologous protein (e.g., a coding sequence of a sweet protein or functional fragment thereof). In some cases, an expression cassette can include a second nucleotide sequence encoding a signal peptide can be downstream of any promoter (e.g., an engineered promoter) set forth in any one of SEQ ID NOS: 1-34 or 65 and upstream of a coding sequence encoding a heterologous protein (e.g., a coding sequence of a sweet protein or functional fragment thereof).

[0048] In some cases, an expression cassette can include a second nucleotide sequence encoding a signal peptide can be downstream of any promoter (e.g., an engineered promoter) set forth in any one of SEQ ID NOS: 3-8, 10-13, 18, 26-32, 34, 56, 58, or 65 and upstream of a coding sequence encoding a heterologous protein, such as a sweet protein (e.g., a coding sequence of a sweet protein such as brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, or mycodulcein protein or a functional fragment thereof). In some cases, an expression cassette can include a second nucleotide sequence encoding a signal peptide can be downstream of any promoter (e.g., an engineered promoter) set forth in any one of SEQ ID NOS: 1-34 or 65 and upstream of a coding sequence encoding a heterologous protein (e.g., a coding sequence of a sweet protein such as brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, or mycodulcein protein or a functional fragment thereof).

[0049] Expression cassettes can further include one or more transcription terminators (also called terminators). A transcription terminator indicates the end of a gene or operon in genomic DNA during transcription. The transcription terminator sequence provides a signal in the newly synthesized transcript RNA that causes the transcriptional complex to release the RNA transcript. These processes include the direct interaction of the mRNA secondary structure with the complex and / or the indirect activities of recruited termination factors. Exemplary transcription terminators include the DHAS1 transcription terminator and the AOX1 transcription terminator. In some cases, the expression cassette includes a transcription terminator having the sequence set forth in SEQ ID NO: 209 or 210.

[0050] Expression cassettes can be incorporated into vectors (also called expression vectors). Expression cassettes and / or vectors can also be incorporated into host cells to facilitate production of a heterologous peptide (e.g., a sweet polypeptide).Attorney Docket No. 54282-0011WO1Vectors

[0051] Described herein are vectors including a nucleic acid sequence encoding a heterologous protein that can be used to produce the heterologous protein. A vector is a DNA molecule (often plasmid or virus) that is used as a vehicle to carry a particular DNA segment into a host cell as part of a cloning or recombinant DNA technique. The vector typically assists in replicating and / or expressing the inserted DNA sequence inside the host cell. Vectors can include origins of replication and partitioning systems to facilitate replication in a host cell. In some cases, the vector provides for low copy number of the vector in the host cell. In some cases, the vector provides for high copy number of the vector in the host cell. In some cases, the vector does not replicate in the host cell and is used to introduce the nucleic acid sequences of interest (e.g., one or more expression cassettes) into the host cell for integration in the genome. In some cases, integration into the genome is by homologous recombination. In some cases, integration into the genome is by non-homologous recombination (e.g., random integration). Integration into the genome of a host cell can include single copy integration or can include integration of multiple copies of one or more vectors or expression cassettes. Included among the provided vectors are multicistronic vectors, such a bicistronic vectors.

[0052] In some embodiments, provided herein are vectors that include a nucleic acid sequence encoding a recombinant sweet protein (e.g., a nucleic acid encoding a recombinant brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, or mycodulcein protein or a functional fragment thereof) operably linked to one or more of the promoters, signal peptides, or a combination thereof. An appropriate vector can be chosen for the preferred host cell. An appropriate vector would be maintained in the host cell long enough for production and / or secretion of a heterologous protein (e.g., a sweet protein), or for integration of the nucleic acid sequence encoding a recombinant sweet protein.

[0053] Described herein are vectors for production of a heterologous protein, such as a sweet protein. A vector containing a polynucleotide encoding a heterologous protein (e.g., a sweet protein) can also include any expression cassette described herein. A vector containing a polynucleotide encoding a heterologous protein (e.g., a sweet protein) can also include a first nucleotide sequence encoding any of the promoters described herein. A vector containing a gene encoding any heterologous protein described herein (e.g., a sweet polypeptide) can include a polynucleotide sequence encoding any signal peptide disclosed herein.

[0054] In some cases, a vector includes an expression cassette including a first nucleotide sequence encoding a promoter operably linked to a protein coding sequence encoding any of the heterologousAttorney Docket No. 54282-0011WO1proteins disclosed here. In some cases, a vector includes an expression cassette that also includes a second nucleotide sequence encoding any of the signal peptides disclosed herein. In some cases, a vector includes an expression cassette including a first nucleotide sequence encoding a promoter operably linked to a protein coding sequence encoding any of the heterologous proteins disclosed here and a second nucleotide sequence encoding any of the signal peptides disclosed herein. In some cases, a second nucleotide sequence encoding any of the signal peptides disclosed herein can be located 5' of the protein coding sequence or 3' of the protein coding sequence. In some cases, a second nucleotide sequence encoding any of the signal peptides disclosed herein can be located 3' of the first nucleotide sequence encoding any of the promoters disclosed herein and 5' of the protein coding sequence.

[0055] In some cases, a vector contains more than one expression cassette, such as two or more (e.g., two, three, four, five, or six or more) of any of the expression sets described herein.Host Cells

[0056] Described herein are cells that contain one or more of the promoters described herein, one or more of the expression cassettes described herein, one or more of the signal peptides described herein, one or more of the signal peptides herein fused to a heterologous protein (e.g., a heterologous sweet protein), and / or one or more of the vectors described herein that can be used to produce and / or secrete a heterologous protein, such as a sweet protein. The expression of the heterologous protein, such as a sweet protein, can be transient or stable. In some examples the expression of the heterologous protein is stable (i.e., maintained over subsequent generations or period of host cell growth). In some preferred cases, the provided cells contain one or more of the described expression cassettes stably integrated into the genome of the cell. Such stable integration is routine, such as by homologous recombination or non-homologous recombination (e.g., random integration). In some examples, two or more expression cassettes (e.g., two, three, four, five, or six or more expression cassettes) are integrated into the host cell genome. In some examples the two or more expression cassettes are integrated into the same locus in the host cell genome. In some examples, the two or more expression cassettes are integrated into different loci in the host cell genome. Integration into the genome of a host cell can include single copy integration or can include integration of multiple copies of one or more vectors or expression cassettes.

[0057] As different host cells can have characteristics and specific mechanisms for the posttranslational processing and modification of protein products, appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of a heterologous proteins. In some cases, a host cell canAttorney Docket No. 54282-0011WO1be a eukaryotic cell (e.g., fungal cell). A host cell can be grown, fermented, propagated, or cultured in any appropriate medium that allows for host cell growth and expression of any sweet polypeptide.

[0058] In some cases, a host cell selected for expression of a heterologous protein (e.g., a sweet polypeptide) can be a fungal cell. The fungal cell can be a yeast cell or a filamentous fungus cell. In some cases, the host cell is a yeast cell. In some cases, the host cell is a filamentous fungus. Yeast cells can include, but are not limited to, Arxula spp., Arxula adeninivorans, Kluyveromyces spp., Kluyveromyces lactis, Pichia spp., Pichia angusta, Pichia pastoris (also known as Komagataella phaffii), Saccharomyces spp., Saccharomyces cerevisiae, Schizosaccharomyces spp., Schizosaccharomyces pombe, Hansenula sp., Blastobotrys sp., Candida sp., Zygosaccharomyces sp., Debaryomyces sp. Yarrowia spp., and Yarrowia lipolytica cells. Fungal cells can include, but are not limited to, Agaricus spp., Agaricus bisporus, Aspergillus spp., Aspergillus awamori, Aspergillus fumigatus, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Blastobotrys sp., Colletotrichum spp., Colletotrichum gloeosporiodes, Endothia spp., Endothia parasitica, Fusarium spp., Fusarium graminearum, Fusarium solani, Mucor spp., Mucor miehei, Mucor pusillus, Myceliophthora spp., Myceliophthora thermophila, Neurospora spp., Neurospora crassa, Penicillium spp., Penicillium camembert!, Penicillium canescens, Penicillium chrysogenum, Penicillium (Talaromyces) emersonii, Penicillium funiculo sum, Penicillium purpurogenum, Penicillium roqueforti, Pleurotus spp., Pleurotus ostreatus, Rhizomucor spp., Rhizomucor miehei, Rhizomucor pusillus, Rhizopus spp., Rhizopus arrhizus, Rhizopus oligosporus, Rhizopus oryzae, Trichoderma spp., Trichoderma altroviride, Trichoderma reesei, and Trichoderma vireus cells.

[0059] In some cases, the host cell for expression of any sweet polypeptide disclosed herein is a Pichia spp., such as Pichia pastoris. In some cases, the host cell for expression of any recombinant sweet polypeptide is Pichia pastoris. In some cases, the host cell for expression of recombinant brazzein-53 is a Pichia spp., such as Pichia pastoris.

[0060] The methylotrophic yeast Pichia pastoris (also called Komagataella phaffi) is known to be safe and is widely used for recombinant protein expression suitable for industrial production. This system allows high-level expression, proper folding, and post-translational modifications such as phosphorylation and glycosylation under the control of a promoter. In addition, proteins can be secreted by the yeast P. pastoris at high levels in minimal medium, facilitating purification from the culture supernatant and reducing downstream costs. The natural secretion of proteins is also advantageous in that the naturally- secreted protein possesses an N-terminus identical to the natural protein if the signal peptide is properly cleaved.Attorney Docket No. 54282-0011WO1II. Sweet Proteins as Heterologous Proteins

[0061] The promoters, signal peptides, expression cassettes, vectors, and cells provided herein can be used to produce or manufacture a heterologous protein, in some preferred embodiments, the heterologous protein is a sweet protein (also referred to herein as a "sweet polypeptide"). A sweet protein is a polypeptide capable of interacting with the human sweet taste receptor. The expression components and methods provided herein can be employed to produce and / or secrete any identified sweet protein. Several naturally occurring sweet proteins have been identified and isolated from a variety of plants, fruits, and fungi. Exemplary natural and mutant sweet proteins are described in Kant Nutr J. 2005 Feb 9;4:5; Ming D et al., FEBS Lett. (1994) 20 355:106-108; WO2019 / 173541; WO2021 / 263158; and WO2023 / 129938, all of which are incorporated by reference in their entirety and are included among the sweet proteins described herein. Non-limiting examples of sweet proteins include a recombinant brazzein polypeptide or a functional fragment thereof (e.g., recombinant brazzein-53), a recombinant monellin polypeptide or a functional fragment thereof, a recombinant miraculin polypeptide or a functional fragment thereof, a recombinant mabinlin polypeptide or a functional fragment thereof, a recombinant curculin polypeptide or a functional fragment thereof, a recombinant thaumatin polypeptide or a functional fragment thereof, a recombinant mycodulcein polypeptide or a functional fragment thereof. In some cases, the heterologous protein is a brazzein or a functional fragment thereof, a brazzein-54 or a functional fragment thereof, a brazzein-53 or a functional fragment thereof. In some cases, the heterologous protein is a monellin or a functional fragment thereof. In some cases, the heterologous protein is a thaumatin or a functional fragment thereof, a thaumatin I or a functional fragment thereof, or a thaumatin II or a functional fragment thereof. Exemplary sweet protein amino acid sequences are provided in Table 1. Sweet proteins also include variants of any of the described sweet proteins that retain the ability to interact with the human taste receptor and impart a sweet taste upon consumption.

[0062] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to polymers of amino acids of at least 5 amino acids long. The polymer can be linear or branched, it can include modified amino acids (e.g., pyroglutamate (pGlu)), and / or it can be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified, for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component or a tag.Attorney Docket No. 54282-0011WO1

[0063] In some embodiments, the sweet protein is a brazzein protein or a functional fragment thereof. In some embodiments, the sweet protein is a Brazzein-54 protein. In some embodiments, the sweet protein is a Brazzein-53 protein. Amino acid sequences of exemplary brazzein proteins are set forth in SEQ ID NOS: 214 and 215. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth in any of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 65. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth in any of SEQ ID NOS: 3, 4, 5, 6, 7, 8, 9, 18, 19, 21, 25, 33, 34, or 65. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 1. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 2. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 3. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 4. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 5. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 6. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 7. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 8. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 9. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 10. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 11. In someAttorney Docket No. 54282-0011WO1embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 12. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 13. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 14. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 15. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 16. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 17. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 18. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 19. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 20. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 21. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 22. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 23. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 24. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 25. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 26. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the codingAttorney Docket No. 54282-0011WO1sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 27. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 28. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 29. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 30. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 31. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 32. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 33. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 34. In some embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the coding sequence of the Brazzein protein is operably linked to a promoter set forth SEQ ID NO: 65.

[0064] In any of the provided embodiments, the sweet protein is a Brazzein protein, such as Brazzein-53 or Brazzein-54, and the expressed Brazzein protein is fused to a signal peptide. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in any one or more of SEQ ID NOS: 66-206. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in any one or more of SEQ ID NOS: 66, 81, 82, 97, 144, 145, 149, 150, 155, 159, 166, 174, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, or 200. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in any one or more of SEQ ID NOS: 81, 82, 97, 144, 145, 155, 189, 190, or 195. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 66. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 81. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 82. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 97. In some embodiments, the expressed BrazzeinAttorney Docket No. 54282-0011WO1protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 144. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 145. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 149. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 150. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein- 54, is fused to a signal peptide set forth in SEQ ID NO: 155. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 159. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 166. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 174. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 189. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein- 54, is fused to a signal peptide set forth in SEQ ID NO: 190. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 191. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 192. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 193. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 194. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 195. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 196. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 197. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 198. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 199. In some embodiments, the expressed Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused to a signal peptide set forth in SEQ ID NO: 200.

[0065] In some embodiments, the coding sequence of a Brazzein protein, such as Brazzein-53 or Brazzein- 54, is fused in frame to one or more coding sequence(s) of a signal peptide set forth in any one or more of SEQ ID NOS: 66, 81, 82, 97, 144, 145, 149, 150, 155, 159, 166, 174, 189, 190, 191, 192, 193, 194, 195,Attorney Docket No. 54282-0011WO1196, 197, 198, 199, or 200 and is operably linked to a promoter set forth in any of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 65. In some embodiments, the coding sequence of a Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused in frame to one or more coding sequence(s) of a signal peptide set forth in any one or more of SEQ ID NOS: 66, 81, 82, 97, 144, 145, 149, 150, 155, 159, 166, 174, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, or 200 and is operably linked to a promoter set forth in any of SEQ ID NOS: 3, 4, 5, 6, 7, 8, 9, 18, 19, 21, 25, 33, 34, or 65. In some embodiments, the coding sequence of a Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused in frame to one or more coding sequence(s) of a signal peptide set forth in any one or more of SEQ ID NOS: 81, 82, 97, 144, 145, 155, 189, 190, or 195 and is operably linked to a promoter set forth in any of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 65. In some embodiments, the coding sequence of a Brazzein protein, such as Brazzein-53 or Brazzein-54, is fused in frame to one or more coding sequence(s) of a signal peptide set forth in any one or more of SEQ ID NOS: 81, 82, 97, 144, 145, 155, 189, 190, or 195 and is operably linked to a promoter set forth in any of SEQ ID NOS: 3, 4, 5, 6, 7, 8, 9, 18, 19, 21, 25, 33, 34, or 65.

[0066] In some embodiments, the sweet protein is a monellin protein or a functional fragment thereof. Amino acid sequences of an exemplary monellin protein are set forth in SEQ ID NOS: 216, 217, and 229. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth in any of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 65. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth in any of SEQ ID NOS: 3, 4, 5, 6, 7, 8, 9, 18, 19, 21, 25, 33, 34, or 65. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 1. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 2. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 3. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 4. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 5. In some embodiments, the sweet protein is a Monellin protein, and the codingAttorney Docket No. 54282-0011WO1sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 6. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 7. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 8. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 9. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 10. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 11. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 12. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 13. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 14. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 15. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 16. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 17. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 18. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 19. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 20. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 21. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 22. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 23. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 24. In someAttorney Docket No. 54282-0011WO1embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 25. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 26. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 27. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 28. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 29. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 30. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 31. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 32. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 33. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 34. In some embodiments, the sweet protein is a Monellin protein, and the coding sequence of the Monellin protein is operably linked to a promoter set forth SEQ ID NO: 65.

[0067] In any of the provided embodiments, the sweet protein is a Monellin protein, and the expressed Monellin protein is fused to a signal peptide. In some embodiments, the expressed Monellin protein, is fused to a signal peptide set forth in any one or more of SEQ ID NOS: 66-206. In some embodiments, the expressed Monellin protein, is fused to a signal peptide set forth in any one or more of SEQ ID NOS: 100, 106, 107, 109, 113, 114, 115, 116, 119, 120, 122, 125, 127, 149, 155, 158, or 203. In some embodiments, the expressed Monellin protein, is fused to a signal peptide set forth in any one or more of SEQ ID NOS: 100, 109, 115, 119, 120, 149, or 158. In some embodiments, the expressed Monellin protein, is fused to a signal peptide set forth in SEQ ID NO: 100. In some embodiments, the expressed Monellin protein, is fused to a signal peptide set forth in SEQ ID NO: 106. In some embodiments, the expressed Monellin protein, is fused to a signal peptide set forth in SEQ ID NO: 107. In some embodiments, the expressed Monellin protein, is fused to a signal peptide set forth in SEQ ID NO: 109. In some embodiments, the expressed Monellin protein, is fused to a signal peptide set forth in SEQ ID NO: 113. In some embodiments, theAttorney Docket No. 54282-0011WO1expressed Monellin protein, is fused to a signal peptide set forth in SEQ ID NO: 114. In some embodiments, the expressed Monellin protein, is fused to a signal peptide set forth in SEQ ID NO: 115. In some embodiments, the expressed Monellin protein, is fused to a signal peptide set forth in SEQ ID NO: 116. In some embodiments, the expressed Monellin protein, is fused to a signal peptide set forth in SEQ ID NO: 119. In some embodiments, the expressed Monellin protein, is fused to a signal peptide set forth in SEQ ID NO: 120. In some embodiments, the expressed Monellin protein, is fused to a signal peptide set forth in SEQ ID NO: 122. In some embodiments, the expressed Monellin protein, is fused to a signal peptide set forth in SEQ ID NO: 125. In some embodiments, the expressed Monellin protein, is fused to a signal peptide set forth in SEQ ID NO: 127. In some embodiments, the expressed Monellin protein, is fused to a signal peptide set forth in SEQ ID NO: 149. In some embodiments, the expressed Monellin protein, is fused to a signal peptide set forth in SEQ ID NO: 155. In some embodiments, the expressed Monellin protein, is fused to a signal peptide set forth in SEQ ID NO: 158. In some embodiments, the expressed Monellin protein, is fused to a signal peptide set forth in SEQ ID NO: 203.

[0068] In some embodiments, the coding sequence of a Monellin protein, is fused in frame to one or more coding sequence(s) of a signal peptide set forth in any one or more of SEQ ID NOS: 100, 106, 107, 109, 113, 114, 115, 116, 119, 120, 122, 125, 127, 149, 155, 158, or 203 and is operably linked to a promoter set forth in any of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 65. In some embodiments, the coding sequence of a Monellin protein, is fused in frame to one or more coding sequence(s) of a signal peptide set forth in any one or more of SEQ ID NOS: 100, 106, 107, 109, 113, 114, 115, 116, 119, 120, 122, 125, 127, 149, 155, 158, or 203 and is operably linked to a promoter set forth in any of SEQ ID NOS: 3, 4, 5, 6, 7, 8, 9, 18, 19, 21, 25, 33, 34, or 65. In some embodiments, the coding sequence of a Monellin protein, is fused in frame to one or more coding sequence(s) of a signal peptide set forth in any one or more of SEQ ID NOS: 100, 109, 115, 119, 120, 149, or 158 and is operably linked to a promoter set forth in any of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 65. In some embodiments, the coding sequence of a Monellin protein, is fused in frame to one or more coding sequence(s) of a signal peptide set forth in any one or more of SEQ ID NOS: 100, 109, 115, 119, 120, 149, or 158 and is operably linked to a promoter set forth in any of SEQ ID NOS: 3, 4, 5, 6, 7, 8, 9, 18, 19, 21, 25, 33, 34, or 65.

[0069] In some embodiments, the sweet protein is a miraculin protein or a functional fragment thereof. An amino acid sequence of an exemplary miraculin protein is set forth in SEQ ID NO: 218. In someAttorney Docket No. 54282-0011WO1embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth in any of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 65. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth in any of SEQ ID NOS: 3, 4, 5, 6, 7, 8, 9, 18, 19, 21, 25, 33, 34, or 65. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 1. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 2. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 3. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 4. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 5. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 6. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 7. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 8. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 9. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 10. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 11. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 12. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 13. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 14. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 15. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin proteinAttorney Docket No. 54282-0011WO1is operably linked to a promoter set forth SEQ ID NO: 16. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 17. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 18. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 19. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 20. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 21. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 22. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 23. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 24. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 25. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 26. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 27. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 28. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 29. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 30. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 31. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 32. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 33. In some embodiments, the sweet protein is a Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 34. In some embodiments, the sweet protein is aAttorney Docket No. 54282-0011WO1Miraculin protein, and the coding sequence of the Miraculin protein is operably linked to a promoter set forth SEQ ID NO: 65.

[0070] In any of the provided embodiments, the sweet protein is a Miraculin protein, and the expressed Miraculin protein is fused to a signal peptide. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in any one or more of SEQ ID NOS: 66-206. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 66. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 67. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 68. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 69. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 70. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 71. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 72. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 73 In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 74. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 75. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 76. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 77. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 78. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 79. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 80. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 81. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 82. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 82. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 82. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 83. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 84. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 85. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 86. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 87. In some embodiments, the expressed MiraculinAttorney Docket No. 54282-0011WO1protein, is fused to a signal peptide set forth in SEQ ID NO: 88. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 88. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 90. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 91. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 92. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 93. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 94. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 95. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 96 In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 97. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 98. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 99. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 100. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 101. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 102. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 103. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 104. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 105. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 106. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 107. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 108. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 109. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 100. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 101. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 102. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 103. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 104. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 105. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth inAttorney Docket No. 54282-0011WO1SEQ ID NO: 106. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 107. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 108. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 109. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 110. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 111. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 112. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 113. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 114. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 115. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 116. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 117. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 118. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 119. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 120. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 121. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 122. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 123. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 124. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 125. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 126. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 127. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 128. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 129. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 130. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 131. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 132. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 133. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 134. InAttorney Docket No. 54282-0011WO1some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 135. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 136. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 137. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 138. in some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 139. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 140. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 141. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 142. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 143. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 144. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 145. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 146. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 147. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 148. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 149. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 150. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 151. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 152. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 153. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 154. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 155. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 156. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 157. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 158. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 159. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 160. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 161. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 162. In some embodiments, theAttorney Docket No. 54282-0011WO1expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 163. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 164. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 165. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 166. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 167. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 168. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 169. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 170. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 171. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 172. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 173. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 174. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 175. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 176. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 177. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 178. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 179. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 180. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 181. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 182. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 183. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 184. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 185. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 186. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 187. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 188. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 189. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 190. In some embodiments, the expressed MiraculinAttorney Docket No. 54282-0011WO1protein, is fused to a signal peptide set forth in SEQ ID NO: 191. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 192. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 193. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 194. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 195. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 196. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 197. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 198. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 199. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 200. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 201. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 202. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 203. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 204. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 205. In some embodiments, the expressed Miraculin protein, is fused to a signal peptide set forth in SEQ ID NO: 206.

[0071] In some embodiments, the coding sequence of a Miraculin protein, is fused in frame to one or more coding sequence(s) of a signal peptide set forth in any one or more of SEQ ID NOS: 66-206 and is operably linked to a promoter set forth in any of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 65. In some embodiments, the coding sequence of a Miraculin protein, is fused in frame to one or more coding sequence(s) of a signal peptide set forth in any one or more of SEQ ID NOS: 66-206 and is operably linked to a promoter set forth in any of SEQ ID NOS: 3, 4, 5, 6, 7, 8, 9, 18, 19, 21, 25, 33, 34, or 65.

[0072] In some embodiments, the sweet protein is a mabinlin protein or a functional fragment thereof. Exemplary amino acid sequences for mabinlin proteins are set forth in SEQ ID NOS: 219-225. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth in any of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 65. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operablyAttorney Docket No. 54282-0011WO1linked to a promoter set forth in any of SEQ ID NOS: 3, 4, 5, 6, 7, 8, 9, 18, 19, 21, 25, 33, 34, or 65. in some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 1. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 2 in some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 3. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 4. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 5. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 6. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 7. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 8. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 9. in some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 10. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 11. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 12. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 13. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 14. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 15. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 16. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 17. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 18. In someAttorney Docket No. 54282-0011WO1embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 19. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 20. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 21. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 22. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 23. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 24. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 25. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 26. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 27. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 28. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 29. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 30. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 31. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 32. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 33. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 34. In some embodiments, the sweet protein is a Mabinlin protein, and the coding sequence of the Mabinlin protein is operably linked to a promoter set forth SEQ ID NO: 65.

[0073] In any of the provided embodiments, the sweet protein is a Mabinlin protein, and the expressed Mabinlin protein is fused to a signal peptide. In some embodiments, the expressed Mabinlin protein, isAttorney Docket No. 54282-0011WO1fused to a signal peptide set forth in any one or more of SEQ ID NOS: 66-206. in some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 66. in some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 67. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 68. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 69. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 70. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 71. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 72. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 73 In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 74. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 75. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 76. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 77. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 78. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 79. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 80. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 81. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 82. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 82. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 82. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 83. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 84. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 85. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 86. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 87. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 88. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 88. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 90. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 91. In some embodiments, theAttorney Docket No. 54282-0011WO1expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 92. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 93. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 94. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 95. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 96 In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 97. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 98. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 99. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 100. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 101. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 102. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 103. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 104. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 105. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 106. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 107. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 108. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 109. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 100. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 101. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 102. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 103. in some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 104. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 105. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 106. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 107. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 108. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 109. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 110. In someAttorney Docket No. 54282-0011WO1embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 111. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 112. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 113. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 114. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 115. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 116. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 117. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 118. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 119. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 120. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 121. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 122. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 123. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 124. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 125. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 126. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 127. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 128. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 129. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 130. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 131. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 132. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 133. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 134. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 135. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 136. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 137. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 138. In some embodiments, the expressed Mabinlin protein, is fused to a signalAttorney Docket No. 54282-0011WO1peptide set forth in SEQ ID NO: 139. in some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 140. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 141. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 142. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 143. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 144. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 145. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 146. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 147. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 148. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 149. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 150. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 151. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 152. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 153. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 154. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 155. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 156. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 157. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 158. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 159. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 160. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 161. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 162. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 163. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 164. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 165. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 166. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 167. In some embodiments, the expressedAttorney Docket No. 54282-0011WO1Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 168. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 169. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 170. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 171. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 172. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 173. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 174. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 175. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 176. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 177. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 178. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 179. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 180. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 181. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 182. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 183. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 184. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 185. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 186. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 187. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 188. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 189. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 190. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 191. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 192. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 193. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 194. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 195. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ IDAttorney Docket No. 54282-0011WO1NO: 196. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 197. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 198. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 199. in some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 200. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 201. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 202. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 203. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 204. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 205. In some embodiments, the expressed Mabinlin protein, is fused to a signal peptide set forth in SEQ ID NO: 206.

[0074] In some embodiments, the coding sequence of a Mabinlin protein, is fused in frame to one or more coding sequence(s) of a signal peptide set forth in any one or more of SEQ ID NOS: 66-206 and is operably linked to a promoter set forth in any of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 65. In some embodiments, the coding sequence of a Mabinlin protein, is fused in frame to one or more coding sequence(s) of a signal peptide set forth in any one or more of SEQ ID NOS: 66-206 and is operably linked to a promoter set forth in any of SEQ ID NOS: 3, 4, 5, 6, 7, 8, 9, 18, 19, 21, 25, 33, 34, or 65.

[0075] In some embodiments, the sweet protein is a curculin protein or a functional fragment thereof. Exemplary amino acid sequences for curculin proteins are set forth in SEQ ID NOS: 226 and 227. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth in any of SEQ ID NOS:: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 65. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth in any of SEQ ID NOS: 3, 4, 5, 6, 7, 8, 9, 18, 19, 21, 25, 33, 34, or 65. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 1. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 2. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 3. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein isAttorney Docket No. 54282-0011WO1operably linked to a promoter set forth SEQ ID NO: 4. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 5. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 6. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 7. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 8. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 9. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 10. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 11. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 12. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 13. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 14. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 15. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 16. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 17. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 18. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 19. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 20. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 21. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 22. In some embodiments, the sweet protein is aAttorney Docket No. 54282-0011WO1Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 23. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 24. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 25. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 26. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 27. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 28. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 29. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 30. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 31. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 32. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 33. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 34. In some embodiments, the sweet protein is a Curculin protein, and the coding sequence of the Curculin protein is operably linked to a promoter set forth SEQ ID NO: 65.

[0076] In any of the provided embodiments, the sweet protein is a Curculin protein, and the expressed Curculin protein is fused to a signal peptide. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in any one or more of SEQ ID NOS: 66-206. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 66. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 67. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 68. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 69. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 70. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQAttorney Docket No. 54282-0011WO1ID NO: 71. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 72. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 73 In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 74. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 75. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 76. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 77. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 78. In some embodiments, the expressed Curculin protein, is fused to a signal peptide setforth in SEQ ID NO: 79. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 80. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 81. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 82. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 82. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 82. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 83. In some embodiments, the expressed Curculin protein, is fused to a signal peptide setforth in SEQ ID NO: 84. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 85. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 86. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 87. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 88. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 88. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 90. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 91. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 92. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 93. In some embodiments, the expressed Curculin protein, is fused to a signal peptide setforth in SEQ ID NO: 94. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 95. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 96 In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 97. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 98. In some embodiments,Attorney Docket No. 54282-0011WO1the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 99. in some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 100. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 101. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 102. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 103. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 104. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 105. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 106. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 107. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 108. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 109. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 100. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 101. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 102. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 103. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 104. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 105. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 106. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 107. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 108. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 109. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 110. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 111. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 112. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 113. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 114. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 115. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 116. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ IDAttorney Docket No. 54282-0011WO1NO: 117. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 118. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 119. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 120. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 121. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 122. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 123. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 124. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 125. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 126. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 127. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 128. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 129. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 130. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 131. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 132. In some embodiments, the expressed Curculin protein, isfused to a signal peptide set forth in SEQ ID NO: 133. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 134. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 135. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 136. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 137. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 138. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 139. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 140. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 141. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 142. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 143. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 144. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 145. In some embodiments, the expressed Curculin protein, isfused to a signal peptideAttorney Docket No. 54282-0011WO1set forth in SEQ ID NO: 146. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 147. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 148. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 149. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 150. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 151. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 152. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 153. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 154. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 155. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 156. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 157. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 158. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 159. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 160. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 161. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 162. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 163. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 164. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 165. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 166. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 167. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 168. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 169. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 170. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 171. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 172. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 173. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 174. In some embodiments, the expressed Curculin protein, is fusedAttorney Docket No. 54282-0011WO1to a signal peptide set forth in SEQ ID NO: 175. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 176. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 177. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 178. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 179. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 180. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 181. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 182. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 183. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 184. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 185. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 186. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 187. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 188. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 189. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 190. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 191. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 192. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 193. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 194. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 195. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 196. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 197. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 198. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 199. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 200. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 201. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 202. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 203. In some embodiments, the expressedAttorney Docket No. 54282-0011WO1Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 204. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 205. In some embodiments, the expressed Curculin protein, is fused to a signal peptide set forth in SEQ ID NO: 206.

[0077] In some embodiments, the coding sequence of a Curculin protein, is fused in frame to one or more coding sequence(s) of a signal peptide set forth in any one or more of SEQ ID NOS: 66-206 and is operably linked to a promoter set forth in any of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 65. In some embodiments, the coding sequence of a Curculin protein, is fused in frame to one or more coding sequence(s) of a signal peptide set forth in any one or more of SEQ ID NOS: 66-206 and is operably linked to a promoter set forth in any of SEQ ID NOS: 3, 4, 5, 6, 7, 8, 9, 18, 19, 21, 25, 33, 34, or 65.

[0078] In some embodiments, the sweet protein is a thaumatin protein or a functional fragment thereof. In some embodiments, the sweet protein is a Thaumatin I protein. In some embodiments, the sweet protein is a Thaumatin II protein. Amino acid sequences of exemplary Thaumatin proteins are set forth in SEQ ID NOS: 212 and 213. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth in any of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 65. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth in any of SEQ ID NOS: 3, 4, 5, 6, 7, 8, 9, 18, 19, 21, 25, 33, 34, or 65. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 1. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 2. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 3. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 4. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 5. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 6. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 7. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the ThaumatinAttorney Docket No. 54282-0011WO1protein is operably linked to a promoter set forth SEQ ID NO: 8. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 9. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 10. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 11. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 12. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 13. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 14. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 15. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 16. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 17. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 18. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 19. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 20. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 21. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 22. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 23. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 24. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 25. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 26. In some embodiments,Attorney Docket No. 54282-0011WO1the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 27. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 28. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 29. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 30. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 31. in some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 32. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 33. In some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 34. in some embodiments, the sweet protein is a Thaumatin protein, and the coding sequence of the Thaumatin protein is operably linked to a promoter set forth SEQ ID NO: 65.

[0079] In any of the provided embodiments, the sweet protein is a Thaumatin protein, and the expressed Thaumatin protein is fused to a signal peptide. In some embodiments, the expressed Thaumatin protein, is fused to a signal peptide set forth in any one or more of SEQ ID NOS: 66-206. In some embodiments, the expressed Thaumatin protein, is fused to a signal peptide set forth in any one or more of SEQ ID NOS: 67, 68, 69, 70, 71, 79, 81, 85, 116, 134, or 150. In some embodiments, the expressed Thaumatin protein, is fused to a signal peptide set forth in any one or more of SEQ ID NOS: 69, 79, 81, or 85. In some embodiments, the expressed Thaumatin protein, is fused to a signal peptide set forth in SEQ ID NO: 67. In some embodiments, the expressed Thaumatin protein, is fused to a signal peptide set forth in SEQ ID NO: 68. In some embodiments, the expressed Thaumatin protein, is fused to a signal peptide set forth in SEQ ID NO: 69. In some embodiments, the expressed Thaumatin protein, is fused to a signal peptide set forth in SEQ ID NO: 70. In some embodiments, the expressed Thaumatin protein, is fused to a signal peptide set forth in SEQ ID NO: 71. In some embodiments, the expressed Thaumatin protein, is fused to a signal peptide set forth in SEQ ID NO: 79. In some embodiments, the expressed Thaumatin protein, is fused to a signal peptide set forth in SEQ ID NO: 81. In some embodiments, the expressed Thaumatin protein, is fused to a signal peptide set forth in SEQ ID NO: 85. In some embodiments, the expressed Thaumatin protein, is fused to a signal peptide set forth in SEQ ID NO: 116. In some embodiments, theAttorney Docket No. 54282-0011WO1expressed Thaumatin protein, is fused to a signal peptide set forth in SEQ ID NO: 134. In some embodiments, the expressed Thaumatin protein, is fused to a signal peptide set forth in SEQ ID NO: 150.

[0080] In some embodiments, the coding sequence of a Thaumatin protein, is fused in frame to one or more coding sequence(s) of a signal peptide set forth in any one or more of SEQ ID NOS: 67, 68, 69, 70, 71, 79, 81, 85, 116, 134, or 150 and is operably linked to a promoter set forth in any of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 65. In some embodiments, the coding sequence of a Thaumatin protein, is fused in frame to one or more coding sequence(s) of a signal peptide set forth in any one or more of SEQ ID NOS: 67, 68, 69, 70, 71, 79, 81, 85, 116, 134, or 150 and is operably linked to a promoter set forth in any of SEQ ID NOS: 3, 4, 5, 6, 7, 8, 9, 18, 19, 21, 25, 33, 34, or 65. In some embodiments, the coding sequence of a Thaumatin protein, is fused in frame to one or more coding sequence(s) of a signal peptide set forth in any one or more of SEQ ID NOS: 69, 79, 81, or 85 and is operably linked to a promoter set forth in any of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 65. In some embodiments, the coding sequence of a Thaumatin protein, is fused in frame to one or more coding sequence(s) of a signal peptide set forth in any one or more of SEQ ID NOS: 69, 79, 81, or 85 and is operably linked to a promoter set forth in any of SEQ ID NOS: 3, 4, 5, 6, 7, 8, 9, 18, 19, 21, 25, 33, 34, or 65.

[0081] In some embodiments, the sweet protein is a mycodulcein protein. Exemplary amino acid sequences for mycodulcein proteins are set forth in SEQ ID NO: 228. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth in any of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 65. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth in any of SEQ ID NOS: 3, 4, 5, 6, 7, 8, 9, 18, 19, 21, 25, 33, 34, or 65. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 1. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 2 In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 3. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 4. In some embodiments, theAttorney Docket No. 54282-0011WO1sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 5. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 6. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 7. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 8. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 9. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 10. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 11. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 12. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 13. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 14. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 15. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 16. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 17. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 18. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 19. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 20. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 21. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 22. In some embodiments, the sweet proteinAttorney Docket No. 54282-0011WO1is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 23. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 24. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 25. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 26. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 27. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 28. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 29. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 30. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 31. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 32. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 33. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 34. In some embodiments, the sweet protein is a Mycodulcein protein, and the coding sequence of the Mycodulcein protein is operably linked to a promoter set forth SEQ ID NO: 65.

[0082] In any of the provided embodiments, the sweet protein is a Mycodulcein protein, and the expressed Mycodulcein protein is fused to a signal peptide. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in any one or more of SEQ ID NOS: 66-206. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 66. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 67. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 68. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 69. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 70. In some embodiments, the expressed Mycodulcein protein, isAttorney Docket No. 54282-0011WO1fused to a signal peptide set forth in SEQ ID NO: 71. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 72. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 73 In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 74. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 75. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 76. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 77. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 78. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 79. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 80. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 81. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 82. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 82. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 82. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 83. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 84. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 85. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 86. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 87. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 88. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 88. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 90. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 91. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 92. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 93. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 94. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 95. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 96 In some embodiments, the expressed Mycodulcein protein, is fused to a signalAttorney Docket No. 54282-0011WO1peptide set forth in SEQ ID NO: 97. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 98. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 99. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 100. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 101. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 102. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 103. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 104. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 105. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 106. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 107. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 108. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 109. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 100. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 101. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 102. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 103. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 104. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 105. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 106. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 107. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 108. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 109. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 110. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 111. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 112. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 113. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 114. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forthAttorney Docket No. 54282-0011WO1in SEQ ID NO: 115. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 116. In some embodiments, the expressed Mycodulcein protein, isfused to a signal peptide set forth in SEQ ID NO: 117. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 118. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 119. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 120. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 121. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 122. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 123. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 124. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 125. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 126. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 127. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 128. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 129. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 130. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 131. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 132. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 133. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 134. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 135. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 136. In some embodiments, the expressed Mycodulcein protein, isfused to a signal peptide set forth in SEQ ID NO: 137. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 138. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 139. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 140. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 141. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 142. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 143.Attorney Docket No. 54282-0011WO1In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 144. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 145. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 146. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 147. in some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 148. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 149. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 150. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 151. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 152. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 153. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 154. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 155. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 156. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 157. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 158. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 159. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 160. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 161. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 162. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 163. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 164. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 165. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 166. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 167. in some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 168. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 169. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 170. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 171. In some embodiments, theAttorney Docket No. 54282-0011WO1expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 172. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 173. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 174. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 175. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 176. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 177. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 178. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 179. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 180. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 181. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 182. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 183. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 184. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 185. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 186. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 187. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 188. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 189. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 190. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 191. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 192. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 193. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 194. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 195. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 196. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 197. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 198. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 199. In some embodiments, the expressed MycodulceinAttorney Docket No. 54282-0011WO1protein, is fused to a signal peptide set forth in SEQ ID NO: 200. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 201. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 202. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 203. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 204. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 205. In some embodiments, the expressed Mycodulcein protein, is fused to a signal peptide set forth in SEQ ID NO: 206.

[0083] In some embodiments, the coding sequence of a Mycodulcein protein, is fused in frame to one or more coding sequence(s) of a signal peptide set forth in any one or more of SEQ ID NOS: 66-206 and is operably linked to a promoter set forth in any of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 65. In some embodiments, the coding sequence of a Mycodulcein protein, is fused in frame to one or more coding sequence(s) of a signal peptide set forth in any one or more of SEQ ID NOS: 66-206 and is operably linked to a promoter set forth in any of SEQ ID NOS: 3, 4, 5, 6, 7, 8, 9, 18, 19, 21, 25, 33, 34, or 65.Table 1. Exemplary Sweet Polypeptide Sequences.SEQ ID Peptide SequenceNO: Description214 Brazzein-54 XDKCKKVYENYPVSKCQLANQCNYDCKLDKHARSGECFYDEKRNLQCICDYCEY 215 Brazzein-53 DKCKKVYENYPVSKCQLANQCNYDCKLDKHARSGECFYDEKRNLQCICDYCEY 216 Monellin FREIKGYEYQLYVYASDKLFRADISEDYKTRGRKLLRFNGPVPPPchain A217 Monellin GEWEIIDIGPFTQNLGKFAVDEENKIGQYGRLTFNKVIRPCMKKTIYEENchain B229 Single-chain GEWEIIDIGPFTQNLGKFAVDEENKIGQYGRLTFNKVIRPCMKKTIYEENGFREIKGY monellin EYQLYVYASDKLFRADISEDYKTRGRKLLRFNGPVPPP218 Miraculin DSAPNPVLDIDGEKLRTGTNYYIVPVLRDHGGGLTVSATTPNGTFVCPPRWQTRKE VDHDRPLAFFPENPKEDVVRVSTDLNINFSAFMPCRWTSSTVWRLDKYDESTGQY FVTIGGVKGNPGPETISSWFKIEEFCGSGFYKLVFCPTVCGSCKVKCGDVGIYIDQKG RRRLALSDKPFAFEFNKTVYF219 Mabinlin-1 EP LCRRQFQQHQH LRACQRYI RRRAQRGG LVDchain A220 Mabinlin-1 EQRGPALRLCCNQLRQVNKPCVCPVLRQAAHQQLYQGQIEGPRQVRQLFRAARN chain B LPNICKIPAVGRCQFTRW221 Mabinlin-2 QLWRCQRQFLQHQRLRACQRFIHRRAQFGGQPDchain AAttorney Docket No. 54282-0011WO1SEQID Peptide SequenceNO: Description222 Mabinlin-2 QPRRPALRQCCNQLRQVDRPCVCPVLRQAAQQVLQ. RQIIQGPQQ. LRRLFDAARN chain B LPNICNIPNIGACPFRAW223 Mabinlin-3 EPLCRRQFQQHQHLRACQRYLRRRAQRGGLADchain A224 Mabinlin-3 EQRGPALRLCCNQLRQVNKPCVCPVLRQAAHQQ. LYQ. GQIEGPRQVRRLFRAARN chain B / LPNICKIPAVGRCQFTRWMabinlin-4chain B225 Mabinlin-4 EP LCRRQ. FQQ. HQH LRACQ. RYLRRRAQ. RGchain A226 Curculin 1 DNVLLSGQTLHADHSLQAGAYTLTIQNKCNLVKYQNGRQIWASNTDRRGSGCRLT LLSDGNLVIYDHNNNDVWGSACWGDNGKYALVLQKDGRFVIYGPVLWSLGPNGC RRVNG227 Curculin 2 DSVLLSGQ. TLYAGHSLTSGSYTLTIQNNCNLVKYQHGRQIWASDTDGQGSQCRLTL RSDGNLIIYDDNNMWWGSDCWGNNGTYALVLQQDGLFVIYGPVLWPLGLNGC RSLN212 Thaumatin 1 ATFEIVNRCSYTVWAAASKGDAALDAGGRQLNSGESWTINVEPGTNGGKIWART DCYFDDSGSGICKTGDCGGLLRCKRFGRPPTTLAEFSLNQYGKDYIDISNIKGFNVP MDFSPTTRGCRGVRCAADIVGQCPAKLKAPGGGCNDACTVFQTSEYCCTTGKCGP TEYSRFFKRLCPDAFSYVLDKPTTVTCPGSSNYRVTFCPTA213 Thaumatin II ATFEIVNRCSYTVWAAASKGDAALDAGGRQLNSGESWTINVEPGTKGGKIWART DCYFDDSGRGICRTGDCGGLLQCKRFGRPPTTLAEFSLNQYGKDYIDISNIKGFNVP MDFSPTTRGCRGVRCAADIVGQCPAKLKAPGGGCNDACTVFQTSEYCCTTGKCGP TEYSRFFKRLCPDAFSYVLDKPTTVTCPGSSNYRVTFCPTA228 Mycodulcein MPDLSSFITIKNNSNHVFTRTAIYSKYAAVQWSPEPQLSISPGKWDLFILKDILSIRGTSGYVQYRVGDGPGWVRVTFSSLVGADEVAEWSSGDLPDGFVLQKPVRTGSRPLQATFEATKQX can be glutamine or pyroglutamate.iii. Methods of Producing Sweet PolypeptidesExpression of Recombinant Heterologous Proteins (e.g., Sweet Proteins)(0084] Provided herein are methods of expressing heterologous proteins (e.g., any of the sweet polypeptides described herein) using engineered promoters, engineered signal peptides, expression cassettes, vectors and / or host cells described herein. The heterologous proteins (e.g., sweet proteins) can be produced recombinantly using a variety of protein expression systems, including, but not limited, cellbased expression systems, and cell-free expression systems. Heterologous proteins (e.g., sweet polypeptides) produced recombinantly are recombinant proteins.Attorney Docket No. 54282-0011WO1

[0085] A recombinant nucleic acid is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of nucleic acid sequence. This artificial combination is often accomplished by chemical synthesis or by the artificial manipulation of isolated segments of nucleic acids (e.g., by genetic engineeringtechniques). Theterm recombinant nucleic acids includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid can include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid can be part of a vector that is used, for example, to transform a cell.

[0086] Non-limiting examples of protein expression systems useful in producing sweet polypeptides disclosed herein include eukaryotic cell-based expression systems (e.g., filamentous or non-filamentous fungal cells, yeast cells, insect cells, and mammalian cells). In particular cases, a recombinant sweet protein is produced by a yeast cell.

[0087] To express a heterologous protein (e.g., a sweet protein) in a cell-based expression system, a gene encoding the heterologous protein can be introduced into a host cell of the expression system by, for example, a vector, whereby the vector further contains a promoter heterologous to the protein (e.g., sweet protein). The vector can also encode a signal peptide whereby the signal peptide is associated with the heterologous protein to facilitate secretion of the heterologous protein (e.g., sweet protein).

[0088] A polynucleotide gene encoding the sweet polypeptide with or without a signal peptide, such as a signal peptide described herein, can be made by various methods, including molecular cloning and synthesis. Molecular cloning methods can involve mutagenesis (e.g., site-directed mutagenesis), restriction enzyme-mediated cloning (e.g., restriction enzyme digestion and ligation), polymerase chain reaction (PCR), and overlap extension. Synthesis can include chemical synthesis (e.g., gene synthesis). The gene sequence can be codon optimized for any desired expression system.

[0089] The coding sequence can be inserted into a vector by a variety of procedures, including, but not limited to restriction enzyme digestion, ligation, and homologous recombination. The vector can be capable of replicating and expressing the polynucleotides in prokaryotic and / or eukaryotic host cells of expression systems. A vector can contain various components that can be adjusted and optimized for compatibility with the particular host cell. A cloning vector and / or expression vector can include additional nucleic acid sequences, including but not limited to, a nucleic acid encoding a signal peptide (also called a signal sequence or signal peptide sequence), an origin of replication, a marker gene (e.g., a selectionAttorney Docket No. 54282-0011WO1marker such as an antibiotic resistance gene), an enhancer element, a promoter, such as any promoter described herein, a ribosome binding site, and a transcription termination sequence.Recovery and Purification of Sweet Polypeptides

[0090] Any heterologous protein (e.g., any sweet polypeptide), can be expressed using an expression system that employs any one or more of the engineered promoters, engineered signal peptides, expression cassettes, vectors, or host cells provided herein, and recovered, isolated, and / or purified. In preferred cases, the heterologous protein (e.g., sweet protein) can be recovered, isolated and / or purified from the supernatant of a cell culture, for example, if the expressed protein is secreted by the host cell into the cell culture medium. In some cases, the heterologous protein (e.g., sweet polypeptide) can be recovered from the host cell, for example, if the protein is expressed intracellularly if the protein is not secreted or not sufficiently secreted. Proteins can be recovered from the intracellular space by disrupting the host cell, for example, by osmotic shock, sonication, or lysis. Once the cells are disrupted, cell debris can be removed by centrifugation or filtration, and the expressed proteins can be removed or recovered from the cell lysate.

[0091] The expressed heterologous protein (e.g., sweet polypeptide) can be recovered and / or isolated from supernatants and lysates by any of a variety of methods, including, but not limited to, chemical extraction, column chromatography, and filtration. In some cases, the culture medium is collected after culturing the host cell. The polypeptides can be purified using any of a variety of methods including liquid chromatography such as normal or reversed phase, high-performance liquid chromatography (HPLC), fast protein liquid chromatography (FPLC), and the like; affinity chromatography such as with inorganic ligands, monoclonal antibodies (e.g., immunoaffinity), and ion exchange (e.g., anion exchange, cation exchange); hydrophobic interaction chromatography; size exclusion chromatography; immobilized metal chelate chromatography; gel electrophoresis; ethanol precipitation; and any combination thereof. In some cases, the polypeptides can be purified by centrifugation and / orfiltration, including sterile filtration, depth filtration, tangential flow filtration, ultrafiltration (UF), diafiltration (DF), and ultrafiltration / diafiltration (UF / DF).

[0092] A recovered and / or isolated heterologous protein (e.g., sweet protein) can be concentrated, dehydrated, dewatered, or dried by freeze drying, vacuum tray drying, spray drying, rotary drum drying, or any combination thereof. Drying can be done in a desiccator, vacuum dryer, conical dryer, spray dryer, fluid bed or any method known in the art. Preferably, methods are chosen that yield a dried product (e.g.,Attorney Docket No. 54282-0011WO1a powder) with preserved sweetness. The resulting concentrated liquid or solid powder can be stored, diluted, or rehydrated. In some cases, the concentrated liquid or solid powder can be stored at -20°C, 4°C, or room temperature without significant loss in sweetness. In some cases, the concentrated liquid can be diluted using water or a fat. In some cases, the solid powder can be rehydrated at a paste or a liquid using water or another liquid in which the solid powder is soluble.

[0093] Although preferred for use in some cases, there is no general requirement that the protein, polypeptide, or peptide always be provided in their most purified state. Indeed, it is contemplated that less substantially purified protein, polypeptide, or peptide, which are nonetheless enriched in the desired peptide compositions, relative to the natural state, will have utility in some cases. Methods of enrichment of a component, such as enrichment of a peptide, are known in the art and are often similar to those of purification of components or peptides.

[0094] In other cases, a preparation enriched with any of the heterologous proteins (e.g., sweet peptides) can be used instead of a purified preparation. In this document, whenever purified is used, enriched can be used also. A preparation can be enriched not only by methods of purification, but also by the over¬ expression or over-production of the peptide by the host cell when compared to a wild-type host cell. This can be accomplished using recombinant methods, or by selecting conditions which will induce the expression of the peptide from the wild-type cells.IV. Definitions

[0095] Reference to the term "about" has its usual meaning in the context of compositions to allow for reasonable variations in amounts that can achieve the same effect and refers herein to a value of plus or minus 10% of the provided value. For example, "about 20" means or includes amounts from 18 to and including 22.

[0096] Unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. As used herein, the singular form "a," "an," and "the" include plural references unless indicated otherwise. For example, "an" excipient includes one or more excipients.

[0097] The term "operably linked" indicates that the linked nucleic acid (e.g., a gene of interest) and the regulatory sequence(s) (e.g., a promoter) are connected in such a way as to permit transcription, thus producing RNA from the linked nucleic acid sequence (e.g., transcribing the gene of interest). In some cases, the activity of a promoter can be measured directly, such as by assessing the level of RNA produced.Attorney Docket No. 54282-0011WO1

[0098] As used herein, the term "amino acid" refers to either natural and / or unnatural or synthetic amino acids, including pyroglutamate (pGlu) and both the D or L optical isomers, amino acid analogs, and / or peptidomimetics.

[0099] As used herein "recombinant protein" is a protein produced from a recombinant nucleic acid.

[0100] The term "purifying" means a step performed to isolate a recombinant peptide from one or more other impurities (e.g., bulk impurities) or components present in a fluid containing a recombinant peptide (e.g., liquid culture medium polypeptides or one or more other components (e.g., DNA, RNA, other polypeptides, endotoxins, viruses, etc.) present in or secreted from a cell, such as a filamentous fungal cell).

[0101] As used herein "enriched" refers to a component, such as a peptide or protein that is found at a high concentration in a solution or composition than in nature when produced the same way.

[0102] The terms "isolated", "purified", "separated", and "recovered" as used herein refer to a material (e.g., a polypeptide, nucleic acid, or cell) that is removed from at least one component with which it is naturally associated, for example, at a concentration of at least 90% by weight, or at least 95% by weight, or at least 98% by weight of the sample in which it is contained. For example, these terms can refer to a material which is substantially or essentially free from components which normally accompany it as found in its native state, such as, for example, an intact biological system, or is substantially or essentially free from other proteins in the system from which it is expressed.

[0103] Where the term "substantially purified" is used, this will refer to a composition in which the specific protein, peptide, or peptide forms the major component of the composition, such as constituting about 50% of the peptides in the composition or more. In preferred cases, a substantially purified peptide will constitute more than 60%, 70%, 80%, 90%, 95%, 99% or even more of the peptides in the composition.

[0104] A peptide, polypeptide or protein that is "purified to homogeneity," as used herein, means that the peptide, polypeptide, or protein has a level of purity where the peptide, polypeptide or protein is substantially purified or free from other proteins / peptides and biological components. For example, a purified peptide, polypeptide, or protein will often be sufficiently free of other protein / peptide components so that degradative sequencing can be performed successfully.Attorney Docket No. 54282-0011WO1Table 2. Exemplary Sequences.Sequence SEQDescription IDNO. SequencePl 1 AGAGATTCTCCGTCCAACTTTGACAGAGGTATTGAATAGTCATTTTCTATTCCCGATTACCCTATTGGTGTTCGC GCTTCTCTCTAAGGTGACGCAATAAGAATGTGGATCGACGATAGCATCAGGAAAGATCGACATCCACGATTCT TGAAAAATATACTGAGGGAGAAAATAAAGTTCACACGTACAATCCTAGCGCACCCCTTAAGGTCCCTCTAGCC CGTGTCCTCTCGAAACGTTACTCCGGAGTCCTTACAATACCAAGTAATTGGGGGTGTGACCTAAACGTCTCCT AGAATCCGGGGCAACACCCTAGAGGCTCATTTCAAAATGAGATCCACTAACGCGGTATCTTAGCCCGTAATCC ACAATAGCCCTGGTACCTGACTCGGTGTGCGTCTGCTATTTTACCACCCAAGTTACTACCGCCAACCACAGTCT TTCAAGTTCAAATCGGACCCGTTTTTTTGTGAGGCACTTTGACGGGGGTGTCGAGATTGTTTTCAATCGCGAA ACCGTGACCTTCCACCCTCGCGAAAGGAGCTCGCTTCCGAGAAGTTCATGACGATTTCACCATCAAAAGGCAC ACATTAAACAATAGTCCAAAAACACCGCTTATCGATCTCGGAATGGTTTCGGATCTTCAGCATCGTTTAAAAAA CTGCCAACCTACCCAATTGCGAGCTCAATGGACL I l l i CCGTGTATTCCGGTGGTTATTTACCAACATTCCAAT ATCGATGATACTCGCCAAATTGGAATCTTTCTGTGTGGCGCACGTCTTTCACCCCAGCTTTTCCATACAAGGCA GTTCGAATATCCCTCCGGCGGTGCAACGGGCAGTCGTTGCATCCTCGTTCTCAAATATCTCCATATCCTAATTC ATGCCCTATAATTCATATATATAGGGCTCTTTCGTCATCTTTTGTCGAATTCTCTTTTTTTCCTCTCCCCCTTCTTT TAATTATCAGTAATCCTCCTCGGG 1 1 1 1 I I I I AAAAGTATTGTCAAACP2 ATCGAAAAGAAGAAGATCCAGAAGGCTAGCCAAAGAAAAAGGACGAGACTTCGAAGACCACCACCAGATTC CGGGGAAGCAAACAGAAGAACAAAAATTAGTGAGAATGCTGTTATCAACTGAAAGAAACAACAAGAGGAGG AATGGAAGAATAGTTCTTTGTCTGGAAGACTTTACGAAGTTCATATTAGAATCGGTGAATGACTCCCATGCCA TCATACAGCGTTGTCTAGTTGTGCGGGACACCCAAGATGACGAAGAGATCAATAAATGGATCGGAAATATTT CCACGAAGATCACCATTTTGGAAACAAACAGTTGAAAAACACCATATAGGAGTAATAGTCTCTAGTAATAATT ATACCCTCAACCTTTGGCCCTCATACTTCGAGTTTTCATTTAAATTAACTGAGACAAGAAAAGACAAAAACGTG CCATCATCTCTCTCTTTTGAATTAGTTTAGCGCTGTTTCAATCAAGTTAGATGTTCTCAACTACCAATAGTCTAT AACAATTTCAAAAAGAGAACCCTAC I I 1 1 CATTGCTCTTACATCATAAAGAAAAAAAATAAACATACTGAACCT TTTAACACTCCGATGGCAAGTTCATCAACTAAAATGCTATTATTCAATCGCTAAGCTACTATATATATATATTTT GACGCTCCATCGATGTGGTGATTGTTGTCCCATCTCTTGTAAGCACTGGATCAGGTACCTTAACAGTAGGTTCC CCATGAAAAACGATATGTACGACATCACAATAGTTGTGGGGTCGTGCTTTTACCGTAGATCGGGTGTCAGTTT CGTGTTAACCAATAAAAAGAGTCCATCCTCGACAAAAAAGGTGGCCTCGGTGTTATGTGCCCGGACACTATTT TTCACTCGATGCTCCTTACTCCCTTGCCAATTAGCGCTCGCTCTTATTTGACAACACCTTTCCTTCTCTCTTTTTCT TCTTCTTACACCAGAATAAGTGATTTAATTATTCGGATCATTACTAGCTP3 2 CAGGTGAACCCACCTAACTATnTTAACTGGGATCCAGTGAGCTCGCTGGGTGAAAGCCAACCATCTTTTGTTT CGGGGAACCGTGCTCGCCCCGTAAAGTTAAI 1 1 1 1 1 I I 1 CCCGCGCAGCTTTAATCTTTCGGCAGAGAAGGCG TTTTCATCGTAGCGTGGGAACAGAATAATCAGTTCATGTGCTATACAGGCACATGGCAGCAGTCACTATTTTG CTTTTTAACCTTAAAGTCGTTCATCAATCATTAACTGACCAATCAGATTTmGCATTTGCCACTTATCTAAAAAT ACI 1 1 I GTATCTCGCAGATACGTTCAGTGGTTTCCAGGACAACACCCAAAAAAAGGTATCAATGCCACTAGGC AGTCGGTTTTAI I 1 1 1 GGTCACCCACGCAAAGAAGCACCCACCTCTTTTAGGTTTTAAGTTGTGGGAACAGTAA CACCGCCTAGAGCTTCAGGAAAAACCAGTACCTGTGACCGCAATTCACCATGATGCAGAATGTTAATTTAAAC GAGTGCCAAATCAAGATTTCAACAGACAAATCAATCGATCCATAGTTACCCATTCCAGCC I l l i CGTCGTCGAG CCTGCTTCATTCCTGCCTCAGGTGCATAACTTTGCATGAAAAGTCCAGATTAGGGCAGATTTTGAGTTTAAAAT AGGAAATATAAACAAATATACCGCGAAAAAGG 1 1 I G I 1 IA IAGCI 1 1 1 CGCCTGGTGCCAGGTGAACCCACCT AACTA! 1 I 1 1 AACTGGGATCCAGTGAGCTCGCTGGGTGAAAGCCAACCATCTTTTGTTTCGGGGAACCGTGCT CGCCCCGTAAAGTTAATTTTTTTTTCCCGCGCAGCTTTAATCTTTCGGCAGAGAAGGCGTTTTCATCGTAGCGT GGGAACAGAATAATCAGTTCATGTGCTATACAGGCACATGGCAGCAGTCACTATTTTGC 1 1 1 1 IAACCTTAAA GTCGTTCATCAATCATTAACTGACCAATCAGAI 1 I 1 I I GCAI 1 I GCCAC I 1 A 1 C 1 AAAAA 1 AC 1 I 1 I G IATCTCGC AGATACGTTCAGTGGTTTCCAGGACAACACCCAAAAAAAGGTATCAATGCCACTAGGCAGTCGGTTTTATTTT TGGTCACCCACGCAAAGAAGCACCCACCTCTTTTAGGTTTTAAGTTGTGGGAACAGTAACACCGCCTAGAGCT TCAGGAAAAACCAGTACCTGTGACCGCAATTCACCATGATGCAGAATGTTAATTTAAACGAGTGCCAAATCAAGATTTCAACAGACAAATCAATCGATCCATAGTTACCCATTCCAGCCTTTTCGTCGTCGAGCCTGCTTCATTCCTGAttorney Docket No. 54282-0011WO1Sequence SEQDescription iDNO. Sequence CCTCAGGTGCATAACTTTGCATGAAAAGTCCAGATTAGGGCAGATTTTGAGTTTAAAATAGGAAATATAAACA AATATACCGCGAAAAAGGTTTGTTTATAGCTTTTCGCCTGGTGCCGTACGGTATAAATACATACTCTCCTCCCC CCCCTGGTTCTC H i l l CTTTTGTTACTTACATTTTACCGTTCCATCACTCGCTTCACTCAACAACAAAA P4 4 CAGGTGAACCCACCTAACTA I 1 1 1 1 AACTGGGATCCAGTGAGCTCGCTGGGTGAAAGCCAACCATCTTTTGTTT CGGGGAACCGTGCTCGCCCCGTAAAGTTAATTTTTTTTTCCCGCGCAGCTTTAATCTTTCGGCAGAGAAGGCG TTTTCATCGTAGCGTGGGAACAGAATAATCAGTTCATGTGCTATACAGGCACATGGCAGCAGTCACTATTTTGC 1 1 1 1 1 AACC 1 1 AAAG 1 CG i 1 CA 1 CAA I CA 1 1 AAC 1 GACCAA 1 CAGA 1 1 1 1 1 1 GCATTTGCCACTTATCTAAAAAT ACTTTTGTATCTCGCAGATACGTTCAGTGGTTTCCAGGACAACACCCAAAAAAAGGTATCAATGCCACTAGGC AGTCGGTTTTA I 1 I 1 1 GGTCACCCACGCAAAGAAGCACCCACCTCTTTTAGGTTTTAAGTTGTGGGAACAGTAA CACCGCCTAGAGCTTCAGGAAAAACCAGTACCTGTGACCGCAATTCACCATGATGCAGAATGTTAATTTAAAC GAGTGCCAAATCAAGATTTCAACAGACAAATCAATCGATCCATAGTTACCCATTCCAGCC I l l i CGTCGTCGAG CCTGCTTCATTCCTGCCTCAGGTGCATAACTTTGCATGAAAAGTCCAGATTAGGGCAGATTTTGAGTTTAAAAT AGGAAATATAAACAAATATACCGCGAAAAAGGTTTGTTTATAGC I 1 1 1 CGCCTGGTGCCGTACGGTACATACT CTCCTCCCCCCCCTGGTTCTCTTTTTCTTTTGTTACTTACATTTTACCGTTCCATCACTCGCTTCACTCAACAACAA AACAGGTGAACCCACCTAACTA I 1 1 I 1 AACTGGGATCCAGTGAGCTCGCTGGGTGAAAGCCAACCATCTTTTG TTTCGGGGAACCGTGCTCGCCCCGTAAAGTTAATTTTTTTTTCCCGCGCAGCTTTAATCTTTCGGCAGAGAAGG CGTTTTCATCGTAGCGTGGGAACAGAATAATCAGTTCATGTGCTATACAGGCACATGGCAGCAGTCACTATTT TGC 1 1 1 1 1 AACC I 1 AAAG 1 CG 1 1 CA 1 CAA 1 CA 1 1 AAC 1 GACCAA 1 CAGA 1 1 1 1 1 1 GCATTTGCCACTTATCTAAAA ATACTTTTGTATCTCGCAGATACGTTCAGTGGTTTCCAGGACAACACCCAAAAAAAGGTATCAATGCCACTAG GCAGTCGGTTTTA 1 1 1 1 1 GGTCACCCACGCAAAGAAGCACCCACCTCTTTTAGGTTTTAAGTTGTGGGAACAGT AACACCGCCTAGAGCTTCAGGAAAAACCAGTACCTGTGACCGCAATTCACCATGATGCAGAATGTTAATTTAA ACGAGTGCCAAATCAAGATTTCAACAGACAAATCAATCGATCCATAGTTACCCATTCCAGCC 1 I I 1 CGTCGTCG AGCCTGCTTCATTCCTGCCTCAGGTGCATAACTTTGCATGAAAAGTCCAGATTAGGGCAGATTTTGAGTTTAAA ATAGGAAATATAAACAAATATACCGCGAAAAAGGTTTGTTTATAGCTTTTCGCCTGGTGCCGTACGGTATAAA TACATACTCTCCTCCCCCCCCTGGTTCTC 1 1 1 1 1 C 1 1 1 1 GTTACTTACATTTTACCGTTCCATCACTCGCTTCACTC AACAACAAAAP5 5 CAGGTGAACCCACCTAACTA I 1 1 1 1 AACTGGGATCCAGTGAGCTCGCTGGGTGAAAGCCAACCATCTTTTGTTT CGGGGAACCGTGCTCGCCCCGTAAAGTTAATTTTTTTTTCCCGCGCAGCTTTAATCTTTCGGCAGAGAAGGCG TTTTCATCGTAGCGTGGGAACAGAATAATCAGTTCATGTGCTATACAGGCACATGGCAGCAGTCACTATTTTG CTTTTTAACCTTAAAGTCGTTCATCAATCATTAACTGACCAATCAGATTTTTTGCATTTGCCACTTATCTAAAAAT ACTTTTGTATCTCGCAGATACGTTCAGTGGTTTCCAGGACAACACCCAAAAAAAGGTATCAATGCCACTAGGC AGTCGGTTTTA 1 1 1 1 1 GGTCACCCACGCAAAGAAGCACCCACCTCTTTTAGGTTTTAAGTTGTGGGAACAGTAA CACCGCCTAGAGCTTCAGGAAAAACCAGTACCTGTGACCGCAATTCACCATGATGCAGAATGTTAATTTAAAC GAGTGCCAAATCAAGATTTCAACAGACAAATCAATCGATCCATAGTTACCCATTCCAGCC I l l i CGTCGTCGAG CCTGCTTCATTCCTGCCTCAGGTGCATAACTTTGCATGAAAAGTCCAGATTAGGGCAGATTTTGAGTTTAAAAT AGGAAATATAAACAAATACAGGTGAACCCACCTAACTA I I 1 1 1 AACTGGGATCCAGTGAGCTCGCTGGGTGAA AGCCAACCATCTTTTGTTTCGGGGAACCGTGCTCGCCCCGTAAAGTTAA 1 1 1 1 1 1 I I 1 CCCGCGCAGCTTTAATC TTTCGGCAGAGAAGGCGTTTTCATCGTAGCGTGGGAACAGAATAATCAGTTCATGTGCTATACAGGCACATG GCAGCAGTCACTATTTTGCTTTTTAACCTTAAAGTCGTTCATCAATCATTAACTGACCAATCAGATTTTTTGCAT TTGCCACTTATCTAAAAATAC 1 1 1 1 GTATCTCGCAGATACGTTCAGTGGTTTCCAGGACAACACCCAAAAAAAG GTATCAATGCCACTAGGCAGTCGGTTTTA I 1 1 I 1 GGTCACCCACGCAAAGAAGCACCCACCTCTTTTAGGTTTT AAGTTGTGGGAACAGTAACACCGCCTAGAGCTTCAGGAAAAACCAGTACCTGTGACCGCAATTCACCATGAT GCAGAATGTTAATTTAAACGAGTGCCAAATCAAGATTTCAACAGACAAATCAATCGATCCATAGTTACCCATTC CAGCCTTTTCGTCGTCGAGCCTGCTTCATTCCTGCCTCAGGTGCATAACTTTGCATGAAAAGTCCAGATTAGGG CAGATTTTGAGTTTAAAATAGGAAATATAAACAAATATACCGCGAAAAAGGTTTGTTTATAGCTTTTCGCCTG GTGCCGTACGGTATAAATACATACTCTCCTCCCCCCCCTGG! I C I C I 1 1 1 1 CTTTTGTTACTTACATTTTACCGTTCCATCACTCGCTTCACTCAACAACAAAAAttorney Docket No. 54282-0011WO1Sequence SEQDescription iDNO. SequenceP6 6 CAGGTGAACCCACCTAACTATTTTTAACTGGGATCCAGTGAGCTCGCTGGGTGAAAGCCAACCATCTTTTGTTT CGGGGAACCGTGCTCGCCCCGTAAAGTTAATTTTTTTTTCCCGCGCAGCTTTAATCTTTCGGCAGAGAAGGCG TTTTCATCGTAGCGTGGGAACAGAATAATCAGTTCATGTGCTATACAGGCACATGGCAGCAGTCACTATTTTGL 1 1 1 1 1 AALL 1 1 AAAG 1 LG i 1 LA 1 LAA 1 LA 1 1 AAL 1 GALCAA 1 LAGA 1 1 1 1 1 1 GCATTTGCCACTTATCTAAAAAT ACTTTTGTATCTCGCAGATACGTTCAGTGGTTTCCAGGACAACACCCAAAAAAAGGTATCAATGCCACTAGGC AGTCGGTTTTATTTTTGGTCACCCACGCAAAGAAGCACCCACCTCTTTTAGGTTTTAAGTTGTGGGAACAGTAA CACCGCCTAGAGCTTCAGGAAAAACCAGTACCTGTGACCGCAATTCACCATGATGCAGAATGTTAATTTAAAC GAGTGCCAAATCAAGATTTCAACAGACAAATCAATCGATCCATAGTTACCCATTCCAGCC I l l i CGTCGTCGAG CCTGCTTCATTCCTGCCTCAGGTGCATAACTTTGCATGAAAAGTCCAGATTAGGGCAGATTTTGAGTTTAAAAT AGGAAATATAAACAAATATACCGCGAAAAAGGTTTGTTCAGGTGAACCCACCTAACTA I 1 1 1 1 AACTGGGATC CAGTGAGCTCGCTGGGTGAAAGCCAACCATCTTTTGTTTCGGGGAACCGTGCTCGCCCCGTAAAGTTAATTTTH i l l CCCGCGCAGCTTTAATCTTTCGGCAGAGAAGGCGTTTTCATCGTAGCGTGGGAACAGAATAATCAGTT CATGTGCTATACAGGCACATGGCAGCAGTCACTATTTTGC I 1 I 1 1 AACCTTAAAGTCGTTCATCAATCATTAACT GACCAATCAGATTTTTTGCATTTGCCACTTATCTAAAAATACTTTTCTATCTCGCAGATACGTTCAGTGGTTTCC AGGACAACACCCAAAAAAAGGTATCAATGCCACTAGGCAGTCGG 1 1 I I A l 1 1 1 1 GGTCACCCACGCAAAGAAG CACCCACCTCTTTTAGGTTTTAAGTTGTGGGAACAGTAACACCGCCTAGAGCTTCAGGAAAAACCAGTACCTG TGACCGCAATTCACCATGATGCAGAATGTTAATTTAAACGAGTGCCAAATCAAGATTTCAACAGACAAATCAA TCGATCCATAGTTACCCATTCCAGCC 1 1 1 1 CGTCGTCGAGCCTGCTTCATTCCTGCCTCAGGTGCATAACTTTGC ATGAAAAGTCCAGATTAGGGCAGATTTTGAGTTTAAAATAGGAAATATAAACAAATATACCGCGAAAAAGGT TTGTTTATAGCTTrTCGCCTGGTGCCGTACGGTATAAATACATACTCTCCTCCCCCCCCTGGTTCTCTTrfTCTTT TGTTACTTACATTTTACCGTTCCATCACTCGCTTCACTCAACAACAAAAP7 7 CAGGTGAACCCACCTAACTAI 1 1 1 1 AACTGGGATCCAGTGAGCTCGCTGGGTGAAAGCCAACCATCTTTTGTTT CGGGGAACCGTGCTCGCCCCGTAAAGTTAATTTTTTTTTCCCGCGCAGCTTTAATCTTTCGGCAGAGAAGGCG TTTTCATCGTAGCGTGGGAACAGAATAATCAGTTCATGTGCTATACAGGCACATGGCAGCAGTCACTATTTTGL 1 I I I I AALL 1 1 AAAG 1 LG I I LA 1 LAA 1 LA 1 1 AAL 1 GALCAA 1 LAGA 1 1 1 1 1 1 GCATTTGCCACTTATCTAAAAAT ACTTTTGTATCTCGCAGATACGTTCAGTGGTTTCCAGGACAACACCCAAAAAAAGGTATCAATGCCACTAGGC AGTCGGTTTTATTTTTGGTCACCCACGCAAAGAAGCACCCACCTCTTTTAGGTTTTAAGTTGTGGGAACAGTAA CACCGCCTAGAGCTTCAGGAAAAACCAGTACCTGTGACCGCAATTCACCATGATGCAGAATGTTAATTTAAAC GAGTGCCAAATCAAGATTTCAACAGACAAATCAATCGATCCATAGTTACCCATTCCAGCC I l l i CGTCGTCGAG CCTGCTTCATTCCTGCCTCAGGTGCATAACTTTGCATGAAAAGTCCAGATTAGGGCAGATTTTGAGTTTAAAAT AGGAAATATAAACAAATATACCGCGAAAAAGGTTTGTTTATAGCI 1 1 1 CGCCTGGTGCCGTACGGTATAAATA CATACTCTCCTCCCCCCCCTGGTTCTC 1 1 1 1 1 CTTTTGTTACTTACATTTTACCGTTCCATCACTCGCTTCACTCAA CAACAAAAP8 8 CAGGTGAACCCACCTAACTAI 1 1 1 1 AACTGGGATCCAGTGAGCTCGCTGGGTGAAAGCCAACCATCTTTTGTTT CGGGGAACCGTGCTCGCCCCGTAAAGTTAATTTTTTTTTCCCGCGCAGCTTTAATCTTTCGGCAGAGAAGGCG TTTTCATCGTAGCGTGGGAACAGAATAATCAGTTCATGTGCTATACAGGCACATGGCAGCAGTCACTATTTTGL 1 1 1 I I AALL 1 1 AAAG 1 LG 1 1 LA 1 LAA 1 LA 1 1 AAL 1 GALLAA 1 LAGA 1 1 1 1 1 1 GCATTTGCCACTTATCTAAAAAT ACI I 1 I GTATCTCGCAGATACGTTCAGTGGTTTCCAGGACAACACCCAAAAAAAGGTATCAATGCCACTAGGC AGTCGGTTTTAI 1 1 1 1 GGTCACCCACGCAAAGAAGCACCCACCTCTTTTAGGTTTTAAGTTGTGGGAACAGTAA CACCGCCTAGAGCTTCAGGAAAAACCAGTACCTGTGACCGCAATTCACCATGATGCAGAATGTTAATTTAAAC GAGTGCCAAATCAAGATTTCAACAGACAAATCAATCGATCCATAGTTACCCATTCCAGCC I l l i CGTCGTCGAG CCTGCTTCATTCCTGCCTCAGGTGCATAACTTTGCATGAAAAGTCCAGATTAGGGCAGATTTTGAGTTTAAAAT AGGAAATATAAACAAATATACCGCGAAAAAGGTTTGTTTATAGCI 1 1 I CGCCTGGTGCCGTACGGTATAAATA CATACCAGGTGAACCCACCTAACTA 1 1 I 1 I AACTGGGATCCAGTGAGCTCGCTGGGTGAAAGCCAACCATCTT TTGTTTCGGGGAACCGTGCTCGCCCCGTAAAGTTAATTTTTTTTTCCCGCGCAGCTTTAATCTTTCGGCAGAGA AGGCGTTTTCATCGTAGCGTGGGAACAGAATAATCAGTTCATGTGCTATACAGGCACATGGCAGCAGTCACTA TTTTGC 1 1 1 1 1 AACC 1 1 AAAG 1 CG I 1 CA 1 CAA 1 CA 1 1 AAC 1 GALCAA I CAGA 1 1 1 1 1 1 GCATTTGCCACTTATCTAAAAATAC 1 1 1 1 G 1 ATCTCGCAGATACGTTCAGTGGTTTCCAGGACAACACCCAAAAAAAGGTATCAATGCCACAttorney Docket No. 54282-0011WO1Sequence SEQDescription iDNO. Sequence TAGGCAGTCGGTTTTATrfTTGGTCACCCACGCAAAGAAGCACCCACCTCTTTTAGGTTTTAAGTTGTGGGAAC AGTAACACCGCCTAGAGCTTCAGGAAAAACCAGTACCTGTGACCGCAATTCACCATGATGCAGAATGTTAATT TAAACGAGTGCCAAATCAAGATTTCAACAGACAAATCAATCGATCCATAGTTACCCATTCCAGCCTTTTCGTCG TCGAGCCTGCTTCATTCCTGCCTCAGGTGCATAACTTTGCATGAAAAGTCCAGATTAGGGCAGATTTTGAGTTT AAAATAGGAAATATAAACAAATATACCGCGAAAAAGGTTTGTTTATAGCTTTTCGCCTGGTGCCGTACGGTAT AAATACATACTCTCCTCCCCCCCCTGGTTCTC 1!! i I CTTTTGTTACTTACATTTTACCGTTCCATCACTCGCTTCA CTCAACAACAAAAP9 9 CAGGTGAACCCACCTAACTATrfTTAACTGGGATCCAGTGAGCTCGCTGGGTGAAAGCCAACCATCTTTTGTTT CGGGGAACCGTGCTCGCCCCGTAAAGTTAATTTTTTTTTCCCGCGCAGCTTTAATCTTTCGGCAGAGAAGGCG TTTTCATCGTAGCGTGGGAACAGAATAATCAGTTCATGTGCTATACAGGCACATGGCAGCAGTCACTATTTTGU 1 1 1 1 AALL 1 1 AAAG 1 LG 1 i LA 1 CAA 1 LA 1 1 AAL 1 GALCAA 1 CAGA 1 1 1 1 1 1 GCATTTGCCACTTATCTAAAAAT ACI I I I GTATCTCGCAGATACGTTCAGTGGTTTCCAGGACAACACCCAAAAAAAGGTATCAATGCCACTAGGC AGTCGGTTTTA! 1 i 1 1 GGTCACCCACGCAAAGAAGCACCCACCTCTTTTAGGTTTTAAGTTGTGGGAACAGTAA CACCGCCTAGAGCTTCAGGAAAAACCAGTACCTGTGACCGCAATTCACCATGATGCAGAATGTTAATTTAAAC GAGTGCCAAATCAAGATTTCAACAGACAAATCAATCGATCCATAGTTACCCATTCCAGCL I l l i CGTCGTCGAG CCTGCTTCATTCCTGCCTCAGGTGCATAACTTTGCATGAAAAGTCCAGATTAGGGCAGATTTTGAGTTTAAAAT AGGAAATATAAACAAATATACCGCGAAAAAGGTTTGTTTATAGU 1 1 I CGCCTGGTGCCGTACGGTATAAATA CATACTCTCCTCCCCCCCCTGGTTCTC I I 1 1 1 CTTTTGTTACTTACATTTTACCGTTCCGTCACTCGCTTCACTCAA CAACAAAA PIO 10 CAGGTGAACCCACCTAACTATTTTTAACTGGGATCCAGTGAGCTCGCTGGGTGAAAGCCAACCATCTTTTGTTT CGGGGAACCGTGCTCGCCCCGTAAAGTTAATTTTTTTTTCCCGCGCAGCTTTAATCTTTCGGCAGAGAAGGCG TTTTCATCGTAGCGTGGGAACAGAATAATCAGTTCATGTGCTATACAGGCACATGGCAGCAGTCACTATTTTGL 1 I I I I AALL 1 1 AAAG 1 LG I I LA 1 LAA 1 LA 1 1 AAL 1 GALLAA 1 LAGA 1 1 1 1 1 1 GCATTTGCCACTTATCTAAAAAT ACTTTTGTATCTCGCAGATACGTTCAGTGGTTTCCAGGACAACACCCAAAAAAAGGTATCAATGCCACTAGGC AGTCGGTTTTATTTTTGGTCACCCACGCAAAGAAGCACCCACCTCTTTTAGGTTTTAAGTTGTGGGAACAGTAA CACCGCCTAGAGCTTCAGGAAAAACCAGTACCTGTGACCGCAATTCACCATGATGCAGAATGTTAATTTAAAC GAGTGCCAAATCAAGATTTCAACAGACAAATCAATCGATCCATAGTTACCCATTCCAGCC I l l i CGTCGTCGAG CCTGCTTCATTCCTGCCTCAGGTGCATAACTTTGCATGAAAAGTCCAGATTAGGGCAGATTTTGAGTTTAAAAT AGGAAATATAAACAAATATACCGCGAAAAAGGTTTGTTTATAGLI 1 1 1 CGCCTGGTGCCGTACGGTATAAATA CATACTCTCCTCCCCCCCCTGGTTCCAGGTGAACCCACCTAACTATTTTTAACTGGGATCCAGTGAGCTCGCTG GGTGAAAGCCAACCATCTTTTGTTTCGGGGAACCGTGCTCGCCCCGTAAAGTTAATTTTTTTTTCCCGCGCAGC TTTAATCTTTCGGCAGAGAAGGCGTTTTCATCGTAGCGTGGGAACAGAATAATCAGTTCATGTGCTATACAGG CACATGGCAGCAGTCACTATTTTGC 1 1 1 I 1 AACCTTAAAGTCGTTCATCAATCATTAACTGACCAATCAGATTTT TTGCATTTGCCACTTATCTAAAAATACTTTTGTATCTCGCAGATACGTTCAGTGGTTTCCAGGACAACACCCAA AAAAAGGTATCAATGCCACTAGGCAGTCGGTTTTA H i l l GGTCACCCACGCAAAGAAGCACCCACCTCTTTTA GGTTTTAAGTTGTGGGAACAGTAACACCGCCTAGAGCTTCAGGAAAAACCAGTACCTGTGACCGCAATTCACC ATGATGCAGAATGTTAATTTAAACGAGTGCCAAATCAAGATTTCAACAGACAAATCAATCGATCCATAGTTAC CCATTCCAGCCTTTTCGTCGTCGAGCCTGCTTCATTCCTGCCTCAGGTGCATAACTTTGCATGAAAAGTCCAGA TTAGGGCAGATTTTGAGTTTAAAATAGGAAATATAAACAAATATACCGCGAAAAAGGTTTGTTTATAGCTTTT CGCCTGGTGCCGTACGGTATAAATACATACTCTCCTCCCCCCCCTGGTTCTC 1 1 1 1 1 CTTTTGTTACTTACATTTT ACCGTTCCATCACTCGCTTCACTCAACAACAAAAPll 11 CAGGTGAACCCACCTAACTAI 1 1 1 1 AACTGGGATCCAGTGAGCTCGCTGGGTGAAAGCCAACCATCTTTTGTTT CGGGGAACCGTGCTCGCCCCGTAAAGTTAATTTTTTTTTCCCGCGCAGCTTTAATCTTTCGGCAGAGAAGGCG TTTTCATCGTAGCGTGGGAACAGAATAATCAGTTCATGTGCTATACAGGCACATGGCAGCAGTCACTATTTTG CTTTTTAACCTTAAAGTCGTTCATCAATCATTAACTGACCAATCAGATTTTTTGCATTTGCCACTTATCTAAAAAT ACTTTTGTATCTCGCAGATACGTTCAGTGGTTTCCAGGACAACACCCAAAAAAAGGTATCAATGCCACTAGGCAGTCGGTTTTA 1 I 1 1 1 GGTCACCCACGCAAAGAAGCACCCACCTCTTTTAGGTTTTAAGTTGTGGGAACAGTAAAttorney Docket No. 54282-0011WO1Sequence SEQDescription iDNO. Sequence CACCGCCTAGAGCTTCAGGAAAAACCAGTACCTGTGACCGCAATTCACCATGATGCAGAATGTTAATTTAAAC GAGTGCCAAATCAAGATTTCAACAGACAAATCAATCGATCCATAGTTACCCATTCCAGCC I l l i CGTCGTCGAG CCTGCTTCATTCCTGCCTCAGGTGCATAACTTTGCATGAAAAGTCCAGATTAGGGCAGATTTTGAGTTTAAAAT AGGAAATATAAACAAATATACCGCGAAAAAGGTTTGTTTATAGCTTTTCGCCTGGTGCCGTACGGTATAAATA CATACTCTCCTCCCCCCCCTGGTTCTC I 1 1 1 1 C I 1 1 1 G I 1 AC 1 I ACAGG 1 GAACCCACC 1 AAC 1 A 1 1 1 1 1 AACTGG GATCCAGTGAGCTCGCTGGGTGAAAGCCAACCATCTTTTGTTTCGGGGAACCGTGCTCGCCCCGTAAAGTTAA I I 1 1 1 1 1 1 1 CCCGCGCAGCTTTAATCTTTCGGCAGAGAAGGCGTTTTCATCGTAGCGTGGGAACAGAATAATCA GTTCATGTGCTATACAGGCACATGGCAGCAGTCACTATTTTGC 1 1 1 1 1 AACCTTAAAGTCGTTCATCAATCATTA ACTGACCAATCAGATTTTTTGCATTTGCCACTTATCTAAAAATACTTTTGTATCTCGCAGATACGTTCAGTGGTT TCCAGGACAACACCCAAAAAAAGGTATCAATGCCACTAGGCAGTCGGTTTTA I 1 1 1 1 GGTCACCCACGCAAAG AAGCACCCACCTCTTTTAGGTTTTAAGTTGTGGGAACAGTAACACCGCCTAGAGCTTCAGGAAAAACCAGTAC CTGTGACCGCAATTCACCATGATGCAGAATGTTAATTTAAACGAGTGCCAAATCAAGATTTCAACAGACAAAT CAATCGATCCATAGTTACCCATTCCAGCCTTTTCGTCGTCGAGCCTGCTTCATTCCTGCCTCAGGTGCATAACTT TGCATGAAAAGTCCAGATTAGGGCAGATTTTGAGTTTAAAATAGGAAATATAAACAAATATACCGCGAAAAA GG 1 1 1 G 1 1 1 A 1 AGC M i l CGCC 1 GG 1 GCCG 1 ACGG 1 A 1 AAA 1 ACA 1 AC 1 C 1 CC 1 CCCCCCCC 1 GG 1 1 C 1 C 1 1 1 I I C TTTTGTTACTTACATTTTACCGTTCCATCACTCGCTTCACTCAACAACAAAAP12 12 CAGGTGAACCCACCTAACTA I 1 1 1 1 AACTGGGATCCAGTGAGCTCGCTGGGTGAAAGCCAACCATCTTTTGTTT CGGGGAACCGTGCTCGCCCCGTAAAGTTAATTTTTTTTTCCCGCGCAGCTTTAATCTTTCGGCAGAGAAGGCG TTTTCATCGTAGCGTGGGAACAGAATAATCAGTTCATGTGCTATACAGGCACATGGCAGCAGTCACTATTTTGC 1 1 I 1 I AACC 1 1 AAAG 1 CG I 1 CA 1 CAA 1 CA 1 1 AAC 1 GACCAA I CAGA 1 1 1 1 1 1 GCATTTGCCACTTATCTAAAAAT ACTTTTGTATCTCGCAGATACGTTCAGTGGTTTCCAGGACAACACCCAAAAAAAGGTATCAATGCCACTAGGC AGTCGGTTTTA 1 1 1 1 1 GGTCACCCACGCAAAGAAGCACCCACCTCTTTTAGGTTTTAAGTTGTGGGAACAGTAA CACCGCCTAGAGCTTCAGGAAAAACCAGTACCTGTGACCGCAATTCACCATGATGCAGAATGTTAATTTAAAC GAGTGCCAAATCAAGATTTCAACAGACAAATCAATCGATCCATAGTTACCCATTCCAGCC I l l i CGTCGTCGAG CCTGCTTCATTCCTGCCTCAGGTGCATAACTTTGCATGAAAAGTCCAGATTAGGGCAGATTTTGAGTTTAAAAT AGGAAATATAAACAAATATACCGCGAAAAAGGTTTGTTTATAGCTTTTCGCCTGGTGCCGTACGGTATAAATA CATACTCTCCTCCCCCCCCTGGTTCTC 1 1 1 1 1 CTTTTGTTACTTACATTTTACCGTTCCATCACTCAGGTGAACCCA CCTAACTA I 1 1 1 1 AACTGGGATCCAGTGAGCTCGCTGGGTGAAAGCCAACCATCTTTTGTTTCGGGGAACCGT GCTCGCCCCGTAAAGTTAATTTTTTTTTCCCGCGCAGCTTTAATCTTTCGGCAGAGAAGGCGTTTTCATCGTAG CGTGGGAACAGAATAATCAGTTCATGTGCTATACAGGCACATGGCAGCAGTCACTATTTTGCI 1 1 1 I AACCTTA AAGTCGTTCATCAATCATTAACTGACCAATCAGATTTTTTGCATTTGCCACTTATCTAAAAATACTTTTGTATCTC GCAGATACGTTCAGTGGTTTCCAGGACAACACCCAAAAAAAGGTATCAATGCCACTAGGCAGTCGGTTTTATT TTTGGTCACCCACGCAAAGAAGCACCCACCTUTTTTAGGTTTTAAGTTGTGGGAACAGTAACACCGCCTAGAG CTTCAGGAAAAACCAGTACCTGTGACCGCAATTCACCATGATGCAGAATGTTAATTTAAACGAGTGCCAAATC AAGATTTCAACAGACAAATCAATCGATCCATAGTTACCCATTCCAGCCTTTTCGTCGTCGAGCCTGCTTCATTCC TGCCTCAGGTGCATAACTTTGCATGAAAAGTCCAGATTAGGGCAGATTTTGAGTTTAAAATAGGAAATATAAA CAAATATACCGCGAAAAAGGTTTGTTTATAGCTTTTCGCCTGGTGCCGTACGGTATAAATACATACTCTCCTCC CCCCCCTGGTTCTCTTTTTCTTTrGTTACTTACATTTTACCGTTCCATCACTCGCTTCACTCAACAACAAAA P13 13 CAGGTGAACCCACCTAACTATnTTAACTGGGATCCAGTGAGCTCGCTGGGTGAAAGCCAACCATCTTTTGTTT CGGGGAACCGTGCTCGCCCCGTAAAGTTAA I 1 1 1 1 1 M 1 CCCGCGCAGCTTTAATCTTTCGGCAGAGAAGGCG TTTTCATCGTAGCGTGGGAACAGAATAATCAGTTCATGTGCTATACAGGCACATGGCAGCAGTCACTATTTTG CTTTTTAACCTTAAAGTCGTTCATCAATCATTAACTGACCAATCAGATTTTTTGCATTTGCCACTTATCTAAAAAT AC I I 1 I GTATCTCGCAGATACGTTCAGTGGTTTCCAGGACAACACCCAAAAAAAGGTATCAATGCCACTAGGC AGTCGGTTTTA 1 I 1 1 1 GGTCACCCACGCAAAGAAGCACCCACCTCTTTTAGGTTTTAAGTTGTGGGAACAGTAA CACCGCCTAGAGCTTCAGGAAAAACCAGTACCTGTGACCGCAATTCACCATGATGCAGAATGTTAATTTAAAC GAGTGCCAAATCAAGATTTCAACAGACAAATCAATCGATCCATAGTTACCCATTCCAGCC M i l CGTCGTCGAG CCTGCTTCATTCCTGCCTCAGGTGCATAACTTTGCATGAAAAGTCCAGATTAGGGCAGATTTTGAGTTTAAAATAGGAAATATAAACAAATATACCGCGAAAAAGG 1 1 I G M I A I AGC I 1 1 1 CGCCTGGTGCCGTACGGTATAAATAAttorney Docket No. 54282-0011WO1Sequence SEQDescription iDNO. Sequence CATACTCTCCTCCCCCCCCTGGTrCTCTTnTCTTTTGTTACTTACATrTTACCGTTCCATCACTCGCTTCACTCAA CAACAAAACAGGTGAACCCACCTAACTAI 1 1 1 1 AACTGGGATCCAGTGAGCTCGCTGGGTGAAAGCCAACCAT CTTTTGTTTCGGGGAACCGTGCTCGCCCCGTAAAGTTAATTTTTTTTTCCCGCGCAGCTTTAATCTTTCGGCAGA GAAGGCGTTTTCATCGTAGCGTGGGAACAGAATAATCAGTTCATGTGCTATACAGGCACATGGCAGCAGTCA CTATTTTGC 1 1 1 1 1 AACC I 1 AAAG 1 CG 1 1 CA 1 CAA 1 CA 1 1 AAC 1 GACCAA 1 CAGA 1 1 1 1 1 1 GCATTTGCCACTTAT CTAAAAATACTTTTGTATCTCGCAGATACGTTCAGTGGTTTCCAGGACAACACCCAAAAAAAGGTATCAATGC CACTAGGCAGTCGG 1 i 1 I A I 1 1 1 1 GGTCACCCACGCAAAGAAGCACCCACCTCTTTTAGGTTTTAAGTTGTGGG AACAGTAACACCGCCTAGAGCTTCAGGAAAAACCAGTACCTGTGACCGCAATTCACCATGATGCAGAATGTTA ATTTAAACGAGTGCCAAATCAAGATTTCAACAGACAAATCAATCGATCCATAGTTACCCATTCCAGCCI 1 I! CG TCGTCGAGCCTGCTTCATTCCTGCCTCAGGTGCATAACTTTGCATGAAAAGTCCAGATTAGGGCAGATTTTGA GTTTAAAATAGGAAATATAAACAAATATACCGCGAAAAAGGTTTGTTTATAGCTTTTCGCCTGGTGCCGTACG GTATAAATACATACTCTCCTCCCCCCCCTGGTTCTC 1!!!! CTTTTGTTACTTACATTTTACCGTTCCATCACTCGC TTCACTCAACAACAAAAP14 14 CATATTCAAATACCAAGCAAATAAACGCAAAGAGCAACATATTAGGATAAACCAACAGGTTAAGTATAGAGC TAAAGCATTGCTGAGCAATATTTCGGATCAACATCAACAGAATAGATCGTCACCACGAAGTATATCCAACTAT TCCCCAAGAATCCAGGCTTATCCCTCAAGAATGGCCTCTCCATCTCCTTCAATGAAGATGGCATTGACAAACTC CGTCAGCTTGCAGGATACAATGGATGCGGAACTAGAAGCGTTGGCAAACGAACAATATTACGTCATGCTAGA TATCCTTAAGGGATTTTGCGATCTTTCATTTGACATGGTAAACATATTTTCTATCCAGATCCCTGAGGTATTACA TCTCCTCTTCGGCTTTGGTGCAGGGTCACTGGCCTTAACGGGAGTCGTATCCAAAACGAGACAAGAACTAATA AATAAACAGATATAAGGGACAAGCACACGATTACCCAATCACTTGATATGCACCAATTTGTTCCGTTGTTTATG CCATATTTACCGAATTTTCTTCCCAGGTTTTTCCGAATGGACATCTGTAGTCCACTTTTTGGTTATCATAATCGTC CCACAAGTCGTGGATTTAACCAGAACCTAGTAATTTTAAGTTCGCTATTAATCACTCAGAATGGTCTCACCTTG CTATTGGCCAAGTCTGGAGTCGCCAGCTACCACCTCAGAGGCTACATAGACCTCCCAATGTCATCTCCTCAGT GCGCTCTTCAATCTCGTGTCTTTTCCGTTAAAACTCCGTTCGTTTCACCCTATACTGCCCCTGGTTGTGCAGCTC TTACCACTTCGCGCCGCTACTATCCGTAGTGGTCGAGCCGCATCAATATCACGTTGAAATAGAATAACTCCCTA CAAAAGCCGCACGCAACCATCAAATCTATATAAGGAACCTCAAATATCTAGCAACATCTTTTCAATTTACTACA ACATATTCGTTAATCATCAATCAATTAGCTAGTACACAACAP15 15 CTACATCGGAACCAATTTTGAATTCGCCGATACGAAACCGGACATCAAGTTCCATCATCATGCAAGATGATCA TCAGGAAGAGCCGTGGTCAGTCAACACTGCAAGTGTCAAAGAGACATCAATTATTGACATTAGTACCCCGGA TGAGGCTTACAATGCTCGCGGGAAAGACGATGCGATACGGGTTGATTCGGAGGGCCCTTCAAAAAGAACAA CTATTCTCAGCCGTCTGATGGAGACACAAGATTCGGACAATGACGGAACGGAGTCTGACGTAGGGGAGAGTT CTAGTCTGATAATTCTTAGTTGACCAGCCTTGCATCGGGTTGAACAAACTTTTGTGGGTTGGGCCACTTTGCGC CAACAACACAAGGTTTTCACACCACCCGGTTGTCATTACCGCCCGGAAAACTCAATGATTGACGGAGCGTAGG TTCACGGAAGTCAAGTTAGAGTAGTCGGAGAGTTTCGGGTGATAAGAATTTCCCGGGTGCTTTGGAGTGCCA AAGTGACTGAATCAGGAACTAAAAACCCGGGCTAACGGCTGAAGGCCTGTGTTCAGTGCACTATATTGTATTC TAGTCTGGGGTAGGTTGAAGTTTGGTGGATTCACGACTCCGGAGTGATGGAGGGACAATACCGAAGATGAG GTCTTGCGAGTGGAAAGATAGGTTAAGAATAATTAATAACATTGTATGAAACAAGATGGGGAGACAATTTTA GCTATCGATCCGTTATCATTGGTCGAATGATGACTTGGAACCTTATTTGCACTTTTTTTGTCAGGTGTTCGCCG AAACTTAAAGATAGTTTTATTGATGTGTGCCAAAAATGTGGGGACAAAAGGTCCTCCACCCGCCATCCCCCGG TCTCATACAAAAAAAAAGAAAAATACCTCTACTAGTCCGGGGTCAAGGCAAGTCATGATAGGCATATAAATA GGGGCAGGCTGGCCGCCATTACGAATTAGATTAACCTTCTCATAGATTATTATCCACAP16 16 GAAGGTGGAAATGGCAGAAGGATCAGCCTGGACGAAGCAACCAGTTCCAACTGCTAAGTAAAGAAGATGCT AGACGAAGGAGACTTCAGAGGTGAAAAGTTTGCAAGAAGAGAGCTGCGGGAAATAAATTTTCAATTTAAGG ACTTGAGTGCGTCCATATTCGTGTACGTGTCCAACTGTTTTCCATTACCTAAGAAAAACATAAAGATTAAAAAG ATAAACCCAATCGGGAAACTTTAGCGTGCCGTTTCGGATTCCGAAAAACI 1 1 1 GGAGCGCCAGATGACTATGG AAAGAGGAGTGTACCAAAATGGCAAGTCGGGGGCTACTCACCGGATAGCCAATACATTCTCTAGGAACCAGGGATGAATCCAGG 1 1 1 1 1 GTTGTCACGGTAGGTCAAGCATTCACTTCTTAGGAATATCTCGTTGAAAGCTACTTGAttorney Docket No. 54282-0011WO1Sequence SEQDescription IDNO. Sequence AAATCCCATTGGGTGCGGAACCAGCTTCTAATTAAATAGTTCGATGATGTTCTCTAAGTGGGACTCTACGGCT CAAACTTCTACACAGCATCATCTTAGTAGTCCCTTCCCAAAACACCATTCTAGGTTTCGGAACGTAACGAAACA ATGTTCCTCTCTTCACATTGGGCCGTTACTCTAGCCTTCCGAAGAACCAATAAAAGGGACCGGCTGAAACGGG TGTGGAAACTCCTGTCCAGTTTATGGCAAAGGCTACAGAAATCCCAATCTTGTCGGGATGTTGCTCCTCCCAA ACGCCATATTGTACTGCAGTTGGTGCGCATTTTAGGGAAAATTTACCCCAGATGTCCTGATTTTCGAGGGCTA CCCCCAACTCCCTGTGCTTATACTTAGTCTAATTCTATTCAGTGTGCTGACCTACACGTAATGATGTCGTAACCC AGTTAAATGGCCGAAAAACTATTTAAGTAAGTTTA 1 1 1 C i GG 1 CLAGA 1 GAGAC 1 G 1 GG 1 i G 1 1 i i G 1 CCGCTAG TTATCAAACTATAAACCTATTTTACCTCAAATACCTCCAACATCACCCACTTAAACAP17 17 GATAGTGTAAGTCAGGTGCATACTCACGTGAAAATCATGGAAAAGGCAGTCGATGTCGGAGGTACTGTTAAA AGGGAAGGAAACCTGCTGGAACACACTCTCATCCTCAATGGGAGCTGGAGTGAGGCGCAGCAGTCAATCGTC TGGCCATCGCCCAAAAGAAATACTCACATACCCACATAGAACCAGTCCAGAATACTGGGGTGTGTAGGTTCCA TTTCATTCTGACTCATCTTCGTCTTGTTGTCI Cl 1 CCGAACATGCGAAGGAAATCTGTACATAAAAATCCTTACA TCAGATTAAGAACAACCTGCGATCACGGGTTGTGTCCCCGGAGTTATGGCGACTTAGGCGGTGAAATCTGGT GGATTGGAAAGAAACCTACGCACTATCGGGTACACAGGAGAATCGGGAAAATGTCACCTGCTTATCCTTACT ACAATTGCATGTGGGGTGATTCTGAAACCTTAGCATAATTTGTAGGCATTCTGGGAAAGATATTTTGCGCCGG CCTTACTAGTATTGTTGAAGTGACACCAAGCAAACCGCTCTAAAAAATCTGTGAACACTGCTTAGCCATCAACA CTAACACTTGGTGGTTATTCTATGACTCATTTAAAGTCGGGGTGTTGGGGTGATTGGAAGATTCCAGAATTAA CCAGGGCCGGGATGTCTTCTCGGGGTGTCACTTTTGATTGTTTGTGTTTTTGGTGGGGGTGAGTTAGGACGTT CGGCAAAAAAATAAAATTCTACGCCAAATTGGGTAATTCGAGACCCTATCAGCCACCAAAACACAGCAATATG TGGGACCGATAGGGGGTGCAATCTGTTTCGCTAATGACGTACTTCCCGGGTGTCCAGATATCGAACACCCTCA CGCACATTCGGATGATGAGAAAATGAGCTAACCCCAGATTTCTTCGAATTTAGTACTTAAGAATACGATAACC CCCGCAATTGACCTTCCCTA 1 1 1 1 1 ACACATCTTATCACACCAAAATTACAAP18 18 GGGTGAAAGCCAACCATCTTTGTTTCGGGGAACCGTGCTCGCCCCGTAAAGTTAA 1 1 1 I I I I 1 i CCCGCGCAGC TTTAATCTTTCGGCAGAGAAGGCGTTTTCATCGTAGCGTGGGAACAGAATAATCAGTTCATGTGCTATACAGG CACATGGCAGCAGTCACTATTTTGCTTTTTAACCTTAAAGTCGTTCATCAATCATTAACTGACCAATCAGATTTT TTGCATTTGCCACTTATCTAAAAATACTTTTCTATCTCGCAGATACGTTCAGTGGTTTCCAGGACAACACCCAA AAAAAGGTATCAATGCCACTAGGCAGTCGGTTTTA I 1! 1! GGTCACCCACCCAAAGAAGCACCCACCTCTTTTA GGTTTTAAGTTGTGGGAACAGTAACACCGCCTAGAGCTTCAGGAAAAACCAGTACCTGTGACCGCAATTCACC ATGATGCAGAATGTTAATTTAAACGAGTGCCAAATCAAGATTTCAACAGACAAATCAATCGATCCATAGTTAC CCATTCCAGCCTTTTCGTCGTCGAGCCTGCTTCATTCCTGCCTCAGGTGCATAACTTTGCATGAAAAGTCCAGA TTAGGGCAGATTTTGAGTTTAAAATAGGAAATATAAACAAATATACCGCGAAAAAGGTTTGTTTATAGCTTTT CGCCTGGTGCCGTACGGTATAAATACATACTCTCCTCCCCCCCCTGGTTCTC 1 1 1 1 1 CTTTTGTTACTTACATTTT ACCGTTCCGTCACTCGCTTCACTCAACAACAAAAP19 19 GTAGTTGTTTTCAGCAGATCCAGGGAGGGCATCGTTGAGGTTTCCTCAAAGGGAAGAAACATGGATCCGGCG ACATCAACAGACAGAGAAGCGGGTAGTGAATCCGAAGCCACAACACAGCCCGATTTGGAAGGGAGCCCACC ATCAAAATAAGTTCCAGCCA M H i l l l C l i l i l C l i C I H I i l i l l l l l GGTCAATTGAGTCAGACCCACCTAACT A! 1 1 1 1 AAAATGGATCCGGTAATCTCGCAAGGAAGAGACTAACCATCTTTCGTTTCGGGGAACCGTGTGCTCG CCCCATCTTGCTAATTnTTTCCCGCGCAGCAGAAGAGGCGTTTTCATCGTATCGTGGTAACAGAATGGTCAGT TGATGTGCCGTACAGGCACATGGCAGCAGTCACTATTTATTTTTTTAACCTTAAAGTCGTCCATTAATCATTACC TGACCAATCAGATTTTCTGTATTTGCCACTTATCTAAAAATACTTTTGTATCTCGCAGATACGGTTCAATGGTTT CCAGGACAACGCCAGAAAAAAGAAGTATCAATGCCACCAGGCAAGTCGGTTTTATGTTTGGTAGTCCCACGC AAAGGAGCACCCACCTCTTTAAAGTTGTGGTTAACCACCTGAAGCTCCGGAATAAACTACTGGCTGTGACCAC AACAGTCCAATGATGCAGAATGCTAATTTAAACGAGTGCCAAATCAGGATTTTCACAGATAAATCAATCGATC CAGAGTTACCCATTCCAGCC 1 I I 1 C 1 GGG 1 CGAGL i 1 GG I 1 GA 1 1 G 1 1 I 1 G 1 CAGGTGCATACGTCTGCATGAAC AATCCAGATTAGGGCAGATTTTGAGTTTAAATTAGGAAATATAAACAAATATACCGCGAAACTGGTTTGTTTA TAGCTTTTCGCCCACTGCCGTATGGTATAAATACATACTCTTCTTCCCCCCTGGTTCTCTTCTTCTTTTGTTACTTACATTTTACCGTTCCGTCACTCGCTTCACTCAACAACAAAAAttorney Docket No. 54282-0011WO1Sequence SEQDescription IDNO. SequenceP20 20 GTTGGAGGGTGAGCTGAGCTCAGATTTGCTCCCAAGTGTTCTACAAGGTCAGCGTGGCCGTCATCGTTGTCGC TGTCACTTTCTACGACAGTCTCATCTAAGTAGAAAACCATATCTAAAGATAGTTAGACTGGAGCCAAGGCCAA TTGTGGGTTCTAGATTGATAAAAAAAACGAGACGATAAGATGAGGAAGGTACCACACATGGGCATTCTTAGT GCGCGAGAGATGATTAGCATCGAGGGAAAGCTTAAACATCTTTGGTCTACGTAAGCAGAGACCAGGCACTAG CAAGCCTAATTAGGGTTAGGGAATTGAATGTCAGCAAAAGCTGAGGCGGCTTCCGAGGGCCAATAGAATAA GAAAGAACAACTTAGGGCGCAAACCTGATTGCGATTTTGGGGCTTTCCTTGGAAAAGACTTGATCCCTACGCT GTGGAAGGCGCACTACTATCGAAGCTCCCTCTAACCTCCCAAAGGAGAAGGAAGGGAAAAAAAAATAGTGA CAAAAAGAAAACAAAGAGCCCAAGACCTCTATCGCCCCATCGCCCAGATCTCCTATCAGCAAAATTATGTAAG CTGCATCTTTTGGTGAGCTAAAGGGGACTTTCGCGCTAACAAAAAGAGCAAACTTGTTTGTTGGGTGATTGTT GGGTGTTCAAGGCACGAC 1 1 1 C 1 AA 1 G 1 ACC I 1 GCA 1 1 GACAGA 1 I C 1 1 CCAACTGCGCCCGATATAACGTAGC ATTGCCAGGTAATGATGGTATACTTTACATGGTCACACTACGACGCTCAACATCAGTCCCTCTTAGTGGAACCA CAACTTGCTCGTTGAATTTTGGAGCGTAATGTGTCATGTTGGGTCCTGCAAAAAGAAAAGTTGGATCCCATAA ATTTAGACTTTGTAGGATGACAATCTACAGAGA I I I C I CGAACTTCGGGCCTTCCTATAAAACAAGATAAACTC CTTCCTC 1 1 1 C 1 CTTTCCTTCTCTTTAGTCTTCTCACTTCATCTACGCCACACAP21 21 TCTGCTACTCTGGTCCCAAGTGAACCACCTTTTGGACCCTATTGACCGGACCTTAACTTGCCAAACCTAAACGC TTAATGCCTCAGACGTTTTAATGCCTCTCAACACCTCCAAGGTTGCTTTCTTGAGCATGCCTACTAGGAACTTTA ACGAACTGTGGGGTTGCAGACAGTTTCAGGCGTGTCCCGACCAATATGGCCTACTAGACTCTCTGAAAAATCA CAGTTTTCCAGTAGTTCCGATCAAATTACCATCGAAATGGTCCCATAAACGGACATTTGACATCCGTTCCTGAA TTATAGTCTTCCACCGTGGATCATGGTGTTCCTTTTTTTCCCAAAGAATATCAGCATCCCTTAACTACGTTAGGT CAGTGATGACAATGGACCAAATTGTTGCAAGG 1 1 I 1 I C I 1 I 1 I Cl 1 1 CATCGGCACATTTCAGCCTCACATGCG ACTATTATCGATCAATGAAATCCATCAAGATTGAAATCTTAAAATTGCCCCTTTCACTTGACAGGATCCTTTTTT GTAGAAATGTCTTGGTGTCCTCGTCCAATCAGGTAGCCATCTCTGAAATATCTGGCTCCGTTGCAACTCCGAAC GACCTGCTGGCAACGTAAAATTCTCCGGGGTAAAACTTAAATGTGGAGTAATGGAACCAGAAACGTCTCTTCC CTTCTCTCTCCTTCCACCGCCCGTTACCGTCCCTAGGAAATTTTACTCTGCTGGAGAGCTTCTTCTACGGCCCCC TTGCAGCAATGCTCTTCCCAGCATTACGTTGCGGGTAAAACGGAGGTCGTGTACCCGACCTAGCAGCCCAGG GATGGAAAAGTCCCGGCCGTCGCTGGCAATAATAGCGGGCGGACGCATGTCATGAGATTATTGGAAACCACC AGAATCGAATATAAAAGGCGAACACCTTTCCCAATTTTGG 1 i 1 C 1 CCTGACCCAAAGACTTTAAATTTAATTTAT TTGTCCCTATTTCAATCAATTGAACAACTATCAAAACACAP22 22 TCTTATTCTCAACGGTCCCTCATCCTTGCACCCC 1 C 1 i 1 GGACAAATGGCAGTTAGCATTGGTGCACTGACTGA CTGCCCAACCTTAAACCCAAATTTCTTAGAAGGGGCCCATCTAGTTAGCGAGGGGTGAAAAATTCCTCCATCG GAGATGTATTGACCGTAAGTTGCTGCTTAAAAAAAATCAGTTCAGATAGCGAGAC 1 1 1 1 1 TGATTTCGCAACG GGAGTGCCTGTTCCATTCGATTGCAATTCTCACCCCTTCTGCCCAGTCCTGCCAATTGCCCATGAATCTGCTAAT TTCGTTGATTCCCACCCCCCTTTCCAACTCCACAAATTGTCCAATCTCGTTTTCCATTTGGGAGAATCTGCATGT CGACTACATAAAGCGACCGGTGTCCGAAAAGATCTGTGTAGTTTTCAACATTTTCTGCTCCCCCCGCTGTTTGA AAACGGGGGTGAGCGCTCTCCGGGGTGCGAATTCGTGCCCAATTCCTTTCACCCTGCCTATTGTAGACGTCAA CCCGCATCTGGTGCGAATATAGCGCACCCCCAATGATCACACCAACAATTGGTCCACCCCTCCCCAATCTCTAA TATTCACAATTCACCTCACTATAAATACCCCTGTCCTGCTCCCAAATTC i 1 1 1 1 ICU 1 C 1 1 CCATCAGCTACTAG CH I! ATCTTATTTACTTTACGAAAP23 23 TGACATTCCTCAGTGTGGCTAATGGTACTTACACATTCACTGTATTCGAGTACCAGTCAGCTTTGATTGCCCGA TTCCTCACAGGTAAGGTAGAATTACCAGAAAGAGAGGAACAAGAGGCTTGGATTCAGAACAGAGTCAATCTG AAGTCTGACACCACC 1 I I 1! CCACATGATTCCATACGAAGAGGCTGGTGAATATTTCCAGGACTTGGTCAGGC TGGCTGCTGATCCTGAATTGACTTTTGACAGCGACAAAATCTACAACGCTACCAAAGCAGGCCAAGAACTCAA GTCGAAATACTGGGCCCGTAACAAAGAGATCAGAAAATTGGGAACCAGTGCTTAATCCATACGTCGCTGGCA TTATTAAACTAGGTTTTGATGAAAACTCAGCATGTGATTGAGAACTCTCAGTTGGTTC! 1 1 1 1 CG 1 I I 1 CACTTT ACGAATTGTTTTAGAAAGGCATCATCTAATGTAATCTGTATACACTTTATTGCATTATATATACTCCACCTTGCT GTTCATCTCGTCATCTTCGGATTCTTAGCTGCTCCATCTGCCCCGGGGGTGTGAAATGTCCGACTCTCCGAGCAGACGGTTGAGCCTCGCGCCGCATCAACGGATAAGGCATGGTAGTGACCCCTCTCAACAGCGGGCCATACAGTAttorney Docket No. 54282-0011WO1Sequence SEQDescription iDNO. Sequence TCTCCGCCCACCGTCGCCGCAAGGATCACCATAAAACCTTGCTGCTCCCGGCGTTCTTGGGTACTTGACGGAC GGAGAACAGACAGGTTTCAGACCCCCCCGGAAGTTGACACCTAGGTCAGTTATAATTGCAAGTCACACTACCT GCACATAGTAAATTGCTCTCACCCGGTTGAGATCCGACCAGTTCTGTTGACTCTGTTTGCTTCCATGACTCTGC TCCCCTTGGCCGACTGATAAGCATGTTCATCCCATCGGCCATTGCCGTGACTCGGGAATGACACCCCAGCAAA CGTATATAAACCCACAATCCCCCCAGATTTACCGCTTTATCACAAAAP24 24 TGTTTATGCCATCGTGAACACAAATATCACAGGTGCATTTGGTGCTATTTCCTGGTGTCTATTAGACTGGCGTT TGGAGCGCCGTTTCAGTACTGTTGCTCTATGCTCCGGTGCCATTTCGGGCCTCGTGGCAGCAACTCCAGCCTC AGGTATCATTCCTCTTTGGGCCAGTGTTATTCTTGGTATTGTATCAGGAGTGGTTTGTAACTACGCAACCAAGA TTAAAGTCATTTGTCGAGTCGATGATTCCATGGATGTTCTAGCAGAGCACGGTATCGCTGGTGTTATTGGTCTC GTCTTCAACGCATTATTTGGGTCGGCTACTGTCATTGGTTATGATGGCCTTACCGAGCACGAAGGTGGTTGGA TAGACCACAACTGGAAACAGTTGTACAAACAGATTGCATTCAI 1 1 i 1 GCTTGTATTGGATACTCGATGGCCATC ACCGCTCTTATCTGTTTCATCCTCAACCGTATTCCA 1 1 I 1! GCAACTGCGAGCTTCAGAAGAGGCTGAGGAGAA AGGTATGGATGAGGATCAGATTGGAGAGTTCGCTTATGACTACGTGGAAGTACGTCGTGATTTTTTGGCTTG GGGATCAGGCCCAAACAATGGCTTCAAGGAGCCGGAAGTTCTGGATCAGGTAGTTCCGGTTAATGATTTCAG CAGTGACCAGAATGTGACTAATGAGACCAACGAATCTGAGAAGCAGTAGAGTAAATATAGAGATGATATTTA GTGTATTCTAATGCTTATGTAATGTATTAAGCAAAAAGTTGTGTTTATGAGTTAGCA’TTTGTCTTAGCAAACAT AAAATTATGTCGACATTTGCAACCCGCATGTCTAGTG 1 1 1 1 I AGATCGATCTTCGATGTGTAGAATAATGCCTC CACGTGATGCCCCGCGATTTTGTTGGGTCTCAATGCCTCCAACATAAACCCATCACGTATAAAAAGCCCTCTTA ACCCTCCCCCCTGTTTCGTTTGCTTCATCACTTAACCTGAACTATCAAAP25 25 TTTTCAGCAGATCTAGGGAGGGCATCATTGAGGTTTCCACAAAAGGAAGAAACATGGATCCAGAGACATCAA CAGAGAGGGAAGCGGGTAGTGAAGCCGAAGCCACAACACAGCCCGATTTGGAAGGGAGATCACAATCAAG GTGAGTCCAGCCA 1 1 1 1 1 i 1 C 1 1 1 i 1 i 1 i 1 i 1 1 1 1 1 A 1 i CAGG I AGGCCCACC 1 AAC 1 A 1 1 i 1 i AACTGGGATCCA GGATCTCGCTGGGTGAAAGCCAACCATC 1 i 1 1 G 1 i 1 CGGGGAALCG i GC 1 CGCLCCG 1 AA 1 G H AA 1 1 1 1 1 1 1 C TCCCGCGCAGCTTTAATCTTTCGGCAGAGAAGGCGTTTTCATCGTAACGTGGGAACAGAATAATCAGTTCATG TGCTATACAGGCACATGGCAGCAGTCACTATTTTGC 1 1 1 1 1 AACCTTAAAGTCGTTCATCAATCATTAACTGACC AATCAGATTTTTTGCATTTGCCACTTATCTAAAAATACTTTTGTATCTCGCAGATACGTTCAGTGGTTTCCAGGA CAACACCCAAAAAAAGGTATCAATGCCACTAGGCAGTCGGTTTTA! 1 I 1 1 GGTCGCCCACGCAAAGAAGCACC CACCTCTTTTAGGTTTTAAGTTGTGGTAACAGTAACACCGCCTAGAGCTTCAGGAAAAACCAGTACCAGTGAC CGCAATTCACCATGATGCAGAATGTTAATTTAAACGAGTGCCAAATCAAGATTTCACCAGACAAATCAATCGA TCCATAGTTACCCATTCCAGCCl I i I CGTCGTCGAGCCTGCTTCATTCCTGCCTCAGGTGCATAACGTTGCATGA AAAGTCCAGATTGGGGCAGATTTTGAGTTTAAAATAGGAAATATAAACAAAGATACCGCGAAAAAGGTTTGT TTATAGCTTTTCGCCTGGTGCCGTACGGTATAAATACATTCTTCTCCCCCCCCTGCTTCTC H i l l CTTTTGTTAC TTACATTTTACCGTTCCGTCACTCGCTTCACTCAACAACAAAAP26 26 1 H 1 1 G I AGAAATGTCTTGGTGTCCTCGACCAATCAGGTAGCCATCCCTGAAATACCTGGCTCCGTGGCAACAC CGAACGACCTGCTGGCAACGTTAAATTCTCCGGGGTAAAACTTAAATGTGGAGTAATAGAACCAGAAACGTC TCTTCCCTTCTCTCTCCTTCCACCGCCCGTTACCGTCCCTAGGAAATTTTACTCTGCTGGAGAGCTTCTTCTACG GCCCCCTTGCAGCAATGCTCTTCCCAGCATTACGTTGCGGGTAAAACGGAGGTCGTGTACCCGACCTAGCAGC CCAGGGATGGAAAGTCCCGGCCGTCGCTGGCAATAACTGCGGGCGGACGCATGTCTTGAGATTATTGGAAAC CACCAGAATCGAATATAAAAGGCGAACACCTTTCCCAATTTTGGTTTCTCCTGACCCAAAGACTTTAAATTTAA TTTATTTGTCCCTATTTCAATCAATTGAACAACTATTTTAAGTTGTGGGAACAGTAACACCGCCTAGAGCTTCA GGAAAAACCAGTACCTGTGACCGCAATTCACCATGATGCAGAATGTTAATTTAAACGAGTGCCAAATCAAGAT TTCAACAGACAAATCAATCGATCCATAGTTACCCATTCCAGCCTTTTCGTCGTCGAGCCTGCTTCATTCCTGCCT CAGGTGCATAACTTTGCATGAAAAGTCCAGATTAGGGCAGATTTTGAGTTTAAAATAGGAAATATAAACAAAT ATACCGCGAAAAAGGTTTGTTTATAGCTTTTCGCCTGGTGCCGTACGGTATAAATACATACTCTCCTCCCCCCC CTGGTTCTCTTTTTCTTTTGTTACTTACATTTTACCGTTCCATCACTCGCTTCACTCAACAACAAAAP27 27 1 i I 1 1 G i'AGAAATGTCTTGGTGTCCTCGACCAATCAGGTAGCCATCCCTGAAATACCTGGCTCCGTGGCAACACCGAACGACCTGCTGGCAACGTTAAATTCTCCGGGGTAAAACTTAAATGTGGAGTAATAGAACCAGAAACGTCAttorney Docket No. 54282-0011WO1Sequence SEQDescription iDNO. Sequence TCTTCCCTTCTCTCTCCTTCCACCGCCCGTTACCGTCCCTAGGAAATTTTACTCTGCTGGAGAGCTTCTTCTACG GCCCCCTTGCAGCAATGCTCTTCCCAGCATTACGTTGCGGGTAAAACGGAGGTCGTGTACCCGACCTAGCAGC CCAGGGATGGAAAGTCCCGGCCGTCGCTGGCATAAACAAATATACCGCGAAAAAGGTTTGTTTATAGC I I I I C GCCTGGTGCCGTACGGTATAAATACATACTCTCCTCCCCCCCCTGGTTCTC 1 1 1 I I CTTTTGTTACTTACATTTTA CCGTTCCATCACTCGCTTCACTCAACAACAAAAP28 28 I 1 I 1 1 G I'AGAAATGTCTTGGTGTCCTCGACCAATCAGGTAGCCATCCCTGAAATACCTGGCTCCGTGGCAACAC CGAACGACCTGCTGGCAACGTTAAATTCTCCGGGGTAAAACTTAAATGTGGAGTAATAGAACCAGAAACGTC TCTTCCCTTCTCTCTCCTTCCACCGCCCGTTACCGTCCCTAGGAAATTTTACTCTGCTGGAGAGCTTCTTCTACG GCCCCCTTGCAGCAATGCTCTTCCCAGCATTACGTTGCGGGTAAAACGGAGGTCGTGCATGAAAAGTCCAGAT TAGGGCAGATTTTGAGTTTAAAATAGGAAATATAAACAAATATACCGCGAAAAAGGTTTGTTTATAGCTTTTC GCCTGGTGCCGTACGGTATAAATACATACTCTCCTCCCCCCCCTGG 1 I C I CI I I 1 I Ci 1 1 1 GTTACTTACATTTTA CCGTTCCATCACTCGCTTCACTCAACAACAAAAP29 29 1 I 1 1 1 G I AGAAATGTCTTGGTGTCCTCGACCAATCAGGTAGCCATCCCTGAAATACCTGGCTCCGTGGCAACAC CGAACGACCTGCTGGCAACGTTAAATTCTCCGGGGTAAAACTTAAATGTGGAGTAATAGAACCAGAAACGTC TCTTCCCTTCTCTCTCCTTCCACCGCCCGTTACCGTCCCTAGGAAATTTTACTCTGCTGGAGAGCTTCTTCTACG GCCCCCTTGCAGCAATGCTCTTCCCAGCATTACGTTGCGGGTAAAACGGAGGTCGTGTACCCGACCTAGCAGC CCAGGGATGGAAAGTCCCGGCCGTCGCTGGCAATAACTGCGGGCGGACGCATGTCTTGAGATTATTGGAAAC CACCAGAATCGAATATAAAAGGCGAACACCTTTCCCAATTTTGG 1 1 1 LI CCTGACCCAAAGACTTTAAATTTAA TTTATTTGTCCCTATTTCAATCAATTGAACAACTATGCATGAAAAGTCCAGATTAGGGCAGATTTTGAGTTTAA AATAGGAAATATAAACAAATATACCGCGAAAAAGGTTTGTTTATAGCTTTTCGCCTGGTGCCGTACGGTATAA ATACATACTCTCCTCCCCCCCCTGGTTCTC 1 1 1 I 1 C 1 1 1 1 GTTACTTACATTTTACCGTTCCATCACTCGCTTCACT CAACAACAAAAP30 30 1 I 1 1 1 G I AGAAATGTCTTGGTGTCCTCGACCAATCAGGTAGCCATCCCTGAAATACCTGGCTCCGTGGCAACAC CGAACGACCTGCTGGCAACGTTAAATTCTCCGGGGTAAAACTTAAATGTGGAGTAATAGAACCAGAAACGTC TCTTCCCTTCTCTCTCCTTCCACCGCCCGTTACCGTCCCTAGGAAATTTTACTCTGCTGGAGAGCTTCTTCTACG GCCCCCTTGCAGCAATGCTCTTCCCAGCATTACGTTGCGGGTAAAACGGAGGTCGTGTACCCGACCTAGCAGC CCAGGGATGGAAAGTCCCGGCCGTCGCTGGCAATAACTGCGGGCGGACGCATGTCTTGAGATTATTGGAAAC CACCAGAATCGAATATAAAAGGCGAACACCTTTCCCAATTTTGGTTTCTCCTGACCCAAAGACTTTAAATTTAA TTTATTTGTCCCTATTTCAATCAATTGAACAACTATCGGTTTTA 1 1 1 1 1 GGTCACCCACGCAAAGAAGCACCCAC CTCTTTTAGGTTTTAAGTTGTGGGAACAGTAACACCGCCTAGAGCTTCAGGAAAAACCAGTACCTGTGACCGC AATTCACCATGATGCAGAATGTTAATTTAAACGAGTGCCAAATCAAGATTTCAACAGACAAATCAATCGATCC ATAGTTACCCATTCCAGCCTTTTCGTCGTCGAGCCTGCTTCATTCCTGCCTCAGGTGCATAACTTTGCATGAAAA GTCCAGATTAGGGCAGATTTTGAGTTTAAAATAGGAAATATAAACAAATATACCGCGAAAAAGGTTTGTTTAT AGCTTTTCGCCTGGTGCCGTACGGTATAAATACATACTCTCCTCCCCCCCCTGGTTCTCI I 1 I 1 CTTTTGTTACTT ACATTTTACCGTTCCATCACTCGCTTCACTCAACAACAAAAP31 31 I 1 I 1 1 G I'AGAAATGTCTTGGTGTCCTCGACCAATCAGGTAGCCATCCCTGAAATACCTGGCTCCGTGGCAACAC CGAACGACCTGCTGGCAACGTTAAATTCTCCGGGGTAAAACTTAAATGTGGAGTAATAGAACCAGAAACGTC TCTTCCCTTCTCTCTCCTTCCACCGCCCGTTACCGTCCCTAGGAAATTTTACTCTGCTGGAGAGCTTCTTCTACG GCCCCCTTGCAGCAATGCTCTTCCCAGCATTACGTTGCGGGTAAAACGGAGGTCGTGTACCCGACCTAGCAGC CCAGGGATGGAAAGTCCCGGCCGTCGCTGGCAATAACTGCGGGCGGACGCATGTCTTGAGATTATTGGAAAC CACCAGAATCGAATATAAAAGGCGAACACCTTTCCCAATTTTGGTTTCTCCTGACCCAAAGACTTTAAATTTAA TTTATTTGTCCCTATTTCAATCAATTGAACAACTATTAAACAAATATACCGCGAAAAAGGTTTGTTTATAGCTTT TCGCCTGGTGCCGTACGGTATAAATACATACTCTCCTCCCCCCCCTGGTTCTC 1 1 1 1 1 CTTTTGTTACTTACATTT TACCGTTCCATCACTCGCTTCACTCAACAACAAAAP32 32 I 1 I 1 1 G I'AGAAATGTCTTGGTGTCCTCGACCAATCAGGTAGCCATCCCTGAAATACCTGGCTCCGTGGCAACACCGAACGACCTGCTGGCAACGTTAAATTCTCCGGGGTAAAACTTAAATGTGGAGTAATAGAACCAGAAACGTCTCTTCCCTTCTCTCTCCTTCCACCGCCCGTTACCGTCCCTAGGAAATTTTACTCTGCTGGAGAGCTTCTTCTACGAttorney Docket No. 54282-0011WO1Sequence SEQDescription IDNO. Sequence GCCCCCTTGCAGCAATGCTCTTCCCAGCATTACGTTGCGGGTAAAACGGAGGTCGTGTACCCGACCTAGCAGC CCAGGGATGGAAAGTCCCGGCCGTCGCTGGCAATAACTGCGGGCGGACGCATGTCTTGAGATTATTGGAAAC CACCAGAATCGAATATAAAAGGCGAACACCTTTCCCAATTTTGGTTTCTCCTGACCCAAAGACTTTAAATTTAA TTTATTTGTCCCTATTTCAATCAATTGAACAACTATP33 33 TTTn'GTAGAAATGTCTTGGTGTCCTCGTCCAATCAGGTAGCCATCTCTGAAATATCTGGCTCCGTTGCAACTC CGAACGACCTGCTGGCAACGTAAAATTCTCCGGGGTAAAACTTAAATGTGGAGTAATGGAACCAGAAACGTC TCTTCCCTTCTCTCTCCTTCCACCGCCCGTTACCGTCCCTAGGAAATTTTACTCTGCTGGAGAGCTTCTTCTACG GCCCCCTTGCAGCAATGCTCTTCCCAGCATTACGTTGCGGGTAAAACGGAGGTCGTGTACCCGACCTAGCAGC CCAGGGATGGAAAAGTCCCGGCCGTCGCTGGCAATAATAGCGGGCGGACGCATGTCATGAGATTATTGGAA ACCACCAGAATCGAATATAAAAGGCGAACACCTTTCCCAATTTTGGTTTCTCCTGACCCAAAGACTTTAAATTT AATTTATTTGTCCCTATTTCAATCAATTGAACAACTATCAAAACACAP34 34 1 i 1 1 1 G i AGAAATGTCTTGGTGTCCTCGTCCAATCAGGTAGCCATCTCTGAAATATCTGGCTCCGTTGCAACTC CGAACGACCTGCTGGCAACGTAAAATTCTCCGGGGTAAAACTTTAATGTGGAGTAATGGAACCAGAAACGTC TCTTCCCTTCTCTCTCCTTCCACCGCCCGTTACCGTCCCTAGGAAATTTTACTCTGCGGGAGAGCTTCTCCTACG GCCCCCTTGCAGCAATGCTCTCCCCAGAATTACGTCGCGGGTAAAACGGAGGTCGTGTACCCGACCTAGCAGC CCAGGGATGGAAAAGTCCCGGCCGTCGCTGGCAATAATAGCGGGCGGGCGCATGTCATGAGACTATTGGAA ACCACCAGAATCGAATATAAAAGGCGAACACCTTTCCCTATTTTGGTTTCTCCTGACCCAAAGACTTTAAAATT AATTTATTTGTCCCTATTTCAATCAATTGAACAACTATP35 35 CAGGTAGAAAATTCACCACTGTCGGAAAGTTGTCTACTTCCGTCGGTTGGAAATACGAGTCTGTTGTTGAGAA GTTGGAGGAGAAGAGAAAGGCTGAGGAAGCTGAGTACCAGGAGAAGAAGAGAGCTTACACCCAGAGATTA GACGCAGCTAGTGCCGAGTTTGCCCAAACCGAGGAGGGAAAGCAGTTGGCTGCCTTTGGTTACTAAATAGTA AAGTAGGGTATCTTCAAGTAATAGTATACTAACCATCTGAAATAACCACCGTCCTGTAG 1 1 1 1 1 1 I I CGATATC GAAGAGCCTATGCTAGTACTGTGGATTTGCGCTCCATCCAACATCTGTGCGCAAACTAAAACTTCCGAGACTG ACATCTACCATCGCTAGACCCTAAGTAAAACCAATCTCGCGTCCGAACTTTTAAATTTCAGTCCTTAAAACTTCA GAGCATTGGTTGTAGTTTCCGGATCTGAGGGGTCGTATTGGAGTCAAGAGACGGAGCTGCCTCCACAGCGCG AAACGTCAACCCCAACACCAACCTGAATTTGCAATCACCATGGGGACAAGTTTCAGCAGTCAATGGGCAATTC AGACGTTGATACGGTACCCATTTGCTAAGCTCAATGACGATCCATCCAACTTCAGAGAAAGGCCTTTCTCTGG TATGCTCTGGTATTCATTCGTCTTTTATCACTCTCGTTGCACAATGCCCGGGTACTCCCGGAACAAGGGAGTCT TCCAGCCAAGCTGTACAGAGTGAAAAATAGAAATACACCTTTGCAATCAAGACGCGCGTTGGCCAATCACAA GACTTAATCGGTGCAAAGAAGGATTACCAAAI 1 I I 1 i 1 i 1 CCCAAAATCGCTATATAGAAATAATGGAGGAAA AAGGGTTAATATAAAGGAGAATTCCCCCGTTTTTUTCCCCTTGTCTTTTCTTCTTCAGGCTTTCTTACAAATCTAT AATATTCCAAAATGGCTGACAACAACAAGTCTAACTTCTTCGTCGACTTCP36 36 GACTGATGAGTCAAGAGCAGAACTTGCTGCTGAAGGAGTTGCTTTGTAGTGTTCGATCTTTCGAGTTATATTA TTATACTAGTGGAAATATAATTATTTTGTGATGGATTGTGTAAGAACAATAAGTTTTCACATGGAAACGCAATA TTAAGGTTTACCCATTGAATTAGATCAGACTGTGAAACAAATCAGCCTTTTTAAACAGGAAATGTAACAATCTA TCAATTGGAAGTTTCAATGGTGG 1 i I i I GGGCGCCTGAGAATAAGCTCTTACTATACCACCACTCTATCATTTA CCAAGACTGATTTGCCTCAGGGCGTGTGGTCTAGCGGTAGGATTCTCGCTTCGGGTGTGAGAGGTCCTGGGT TCGATTCCCAGCTCGCCCCGAGTTCAA 1 I 1 I 1 1 C 1 AAGAAAI CAGA I I CGAGCAI CGAACG 1 1 I 1 I 1 CACAAGTT TnTTCTTGATCTCAAAAAAAATTTCAAATCATCGTTTTCAGCACCTACACAGATTACAAACCTAATCTCATCAG TCTCCCGTCCAATAGAAGTTGCCCCATTAAAGCCGACCTCATCCCTCATACGAGGGCAATTGTCGTACATGATG TCTCCTTGTTCCTCCTCCTGCATGTAATTAAAGGTCGTTTCTTTTTTCTTTAACGGACTGATCCCCCTGAACCAAG TGCTTTCCGCTAATGCCCTCCTAGTGTTCACTGCTCAAATCTCATCTTTGTTTCGCGTCAGCCTTCATCCCTACTT TTGTCAGCGTCTACATTTGAAAAAAGGTAAACAAAATCGCGACGAGATTCTTTCAAATGCAGCCTCACAGGAG GAGATCGAGTCTCGATGCTACCTTGGCACTAGGTATCGGCCTTTTAGTGGGCCAAAATTCTTCCCTGTTTTCTC I I L I I CL i 1 i 1 L 1 i CACA I I I I GALGA 1 i 1 1 LA i ALAAAAGG 1 LAL i A 1 A 1 LL I I LAL 1 LAL 1 L 1 A 1 I I 1 I I AAGTGI I I I 1 CCCACACTAGTCATTCCTTTTATCAACCAttorney Docket No. 54282-0011WO1Sequence SEQDescription IDNO. SequenceP37 37 AACACGAACACTGTAAATAGAATAAAAGAAAACTTGGATAGTAGAACTTCAATGTAGTGTTTCTATTGTCTTA CGCGGCTCTTTAGATTGCAATCCCCAGAATGGAATCGTCCATCTTTCTCAACCCACTCAAAGATAATCTACCAG ACATACCTACGCCCTCCATCCCAGCACCACGTCGCGATCACCCCTAAAACTTCAATAATTGAACACGTACTGAT TTCCAAACCTTCTTCTTCTTCCTATCTATAAGAP38 38 GCCATTATCTGCTGATGGATTATGACTTGCAGTGATCATAATTCCACCAAAAGATTTATAGTAGTCGACAGCAA ACGGAACAAATGGAGTTGGGATATCACCACCTTCTCTATTACTTACATAATACACGCTAAATCCI 1 1 I AGAATG AATGCTGTGGCTGTGTATTCGGCAAACTGTTTAGAGTTGTGACGATGATCATGTCCAATAACTATTGATTTACC GCCAGCTTTTGACATATAGTTGGCCAGTCCCTGAGATGCTTGTATTATCGTGAGATCATTCATTAGACTAAAAC CAGCACCCATTCTACCTCGAAGTCCCGCTGTTCCAAAAGTAATTCTTCTTCGTAAGCGTTCTTCAAGAACTTTAA ACTTTTCATTCTCAAGAAGTTTGAGAATCTCAGATCTAGTGGATGGATTACGATCAATGCTAAGCCATTGATGC GCTAACGCCTTAATTGATGGGGACATGATGTCAGATGTAATACCTTCTTTACCGAAATTTAGCTATCTCACGTA GCCTAGAATGGCCGCTGCTAATCGGCCTATATCTAAAACGGCATATCGAGGATCGATGAAGTTTACACGTGAC GCATTCAGTGTAAGTAAATTACATGCAGTGCCGGCTACTTGACTAAAGTAAGAAAAAACTCAGAAATCAAAG AAATAACAGAAGCTGTACGACACAACGAAATAAATACAAACTTTCTTAGGATGCAATTTAACAAGAATCGTCT TATTGTCTCTCGGAAACATTCAAGAATTTCAGCCCATTATCCACATTCAGTCATGGCGCATTATTTAGATTGTGT TGTTTGATAAAAAAAGAATACAGCAAGTAACAACGAGTAGTCAGTTACTGAGATAT H i l l AGTACCGTCGAT CCGGTTACGGGGAATTTAACTGCAATATATCAAACGTTAAACTGGATCGAGTTCAAAAAAACAAGCTCTAACT CAGTCAAGCTTTATGTATAGTTTCCTAATCAGGTAAT! i I I IP39 39 CCCATACTAAATGTGTATGATCATCGTCGCACGTTTGCTTTGCCATGCAGGAAGACATAGTTACTAATAATTGG CCCACCTACCATGTCAAACTGCTAGTGGAAACAGATGCACAGAAGAATAGTTGCAATTGAAAAATGTTTGAAT TGTCATGACAACTAATAACAACTAGCGAACTACAACTAGGCCAAGAAAACTTCCTTGCTTACTCTCGTCATATT TCACTCTAATACGGCATCCGTACTACGTTGAAAGAACACTTGCAAACCCGAAACAGGTGCAGTCTAAAAAAAG GCCACTCACTCCTCTTCAACTGGGACAAGTGAGGACAAATCTAGCAAGATGGCTTGAAAACTTGAAGTCGGA AAACCTGTCAAGCCTAAATCTATTAATAACTACTCCTACI I 1 I I CGGCACAAAGC I GGGCA 1 1 1 I CI CCTCTTAC TATCATTTACCTCCTGATAAGATCGTAGCACAATTTCAACGCAGATTGCTGTCGTCTTTGAACTCTCAGTCCCTC TTGGCCTACAAAGGTTAAGTGAGATAGCCAATTTUTAGACCACCTGAAATTCCCATGTGACCTGGCATGTGAT TATGCACGTAATTACTGTGTAGACCTAAAAATATCTCATCTGACAAAACGGCGTCATAACCTAAAATACCTCAG ATTTATGCAACCACACATTGATTTAATTACCAGAGAGATCGCTAACGTTCTGAGAACTATTTTGTGTATACTTC CTGCATCATCTGCCAATTGTTGGATCTCCCTAAACACCCACGTTGTCACGACAACTTATTAATGGGAACTAATA ACAACAGATTATGCTACACGGGTTGCCCGTTCTTTGCATATACCGCCATGAAACTTTCATACGACGTGCCTGGC TGTAGCGTGTGGCATCAATCAGCTTTTTTTTTAATTGAAGCAGGAGCGGATCATCTTATCGTGTAACCTTTTCC AGACTTCTCTACTGCTTCCTTAGCTTTATTGCACAACGGGGP40 40 CATATCTCAAGGCATCAAAGGTTCTGGATCTCTCGTTGATACATTCCGCGATGGGTTGCTCTATTCAAAGGAAC TTGCTGACCTGAAAAGGTTTGAATATGCTGAGGATCTGGAGTTTTATGATGCTGAGGAAGAAGAACAGAACT TTAAGCAAGGGATCACTGGCAACGGAAAAACTAGCAAACACCAGAGAGTCTTATCCCAAGATATCTCCAATA ATTCCGTGAAAATGACCCCAGTAAATGGTATCAACAGTGATTCGTATGTATCGGTGAATACATAGTACCCTCCT ATTTAGGCAAATGTCATGCTTCAAATATAATACCCACGTTTGTTATTGTTACCCCTATCCTTTTGTCTAGAACAC GTTTGTCGCACACCAACTATGCCTAGAACCCTGTAGATCACTCTCATTGGCTCGAACGATGGGGATACAGAAT GAAACCTGGTGGAAAGTTGTTTACATTTGGAATTGAGTTAGCCCCTGTGATTATGACAATCTGCATGCTGATG CATTTGATGCATGTGCATTCTAATCTGAGAATTCCACTCAGTAGATCGCAACAAAGAAGACAAAAAAGTAGGA CAA 1 I I C 1 L 1 GG 1 AAAGCGAG 1 1 GAA 1 GA 1 CAAAG 1 1 AAGA 1 AAGC i AGCC i A 1 1 1 A CALC I G I l G l i l CI C I G TTTGAAAAGGCC I 1 I 1! 1 G I GA 1 GA 1 1 1 1 I 1 I I GACTCATCACGTTATTCCAAATTTCACTCGAAACAATAGGTC GTGCAGATGCATTTTCATACACTTAAAATCAGTCTTCTTGTCTAATATTAAGAAACGCGTTATTTACGTCTCCCC CTTTTTGGAACCCTGGCACTCAGGGTTTGTTAGAGAAGTTATAAGACTCCTGTGGTTCCCTGAAATCGTGTTGT TTGTGATTCTTTTTGATACATCAAGTCTTTTTCAAAAAACAAAAGAAGATACTCTTGAGCCGTTTTCTTCAAATCCCAACTATCTGTCACTCCTTTAAAACACGTTCACTATTCCAAttorney Docket No. 54282-0011WO1Sequence SEQDescription IDNO. SequenceP41 41 GAGGCCAGCGCTGCGGCCGTCTGCGGGCAGAAGGGCCAGAAACGGCAGCCAGTGGGAGTGAGACGAGCGC CGCCCGCCTGATTGTGATGATCTTCCCCCCCGCTGGGCCCACAGATGGCGCCAGGATCACCACCGGCGTGCGT CGTGCTACATAGACGGAAGGCGAGGGGAGGGCGAGCAAGAAAATTTTGTCGCTTTGCCGTGCGCTATTGCG GTGTGCTTACCAAGTGAGGGGAGGGAATGAGCACGCTCGAGGAGCTAAAAAAAAACTACAATAACAAAGAC AATAAGATGACGGTGACAACTGCAATGACAACAACGACGATGACAACCGGCGTGGTATGTAGCATTCGTAGG GCATACGTACGTTCATCACGCCTTGGCCTTGGCCTTGCCCACGCGCATTGGTAAAAATAGCACGCCCACGCCC CCGGCAATAACTACAACAACAACGACAACAACGACAACAACAACACCCGAGCCGTAGAAAAGCGTGGAAAA ACAGCAGGCAGTAGTCGCCGCCGTCGCTGGCGGCCCCCCCAACACACGCACGCACACACAGCATGCTGCCGG GCCATGCTCGGGACGCAGCTGCCATTGCCACGGGCTGCTAAAAATAGCAGCACTCCCGGCTGCCGGCTGCCT GGTTTCCCAAGCAAGCCGGCGCGCCTATGCCTCGCGCCGTATTTGTG I 1! 1! CCCGATGCGGTACCGGTGACC TCGATAGGGTACCGCGTTGGGTGGAAAAAGAAACAAATCGCACGGAAAATACTTCGGAAGAGGTGGTGGGT AGCACGCTGGAGCAGGCTCGAGAAGGCTGGATGGAACTGGTCACAGAGGGTCACCTTTTTTCTATAAAAGCA TGTGGTTCCCACCC 1 1 1 1 1 1 C I 1 C 1 C 1 CA 1 C I GGA 1 1 CCA I 1! C 1 1 C 1 1 1 1 CTCTTTGCCTTAATCTATTTTCTTCTC TTCTTTCTACAACAAACATCTAACTGTTCTAGTCTTTCGCTTATCAATCAATCCATTAACAP42 42 GATGAGTCCTGAGCTAGTTTCACCGTTCCGGTGGGATCCACTGGAGCAGACAAGCTCACACTTGCGGTTGTCT CGTATTAAGCAATCCGACAAGGCGATATCGATTTTTAGGCTCAGAGCGGAGTACATCACTTCATCATGTTTTTG TTATTAAACTTTCATATTAAATAGCCCTCAGTGCCTTAAACCCCACCCAGTAGTGCACCGGCTAGTGGGTATGC AGGAGGGTCCTGCAATCGACATCTTGATCTGTTCTTGCCTTGTTCCGACGGCATGATAAGACTGGCATTAAGC CAGAAATTACCCTTAATGGTTTTCTCACTAGCCATCTGAATCTCAACTTCCAATGTTTTAGGTGAGAAATGCAC CAAAAACCACCATATTCTCCCGAAAAGGAAAAAATCGCAACTTGAGGTCAAAAGCAACGATCACCAGTCTATT GTGGACCCCTTGAAAGAAAGCGGCATTGGGTAAATAGCCCTTTGTGATGGGCTGCTTCCCAAAGTGTTTCATC AACGGACCCATCTGAGTCTCCGGTACCCGTCATGTAGCAAATAACTGAAACTGGAAATCTATACACACTUTTTT CAAGCCGCAGCGTAGGTCTAGCCCCAAGTGGAGGTGGTGTGGTTAGCGCTTGCCAGCCTTACCAGTCAGCTT TTTCACTGCACCAAGTGCTCTAGCAGTGTGTTTTCACCTCTTCCCAATTCGGCTAAATTTAGTTATGCTCCACTT GCGGTTTCAAGCACTCCATGCGCTATCACCCCCAGGACCCGCCTTTAGGGGCTATTAATAGGAAAATTTCCGG GGCGCCAGTGTTTTGTGTGAACTTTGCAGGTTTCCAAATAAAATTCTTCCTGCCGGTGGAAGTCTGCCCTGTGT GGTATATAAAGAAGTGTAGCCCACCTTTGGAACCTTTTCTGTCAGAATCCTCTTTCTCCATATTCAACCTCGAAT TAATCCTTCCCAAAAAGTCTCTCGCTTCATACCAATCACTACAP43 43 ATAAATAATTATTTGTTCATTTAAGTTGTATCTTTGATATTTCCTTTATGGAAGGGACCGCAAAAAGACTTTGAT TATTATTCCTCACCATTGCTA 1 1 1 1 i 1 i 1 i 1 G i 1 AAGA i A 1 1 AC i 1 1 AAA 1 AGC I l l i GTAAATTAATCAGATTAA AATTGCTGGTTAATACAACTTTATTGACATTTTAATGAGTCAGTGAGTCAGTTATTCTTACAGTATTGCTAAAC GTTATAAGGTATAATCAATAGTATCTCGCTTTCTGACTACCTCACTCATTACTAATAATCCAGTAAGTAAGATGT ACTTTTCAAACAAAAAATTGTTTGTTTTCATTTCATGTCCAAGCTGCATTAATTGTTAGCGCCATGCATAATGTT ACATTAAACAATTGTTTGATCATACTGATTTTCTTGATTATTTGAATAAATTCTTTGGTTTGCTTGTTTACCTTTT AATCTTTCATTGTTTTCAACATTGTTGTTTGCTCACACAAAACCAAATACAAACAAGTAAATAAGGAAACACTG ATAATAAATACACTAAAAATAAATAGCAAAAAAAAGGAGACAAATTCAAAAGAAAAAATACAGACAAAAATA ATTTAAAAAAACAAATAAAAAAAAAAAATAAATAAACAAATAAACAAATACTAAAAAAAGAAAACAAACAGG CCTACAAAAACTTTGTTTTGTTTGTTTTCTTGCTTCTCTGCGGTGCTGCCTATTAATGTCCAATTTCTTTTGTTTTC CTTCTTTCTGTCTTCCTTCCAATTCTTATGTTTTCTTGTTTTCTAACACAGATTACATCCATCACCCTACATCCACT TTCTGTTTCCTACACTCACTTCCTCTAC I I I I 1 I 1 1 1 ACTATATAAGGTCGGCAATCCCTCCATTATATCTTAATAA TTTTCCATACTCTTATAAATCTTCTTCTTCCTTTTCTTTCTCTAATTTAGATTCATCCAAATTCTAGTCTCTCGCTTT AGATACCAATAAATCAACAAAAP44 44 CATCCAATCTTTTCGTAGCGATCTCGTTCTCAACCGTGGTCCGACTTCCATGCCCTGAGAGGTAATAATACCAC GCCGTGTGGTGGCAAATTTCCACCTCAAGCTGGATACGAAGCTCATACGGAGACCGTACAAAAGAAGCGCAA TGGGAAAATCGACGTGGGCTGTCCCTC 1 I I I I I 1 I GCGCCC I I CCCC I 1! 1 C 1 C 1 CC 1 1 1 I 1! 1 I CTTGTATCCAC TCCGCCCACCCCCCCTGCTCTCTGCCCACACCATACGAGGTGCCCTCCTAATGACTGACCACCAAAAAAAAAGGGAGCAAAAAGGAGATTATGGATCACCCATTGCACGGATCTGGGTTAGTTAGCGCTGGTCAATCTCCI 1 1 1 1 1Attorney Docket No. 54282-0011WO1Sequence SEQDescription iDNO. Sequence TTCTATTTTTTCCTATTTTTCTTTTCTTTTTTCTTTCTTTTCCTGTCTGCACGCCCATCCGTCCCATCTTGCATCCGC TGGGGCCCCTG 1 1 1 I I 1 i I I CAG 1 C 1 1 G 1 C I 1 I G 1 1 G 1 1 1 1 1 1 1 AA I CCA i 1 1 C 1 1 1 A 1 1 I G 1 C I 1 1 1 1 1 AGCATGG TTTTTTTTTTCGGGGCCGTTCTTTCGGTTGCTTAGCTTCGTTGCTGAGCTGCTCGTTCTCCCCTTTCCGTTCCCAA TCTTTTCCCCTTCCCCTGCTACCTAATCCCAGCCCACACGCACACGAGCACACACACACCCCCCC 1 I CI 1 1 1 CTTC CTCTCCCCCCCAAACCAAGAGGAATGTGGGCGAAGGGGAAAACACAAGGCCAATGCGGTCTCCCATTCCTGT ATATAAGACCTCCCmCTTACCCTTCCAGCCCATTCCCCTTTCTCCTTCTTTTCTTCCTTCTTTCTTTTTTTTCTCTC I I i 1 C 1 C 1 1 CACCCACAC 1 CAC 1 C I I AcAA i 1 AA 1 CACCC i GAC 1 1 I I ACAGTC AATTTCACTCGTTAAACTCACC TCAACGCCAAAAACCAAAGCTTTTGCTCTACTCCAATCTCCCAATTTACAACCCAGTCAACTCGACCAGGAAAA CCCAACCAGTCCCCAACCGTCAAAP45 45 ACAACAATACTGCTTTTGACTCCAAATAGTACTGTAGCATGTAGTGATATTGTTTATTATATCTTCTACTAATAT ATTAATTATGTCTTCTGCTAATATATTAATTATGTCATTACACCTAAAACATTTTAAGAATTAATCCCGTTGAGA AATAAACAAAAAGTATCCCTCAATACTACTCAATTAGGTAAATTAGCACCCGTTGCAGCCTTACCATTGCCATG GCCAGATGCACGATAATGTATATAGAAGGACAAACTTGCATTAGTACCACCAAGGCAATAAGAACACCAGCC ACTGTAGACGATCTACACTTACAAGGGGCAATTGCTAATAAGTAATGGCAAATAAGCAATAAGCGGCGAACA ACGAGATACTATTCATGGAGAACCTTCGGCAATACACGAGAGATTATAGCAATACACGAGAAACCATAAGAT ACTAAGATAAATCATGGCAAATCATATTAACTATTGACCTCTGACAAACAGTTATGGCCCTTTAAAGAAGGTA AAACGTGGGAAGCCTTGGGACAGGAAAAAAAAAAAAAAACCTTCTCTCTCAATGAGCCAACTTTTCATTACAT CATCATCATCCACGATTTAATTGGACAATAGGAAAATGCAAAACAAATAAAGCTGAGTAAAGAGCGGCAAAA ATATGCAAAAGAGACAAAGATTTGCCAAAGAGGCAAAGATCTGCAGAAATGGGAAAAAAAACTTCATAAATT GCAAAACGCGCTTCTA 1 I 1 I 1 AGTACATTCGACAGCGGCCGTGCTGTTTATCTTTTGCCGCTTACGGAAGGCGC GCGCCGCCGGTGGCTGTTTTCTGGTAAAGTGACTCTTCCACGGGGGGGAAGCTATAAAAAGCGTGAAATCCC TCCCACA I I I I C 1 AA i CCCAG 1 GG 1 AACCCCAAC I I C I I I I CI A IA I H I i l i lA I I I I H H CH I C I CACTTATCA AC 1 I 1 I ATCGTTCATAGTCTCTCGCTTACAAACTAACACAATAAAAP46 46 GAAAGGCCAGATGCGTGTGTGTCCACAA 1 1 I C 1 GTGCATAACTTCGGGCAATGGAGAGCGGACCTTTCAATCT GGCTGGTGGTGATACAACTTAAAATAGAATTTTCAGGAACGAAATGAGGATTACGACTAACTGATATGGCGG TGTCGGGGTGATGTTTCTGCTGGATGATGCTGCCAATAACCCATTACTTCAGGTCACAGGTGCGGGAGGCCT GGTACTATG I I 1 I 1 CACA I GGCGGAA I 1 1 C I AGTAATTACAGTGCGTACGTACATACGATTGCTTCGTATTGCG AATTCCGCACATTGTCCATAACTGGTGTTAAAAGATTGCTTGCTCATCGGCCCTGTAACTACTATGCCCAAATT GGTGCCCGGATCGTCGTCGCATTTGCCTGTCAAGCACACCACTGGCAGAACCCGAGGCGTGTTGACCAATCAT GGTCCCTCGATGGTGCCTGATTGGGGAAACTCGTATGTTCTCCCTGAAACATAGACCTCGATTGTGTCAATTCT GGAATACGTGGGGGGATATTCCCCAAAATATCTAAAATATGTCTAAAATAAGTAATTACTCGAGCAAAACTGC CCAATGCGGTAATTGGATAAGTGGGAGAATTTTGCGACTAAGCATTCTTGTCGCCCAAAATAGCATCAAAACA TCGATGTCGACCCGGTCCTGACTCTTTGAATCGTAAAAAAATTTCTTCAAACTACTAATTATAGCAGATTGTCG TGCAGAACCCAGCAATCTGCCCTGAGAGTGCGTCTCGAACAATAGTGCGTTGTTTCTTTTCAGCCCACCAATA ATACTCCAACAATACCAAATCTCAGTTCATATCAACTGCTCCGATTATTTGTTTACCTTTCGAGGCACAGGTAAA TTCTTGCTTTTTCCAGAAAGGGACTGAAGCCCAATGTTTTGGGAGGTATAAAACGGGAGCATCCGCTAGGTAA ATTCTCAACTAACTTTGTTAATTCAATCGTCTTTCGCTTAATTAAAAP47 47 TTCATCAGTTGCCCATTCACTCTTATCTGGCTTCAAGGCTTTACTGTTTCCCCTTTAGCTATCCTGATGCCCTACC AAATCGATTGTTGCCCTTACACCAATGTACGATCACAACAATTCCCATGTTGTTAGTCCCTACCATTTGCGAAG CTCGGAGGCCTAGGTCGTTGAACGTCACACATTACAGCTGCTCCGAAATTCGCATAAGGAACACTCGCACCAA TCACAAGGTGATGGAAATTGCTTACGGAGTAGAAACTCCCAATCCCGAAGGTAAATACTTTTCTAGTGCACCC CGACATTCGACTCAAAAGGCTTAAACTAAACTCCTAAAATGTCCGTGGTTGACCAATAGAAAGTATCACTCAG CTCCCTGATTGTTCATAGCCTAACTGTTTCTGAATCTCTCCAAGTTTATTGCTGTCGGGTGAGCCTATGATTATC CCCTTTCACAATAGGCTCATTGTGTCTTAGGAAGTACCTGCCCACTTCCCCCTGATAAACTTTCCACCATCCCCG GTCATTCGCTCATGACCTTGTTATTACCATGCCAAAACATCCCATAATGAAAGGGTATCGGCAACATGGGAGC TAAATTTCAGACCCTCGAGATGGAGTCGGTAATCGTTCGAGAATCACATGGCCACCCCACATTTCAATTGTAGATCAGACTGTCAATCTTGACATAACCGTCGATAAATGACTTAGATTTCCTTCAGATACTCAGATTATCAGTATCTAttorney Docket No. 54282-0011WO1Sequence SEQDescription iDNO. Sequence GGACTCTCCTGACCTTTTTCTATTTGCTCCAAAGTCTTCGAATCTTTCCTATCTTGTTGGAGTCTGACAAACTACT TTAACGTTATTGGCTGAATTCCACCCTCGGATCCAACTTCTCCTTTTCGCTACCGAGCCAAGGCAAATGTCTGA TGCAGCTAGTTnTACTGGCATACCAGGAGATCGCATTCGGGACATATATTATGGAAGTTCCCTTCTnTTTTTC CTTC 1 1 C 1 i 1 1 1 CCC 1 1 1 1 GTTCCCGTTATACAGTP48 48 TATTTTGTCGAATGTTGCTGCTTAGTAAATTAGAGATACCGATTTGCGCGAAAATTTGACACTAGATAAAGGG TGCTGCGAACGAAACACACTCGCACATATCTTACGTAATACATTTTTTGTAAGTTCCACAAAGTCTCTATGTAG TTCCCGACGGACCTTCTTGATACAGGCTGCGACCCGCCTACCGGTTATCAGCTCATCGGGTCAGCCCATCTCTA CGCGCTTGTCCCGTACACCTAAAGTTTCAGTTCCACATAGACCGGAGTCCGCTGAAATCTTATTGCAAGAAAA GCGGGCAAGCTTTTCGCTGTTTTCTGCAAGTTAAAATTTGCCAGAAAGTAATTTATTAGAAGCAGCGAAAAAA AGAGGGGCACTCAGGCATCTCCGAGATACCGACAGAGGGCGGAGACAACTGCTGCCAAGACTTCTGAGCAA TTGTATGGTAGCACTTACTACTATAGTAGCTAAATAAGATATGGAACATGCATTAAGTATCGCCATCCACCCCC CGGACTCCACATTACGCTTTACTCCACAAAATCGGCACAGGGGAACGGGGGGCGGGTAGATGAAGTACGCCT GAAACAATTATCCTAATCCCCTCCTACATTAAAAAAACCCCTTGGATCTTTGTCACCCCCCTCGCCCTAAGCTTT GGGGTTCTAGTGATGCGTAGGGGAAAAAAACCCTTAGGGCCCCAAAGGGACTAAGGGATCACTAATAGAAC AATTTCACACCGGAGCCCGCGATAGAAATAAATAAGGTGACCGGAGGGACGGTAACAACAGTCCGAATGTT GTGCCAGAAAATGGCTTTTACCTGGGGTTCTGTCCCGCATTGTCATCCCCAAATATGACACCGAGAATGACTT CTCGGAGCAGAATACTTATCCCCATCTTGTATATAAATAGAGAATAATTTTCCTCCAGTTTACTCAATCATTCAC CAGACAAGCAGTACAACAAGAGCTTCTTTCTTACTACACACCTTCTTAATTATAAACTAAACTP49 49 CCATAAATATGGGTCGTGCACTACACACCCCCTTGGACCGCCCCCCAGGGTTTCTAACCGCTCGAAATTGTGA ACTGTGGTTGGCCAATCCAAGCGCGCCCTCGACACTCCTCAACGCTG 1 1 1 1 1 TATATTAACTAACCCCTTCCTTT CCTTTTCTCTCCTACACCCAGTGTTAAATCTTTATCTTTAATAATATTCAAAGATGCTTTCAGCACGCCCCGTCAT TAGAAGAGCTGCTCGTTCTGCTGTCGCCATCAATGTCGCCCGCTCTGTTCCTCGCGTGGTATGTATTTCCTGAT GATTTGAATCAC 1 1 1 1 1 GA 1 1 1 GGC 1 G 1 GAAL 1 GGC 1 CCCCCA 1 GAAAAG 1 i 1 G 1 CTTTACTCAACGTTGAAGC ATTATTGATGATTATTTTGGATTGTAGAGGATCAATTCCATAGAATGCTTTAAATATTTCACACATTAATGTGTT TTCGAACAGGACAATCGCTTCAAATGGTGTGGTGAAATCTATCAAAAGTGTACnTTTTCTTTCCATTGACAACT ACTAACATATCATTAGGTCCGCCCATTAGTTTCTAGAGGTTACGCTGCCGCCAAGGCTGCTCCAACCGAAGTTT CTTCCATTTTGGAAGAGAAGATCAGAGGTG 1 I I C 1 GCCGAGGC I GAC 1 1 GAACGAGAC 1 GG 1 AGAG 1 C 1 I G 1 C TGTTGGGTAAGTTTTTCTGAATTTTTTTTTGAATATGTCATGGGCTGATCTTAGGGAGGCATGATACAACAGTG CTTTACTCCACAATTGTGACGTATTGATTGATGTGTTGTCCTCAGATATC 1 1 C 1 1 G I CCAGA 1 CCA 1 I I I I 1 i 1 i C AAGTTTTCTCGACATTTTATTGGACAGTCGGAGATGCTCGACTTGACTCCCTAAGAACTACGCCCTTACAAACA ACCTTAAACTGAAGCTCAGTAAACTAACATTATAGTGATGGTATTGCCCGTGTCTTCGGATTGAACAACTGTCA GGCTGAAGAGTTGGTTGAATTCTCCTCAGGAGTCAAGGGTP50 50 GCTCCTATGTTGACGGAGAGTGTTGGGTCTAACATCATGGCACATGGTAGAGGAGGTGTTAAGACATCTAGA GAGCGTGATAGAGAGGAAGAGATCAGAGAATACGAGGAGACCAATTTCACTAGATTACCAACTTCGGTTACT GAGAAGTCAAAGAAACAAAAGAAAGATCATAGATTGAACACCTTTGCAGGAGAGGATTGGTCATTCTTTGGC AAGGACAGAGATGAAGACATGAAGAAAAGTGCGAGGAAGAATAAAAATACTGCTTCCTCCGCCTGGGAAAG AGCAAAAAGACGCAGAGGAAACTAAAGTGTGTAATCATATATATAATAAATGAGGAATAATAATTGAATAGA GATTTAACGAGTCGAAG 1 I I C 1 GAAATATACGCACAGTTTATATTTATGATTTTGATATCTAACTACAGTCTTCT CCATATATTTAACTATAAATAATAAAGTATATAACTCTTATGAAACTGTTTCACCACATTTTTTTCTACGTAATCG AACTCCGAATGCGGTTCTCCTGTAACCTTAATTGTAGCATAGATCACTTAAATAAACTCATGGCCTGACATCTG TACACGTTCTTATTGGTCTTTTAGCAATCTTGAAGTC 1 1 1 L 1 ATTGTTCCGGTCGGCATTACCTAATAAATTCGA ATCGAGATTGCTAGTACCTGATATCATATGAAGTAATCATCACATGCAAGTTCCATGATACCCTCTACTAATGG AATTGAACAAAGTTTAAGCTTCTCGCACGAGACCGAATCCATACTATGCACCCCTCAAAGTTGGGATTAGTCA GGAAAGCTGAGCAATTAACTTCCCTCGATTGGCCTGGACI 1 1 1 CGCTTAGCCTGCCGCAATCGGTAAG7TTCAT TATCCCAGCGGGGTGATAGCCTCTGTTGCTCATCAGGCCAAAATCATATATAAGCTGTAGACCCAGCACTTCAATTACTTGAAATTCACCATAACACTTGCTCTAGTCAAGACTTACAATTAAAAttorney Docket No. 54282-0011WO1Sequence SEQDescription iDNO. SequenceP51 51 GATAAAGAACGACCGGAACCAATACGGGGTTGTGCAGGTGGGAATAAATATGTTGGTTTGGATTCTTGACGT GAAGAAGGTATTCTAGTCGATGAAGTGGTTGATAAGGATATGGCGTCACTGAGTTGTTTTCTTTTCCTATGTT GCGGTGTTGGGTCAGGAGTTAATTGATTCACCTCCATAACTCTGGAATTTCTTGAATGTGGGGTTTTCAGATG GGCATCTTTCTTGACGGGGTTGTGAGTAACGGAGGAACCTGGTGTCTTGGGTGTGAACGGTGTTTGAGCCTG TACGCGGTTACTTCTGGGCGGAGTACTCGGAGTCATGAGAGCCATTGATTAGAAGGTGAATGAGGGAGTCAC CACTCTAAGCAAACAAAATGAGGTCGAAGCAAAAAATAAAGTAAAGTAGCACTTCTGGCAGGTTAGATCAAA GAGTGACGGGAGATTTGAAGATGGCTGG 1 1 1 i 1 CCTTAGTCTTGGAAGAGGTTTGTGTGGGTATCAGCGAAT ATTCCCCGATTAGGCAAATTAGTTGCATTGAAATTAACACGACATGGTGATTTGTGGTAACAAATATCTATTG GTGGTTGGTGTGTGGGTGTAATAGTGGTCGTGTCATGATGATGGTGTTCAGGTGTTGTCATAGATCGGTCTTC AGTAAGAGAAGGAAGCTTGGTGACGATCACAGCTATGATGTAATAGAAATTGCTAAGCAATTGTGAGGTGTG ATGTATTTTGCAGAGCAATTGTGCGGTACAACGGGGTGTTATTGTCTTCACAAGGCATTTATTGCGAATTTCGT AGTTGAAAGAATATTTTAGCACAGGGTGCTTGACCCCTATTGTTGCTCGCTAAACCATGATTGCTAAATGATG ACATAGCAATCACTTTACTAAGATTGCTATAAGGACACCTTTCTTAGTATAAATGGACACTCTTTTCCCCTGCTA AACTTCTTTTATTTTTCACACTTAAACAGTTACAAAACACAAACACAACTAGAAP52 52 TTTATTTTATCAATCCCTGGATCTGCCTGTAAGTAATACTACCGCCGAAAAAAAGAAGGTTCGGACCGGGACC GGTCAATCCGACTTTACGTTTCTGTTGTGCACTGGATCTATTCTAGGCACATATCTGAATTGGAACGTGTCACG TTTCGTAGTTATGACTAAGGCGATTTATGAAGTCATCACCAGATAATCTCTTTACAAGGAGACGGACGCCCTTC TACATACACACCTTCATCCTCTTGAAGGGTAGGAAAAAAAAAAGATTGCAGCACCTGAGTTTCGCGTATGGTC TCCCACTACACTACTCGGTCAGGCTCTTAGCAGCTTAACTACGGTTGATCGGACGGGAAACGGTGCTTTCTGC TAGATATGGCCGCAACCGAAAGCTTTCTTTTACAGCTAGCTATTACCAGCTTACATGTATACACAACAATGTCC ATCATAAATCAAAAAAGAGTTTCTTTACAGAGTGCTTGTGTTTCCTTGCGGTTTTGTGTTTCTGATGATGGGTA ATGATTCTTTAAAGCTAAGATGATTACATGAAAAAGGCTCACCACTTGGAGAAGGGCACTCAGTTAGCTAACA TTCAAATACGGTTTTGGATCTCATACCATGAAAAGTAATGTATCAATAAATCAGCTTCAGGGTTCGCCCCCACT ACTGGTGATCTCATATCTTCTGACCTTCAACCTTGCAATAATTAGTTTACCCAAGTATGAAAGTTCTCTCTTTGA TAGTCTCTTTCAGTGCCTGCAGTGTATAAAATACCGTCTATCGCAATGGGTGTTCGACATTGTAACCACCGAAA GCAATATGCTACCAGTTGGTAGTACCGCTGATAGTAGCAACTGTACCAGCTAAATCATTGGATCAATCCACAT ATTATTCTCGCTAACCACTAACAACATCCAAACATCATCTCAATTCCACCAATAAACGCGCGCTCATTGACAAC AGAAAATCAGTAATCTTCAGTAACCTCAGTAATAACTCCACCATAP53 53 TTATCCGATGCGCTTCAAAGCTGGAATTGTAAATATAGAGAAAAAGAAGGATGTTGTTTTA i 1 C 1 1 GAAAGAG TATAATTTTACTTCTAGCAACTCTCCCACTTCGCTTGACTTCATTTATTTCTTGGGCACATAGGCGTAGTAATCT AGACCAACAGATAATTTGCCGGAATGATATAGCGATTGGAAAATGAACTGAAATTTTTTGCTGTCTTTCAATTT GACGGGCAGTTCATCAGTGACCGACCATATAAATACGTTGAGAATGTTATTCTTCCTCGTAGTTGAAGTGGCT TCATAATTTCAGAACTCAATAGATAAACTAGGATGTTTTAAAGCAATTAATGCTCACAAGTAAGGAGCGACTC TCTTGCI i 1 i CGAATACTAAAAGTATCGTCCCAACCCAGAAAAAAAGACCTCTTAACTGCAAAATAAACTCTAT ATATTTCTTCTAAAACAGTTTCAGGTTGGATAGTATCGCATTCTCATCACTTCTAACTAGTAGGCCATGAGATA TATTAACGTTTACTTGAGTTCTAAGTTCTCCGAATTAGATGCACAGCACAAACAAGATTAGGTTTCACTTGGTA CAAAATACGAACAGAGTTTAAGGTCGTAATTTCATTTCGTTATTGATCCCCACAATCTATTCTTATCACAGTCAT CAGATAGTCGCGAAAAAGCATGCAGAAAAGGGGGTCGTCCCTATCTAAGTTGTAGCATTACAACAAATATGA CTACACTCAGTGTCGCAATCGGTATAGCCAACGCTGCAAAATGGATTCTACTGAGAATGGTATGATGATCCCA GGATCAATTTCCCAAAAATTAAAAAAAGTAAAATAAAAAGCATCAGATATTAGGGAGGTGGTAAGATTGCTC TGCAAGCGATCACGAGATTTTAGGTTTTCCTTTATGTACTATATAAAGCGCAGATTGGATGCCGCTTTTCCCTC CTGGGCTATGATAATATAGCGAACGAAATACACGCCAAAATAAAP54 54 CTACGGAGGAAAAGTCTCACAAGCTTTTAACCAAGTTGAATCACGACGACAACGATAAAGAAATCCTCAACCA TCTAACACATGAAGTACAAAGTAGAAATGTGATCTTATTGGACAAACTAGAGGAGCTCAACAAGGAACTGGG CTGGATTAAAGACCGAAAATGAGGAACCATGAGCACTGGGCGTTTCCAGAAAAACTGCAACCAACGATGGG AAAATGATACCACACTACTATGGTCACCCCACATTGTGAAATTTCAAACCAAAAAAGATCAACCCCATAATTCCCCAGAGGGTTTTCCCAACAATTTTCCAACGGACTTGATAATGAGTCAGATCATTTGAGCATATTCATCTTACCCAttorney Docket No. 54282-0011WO1Sequence SEQDescription iDNO. Sequence CTTATTCCGTGACAATTTACCTATTCCATTCAAAGCATACGGTATCCCGTGACCTTCTCATGGAGATCATTCTCC ACCGATACAGCATATACACAGATATACCCAACTAATATCAATTGGACCTTGATATGGTCGACCTTGATGGTCCC GTCCAACCTTAAAACTTAGTTTAATGCTATACTTTCGCCTTGAACCAAATCTGTCTCCCCCTCAATCATCTCTAT GCAAGAAGGTCAACACTGATTACGTGAGCAACAGCCAGCAATCGTTCGAGTCCCCGCCAAAAAAGGCGGAGT TACTGCTCCTTGTGACCACACCCCCTGAGACCACGTCCCTAAACGATCCTTGTCGGTTCCTTCGTCCAATTGGC AATTGCCACGCATACGTGAATCGTTATTGTTTCGCCTACCTTGCGTCATTCGTTCCAGAATGTTCGACATACTCC TCTAGAACATACCGTCACACCACCATCTTAAGTTATCTTCACGTGACCATGACGTACATTGTAGTTGACTACCC CATTCTCATCATTCCGATGCGGCCAAAAATCTCTATATAAAGACCGTATCCCCTAATATTCTCTTCTTGTTAAGA CATTAACTTAGTTAATTCACCAATTACTCACTTATAAACAAACAAAP55 55 TCCAGTGTAGCACTAAAATCTAATATCTTCGGCTTTATAC’fTnTrGTTCATCCGAAAGCTTACGAACAATTCTT TCTCCTGTTTTATTGTGGATATAGACAATTTCGTCAGTTTCTTGGAGAGAAGAGTTATTTCCGGTTTTGGCTGG CCCTATAAACGGGTTCTTGGATTTGGATCTAGTAATAAAAATGTCACTGTCATTCTCGGAGCTGAACTTTCTGT TGTACGAAGATGGGTTGTTCCACTGTTTTGCCAGCTCTTCATTGATGATrnTTTAGTGGGTGTTCTTGGAGGT TCACGTTGCCTATAATCTTGACGTTCTTCTTCATCACTATCGATGCCATCAAAATTAAGCGTCCTTATTGCAGGC TTTTGTGATTTCAACTGCAATCCTTCTATCTCTTCATCAGAGCTTTCGAACTGAATACTATCACTCAAAACTGGC GACATTGCACATTTCCGCAAACCATTTCGGGAATCTATGCTAGCTCTTCTAGACGATAAAGAACGACCGGAAC CAATACGGGGTTGTGCAGGTGGGAATAAATATGTTGGTTTGGATTCTTGACGTGAAGAAGGTATTCTAGTCG ATGAAGTGGTTGATAAGGATATGGCGTCACTGAGTTGTTTTCTTTTCCTATGTTGCGGTGTTGGGTCAGGAGT TAATTGATTCACCTCCATAACTCTGGAATTTCTTGAATGTGGGGTTTTCAGATGGGCATCTTTCTTGACGGGGT TGTGAGTAACGGAGGAACCTGGTGTCTTGGGTGTGAACGGTGTTTGAGCCTGTACGCGGTTACTTCTGGGCG GAGTACTCGGAGTCATGAGAGCCATTGATTAGAAGGTGAATGAGGGAGTCACCACTCTAAGCAAACAAAATG AGGTCGAAGCAAAAAATAAAGTAAAGTAGCACTTCTGGCAGGTTAGATCAAAGAGTGACGGGAGATTTGAA GATGGCTGG I I 1! I CCI I AG I CI I GGAAGAGG! 1 I G I GTGGGTATCAGCGAATATTCCCCGATTAGGCAAATT AGTTGCATTGAAATTAACACGACATGGTGATTTGTGGTAACAAATATCTATTGGTGGTTGGTGTGTGGGTGTA ATAGTGGTCGTGTCATGATGATGGTGTTCAGGTGTTGTCATAGATCGGTCTTCAGTAAGAGAAGGAAGCTTG GTGACGATCACAGCTATGATGTAATAGAAATTGCTAAGCAATTGTGAGGTGTGATGTATTTTGCAGAGCAATT GTGCGGTACAACGGGGTGTTATTGTCTTCACAAGGCATTTATTGCGAATTTCGTAGTTGAAAGAATATTTTAG CACAGGGTGCTTGACCCCTATTGTTGCTCGCTAAACCATGATTGCTAAATGATGACATAGCAATCACTTTACTA AGATTGCTATAAGGACACCTTTCTTAGTATAAATGGACAC 1 C 1 i 1 i CCCC 1 GC I AAAC 1 i C i i i 1 A 1 1 1 i 1 CACAC TTAAACAGTTACAAAACACAAACACAACTAGAAP56 56 CAAACATTTGCTCCCCCTAGTCTCCAGGGAAATGTAAAATATACTGCTAATAGAAAACAGTAAGACGCTCAGT TGTCAGGATAATTACGTTCGACTGTAGTAAAACAGGAATCTGTATTGTTAGAAAGAACGAGAGTTTTTTACGG CGCCGCCATATTGGGCCGTGTGAAAACAGCTTGAAACCCCACTACTTTCAAAGGTTCTGTTGCTATACACGAA CCATGTTTAACCAACCTCGC 1 i 1 1 GACTTGACTGAAGTCATCGGTTAACAATCAAGTACCCTAGTCTGTCTGAA TGCTCCTTTCCATATTCAGTAGGTGTTTCTTGCACTTTTGCATGCACTGCGGAAGAATTAGCCAATAGCGCGTT TCATATGCGCTTTTACCCCCTCTTTTGTCAAGCGCAAAATGCCTGTAAGATTTGGTGGGGGTGTGAGCCGTTA GCTGAAGTACAACAGGCTAATTCCCTGAAAAAACTGCAGCTCAGGGATTCCCACTATTTGGTATTCTGATATGI 1! 1 1 CC 1 GA 1 A 1 GCA I CAAAAC 1 C 1 AA I C 1 AAAACC 1 GAA 1 C 1 CCGC 1 A 1! 1! I I 1 1 1 1 1 1 1 1! GATGACCCCGT TTTCGTGACAAATTAATTTCCAACGGGGTCTTGTCCGGATAAGAGAATTTTGTTTGATTATCCGTTCGGATAAA TGGACGCCTGCTCCATAI 1 1 1 i CCGGTTATTACCCCACCTGGAAGTGCCCAGAATTTTCCGGGGATTACGGATA ATACGGTGGTCTGGATTAATTAATACGAGATCTCAGGGATTCCCACTATTTGGTATTCTGATATGTTTTTCCTG ATATGCATCAAAACTCTAATCTAAAACCTGAATCTCCGCTATTTTTTTTTTTTTTTGATGACCCCGTTTTCGTGAC AAATTAATTTCCAACGGGGTCTTGTCCGGATAAGAGAATTTTGTTTGATTATCCGTTCGGATAAATGGACGCCT GCTCCATA! 1 I 1 I CCGGTTATTACCCCACCTGGAAGTGCCCAGAATTTTCCGGGGATTACGGATAATACGGTG GTCTGGATTAATTAATACGCCAAGTCTTACATTTTGTTGCAGTCTCGTGCGAGTATGTGCAATAATAAACAAGA TGAGCCAATTTATTGGATTAGTTGCAGCTTGACCCCGCCATAGCTAGGCATAGCCAAGTGCTATGGGTGTTAGATGATGCACTTGGATGCAGTGAGTTTTGGAGTATAAAAGATCCTTAAAATTCCACCCTTAttorney Docket No. 54282-0011WO1Sequence SEQDescription iDNO. SequenceP57 57 CAAACATTTGCTCCCCCTAGTCTCCAGGGAAATGTAAAATATACTGCTAATAGAAAACAGTAAGACGCTCAGT TGTCAGGATAATTACGTTCGACTGTAGTAAAACAGGAATCTGTATTGTTAGAAAGAACGAGAGTTTTTTACGG CGCCGCCATATTGGGCCGTGTGAAAACAGCTTGAAACCCCACTACTTTCAAAGGTTCTGTTGCTATACACGAA CCATGTTTAACCAACCTCGC 1 i 1 1 GACTTGACTGAAGTCATCGGTTAACAATCAAGTACCCTAGTCTGTCTGAA TGCTCCTTTCCATATTCAGTAGGTGTTTCTTGCACTTTTGCATGCACTGCGGAAGAATTAGCCAATAGCGCGTT TCATATGCGCTTTTACCCCCTCTTTTGTCAAGCGCAAAATGCCTGTAAGATTTGGTGGGGGTGTGAGCCGTTA GCTGAAGTACAACAGGCTAATTCCCTGAAAAAACTGCAGATAGACTTCAAGATCTCAGGGATTCCCACTATTT GGTATTCTGATATG I 1! 1! CC 1 GA 1 A 1 GCA I CAAAAC 1 C 1 AA I C 1 AAAACC 1 GAA 1 C 1 CCGC 1 A 1 1 1! 1! 1! 1 1 1 1 TTTGATGACCCCGTTTTCGTGACAAATTAATTTCCAACGGGGTCTTGTCCGGATAAGAGAATTTTGTTTGATTA TCCGTTCGGATAAATGGACGCCTGCTCCATAI 1 1 1 1 CCGGTTATTACCCCACCTGGAAGTGCCCAGAATTTTCC GGGGATTACGGATAATACGGTGGTCTGGATTAATTAATACGCCAAGTCTTACATTTTGTTGCAGTCTCGTGCG AGTATGTGCAATAATAAACAAGATGAGCCAATTTATTGGATTAGTTGCAGCTTGACCCCGCCATAGCTAGGCA TAGCCAAGTGCTATGGGTGTTAGATGATGCACTTGGATGCAGTGAGTTTTGGAGTATAAAAGATCCTTAAAAT TCCACCCTTP58 58 AGATCTAACATCCAAAGACGAAAGGTTGAATGAAACCTTTTTGCCATCCGACATCCACAGGTCCATTCTCACAC ATAAGTGCCAAACGCAACAGGAGGGGATACACTAGCAGCAGACCGTTGCAAACGCAGGACCTCCACTCCTCT TCTCCTCAACACCCAC 1 1 1 1 GCCATCGAAAAACCAGCCCAGTTATTGGGCTTGATTGGAGCTCGCTCATTCCAA TTCCTTCTATTAGGCTACTAACACCATGACTTTATTAGCCTGTCTATCCTGGCCCCCCTGGCGAGGTTCATGTTT GTTTATTTCCGAATGCAACAAGCTCCGCATTACACCCGAACATCACTCCAGATGAGGGCTTTCTGAGTGTGGG GTCAAATAGTTTCATGTTCCCCAAATGGCCCAAAACTGACAGTTTAAACGCTGTCTTGGAACCTAATATGACAA AAGCGTGATCTCATCCAAGATGAACTAAGTTTGGTTCGTTGAAATGCTAACGGCCAGTTGGTCAAAAAGAAAC TTCCAAAAGTCGGCATACCGTTTCTCTTGTTTGGTATTGATTGACGAATGCTCAAAAATAATCTCATTAATGCT TAGCGCAGTCTCTCTATCGCI 1 L 1 GAACCCCGGTGCACCTGTGCCGAAACGCAAATGGGGAAACACCCGCTTT TTGGATGATTATGCATTGTCTCCACACTGCTGATAGCCACGTTCATGATCAAAATTTAACTGTTCTAACCCCTAC TTGACAGCAATATATAAACAGAAGGAAGCTGCCCTGTCTTAAACCI i 1 i 1 1 1 1 1 ATCATCATTATTAGCTTACTT TCATAATTGCGACTGGTTCCAATTGACAAGCTTTTGATTTTAACGACTTTTAACGACAACTTGAGAAGATCAAA AAACAACTAATTATTCGAAACGP59 59 TGGGTTGTATCCATTCACTATTTACTCTTTGTTTCATTTCTTGAATTATTTGGATACTACTCTGCTGGCAACTCTA CCAGTCTCAAACGCAGACCAGGTTCGCAATTTGATTAGAATGTTCGTGAGCTCTTACAATGAAAAGTCCATGT ACCTTGCGGCTAGTTGTGAATTAI 1 1 1 1 AGTTCCTTCTTTGTTGCTATCCTCTTTGAAGTCGATTATATTGCTGG AATGGTATAGGGCTCCCTTTTCATTTATCAGGCAATTAATCGTGGTATrCTCCGTGATCTCGTTTCTGAGATTAA GATATCAACAGAATGTTTACATGAAACAATTAGTTGATAGTTATGATTTGAAGATCAGTCAACTCTTATACCAT CCCCAACTTCCTCAAGGATTCAGGTTGGGATATTTACGATTTAAGAGTCTATTAACAAGCACGCTAGGATACTT AGAATTGGAAAAAAAGACCAGATAATGAGATTGAACTCGAAATTTAGGATCACCCATATGACGAAGAATTCA TTTAGATTATTGAAGGTGTTTTCATGTTTACCTCCATGAGACCATTTCTGTCACAGCAAATACAGGCAACGCTT TTCACCAGAGCTTGTTGGTACAACTTTTCAGATGACGCCAAATTCTCACGCGCCTCACTTTGTGCGGCGCTAAC AATAGGCCA i 1 1 1 1 1 1 G 1 ACL 1 CLCGGA 1 GG i 1 LAGC 1 LAA 1 LAL 1 CGA 1 i GAGAGG I I i 1 1 GTTCCGCGATTTT TGTTCACCCCACACTTTTCTCGAAGGTTCTAGCAATCAAGATAAACACCGCAAAGAGAGCCGCAGGAACCATA TGTGGTACCACAAGTGGTCTTAAACAACTCTGGTAGAATTCGATGGAATTCGATGGAAGCCGATCGACTCCGA TCGAATTGAAGCAATTCGTATATATAAGGAGAACCTAGTTCCACCCCTTACTCGACCATTAGTTTACAAGACTA ACTTCACAGAAGCATAGAAATTAAACAAAGTTAAACATTP60 60 ACGAGCCA 1 1 1 1 I CGATCCGTGTCAGTTCCAGACCAGCAGTTTAACTACGCAAATCCACAGGAATTTCTACATC ACAATACCAATGGTAATACCACGACGTCAAGGAATGGAAACGACGACTTGGAGGAAAACTTCGTCAACCTCT TGCGGAGTACCCGAGGCTAAGACAATAAGAAGAAAAAAAAAGAAAAGCGGTGGGGGAGGGATTATTAAAT AAGGATTATGTAACCCCAGGGTACCGTTCTATACATATTTAAGGATTATTTAGGACAATCGATGAAATCGGCA TCAAACTGGATGGGAGTATAGTGTCCGGATAATCGGATAAATCATCTTGCGAGGAGCCGCTTGGTTGGTTGGTGAGAGGAGTGAAATATGTGTCTCCTCACCCAAGAATCGCGATATCAGCACCCTGTGGGGGACACTATTGGCAttorney Docket No. 54282-0011WO1Sequence SEQDescription iDNO. Sequence CTCCCTCCCAAACCTTCGATGTGGTAGTGCTTTATTATATTGATTACATTGATTACATAGCTAAACCCTGCCTGG TTGCAAGTTGAGCTCCGAATTCCAATATTAGTAAAATGCCTGCAAGATAACCTCGGTATGGCGTCCGACCCCG CTTAATTATTTTAACTCCTTTCCAACGAGGACTTCGTAATTTTTGATTAGGGAGTTGAGAAACGGGGGGTCTTG ATACCTCCTCGATTTCAGATCCCACCCCCTCTCAGTCCCAAGTGGGACCCCCCTCGGCCGTGAAATGCGCGCAC TTTAGTTTTTTTCGCATGTAAACGCCGGTGTCCGTCAATTAAAAGTCGCAGACTAGGGTGAACTTTACCATTTT TGTCGCACTCCGTCTCCTCGGAATAGGGGTGTAGTAATTCTGCAGTAGTGCAA H i l l ACCCCGCCAAGGGGG GGCGAAAAGAGACGACCTCATCACGCATTCTCCAGTCGCTCTCTACGCCTACAGCACCGACGTAGTTAACTTT CTCCCATATATAAAGCAATTGCCATTCCCCTGAAAACTTTAACCTCTGCI 1 1 1 I CI I GA I 1 1 1 1 CCTTGCCCAAAG AAAAGP61 61 GAATTCGGACAAATGTGCTGTTCCGGTAGCTTGTAGGAAGCGGCATCCGTAGGGCAATATACGACTATAGCT TCTAAAGCGTAGTACAATGAAATGTTCGAAGGAACAACAAACGGATTTGI 1 1 1 1 CGTAGGCTCAACCCGTTGA GGTGTAACTCTTTAGCGAAAGGGTAAGATTGATTGTTCGAAGTAGGGCCTCAAAGGGAAAGAGAAAAAAAA AAATACACCGAAGAGTTACGTAAGCATATATTTTTTACGTAAAGCATGATTGAATTTCAGCAGTATTGTTTAAC AAGGCTGATGTCGTGTGCCAATCAAAACAAAAGAGATTCGCATAATGCCATAATTGGGGTGTGTGGGCGCCC CCTAAAACGTCTTTCTCATCATCATCTGCAACCCCCATCGAACCTCATTAAATCACATGACTTGTGCGATCCTCG GTCAACTCGTTCCGTGCACCCATTCCACCCCGGGCTGACCAACGCAAGGTTCTCCGAGAGTCCGCTACCCCAG ATTTATATCAGCAACCAGTCACCI 1 1 1 1 CCGGGCACGACTCTATATGCCCTGGAAAACCGGAGACGATGAGCC TGACTATAAAAGGTGACAGAACCCCCAACTCTGGTTAATCTCTTCAACAAATACTTTATTTTCTTTCAATTCAAA GAACACAGTATCAAGTATATCAAGAP62 62 AAAGTCAGCGGAATGTTTGAACAGGGTCCATCTGAGAAAGAGGAGCCAGCACAGGAATCGGTGGTAATAAA CGAACTCATGGAAAAAGCACAGTCCAGGCCTGAAAAGCCACCCAAAAGACTGGCAGAGTTGGAGGAAATCT GGGTGGATGGTTTGCAAAAGAAATACGGTAACGACTATGAAAGAATGAAATGGGATCGCAAACTGAACCCC ATGATGCTAACGCCCCGCAAGTTGGAGAAACTGTTTGAAAGGAAATTGCAGGTCGAAGATTACGACAGAAGA CATACAGCATGATTAGGTCACACGGCTTGTCG 1 1 1 1 1 C 1 1 1 C 1 1 1 1 1 1 1 I ACCCACGTAGAAGGATTATAGGGA CTGAACTGACATGACATGTGACTGTAACAGATAGGTAAGTAAGGCACATAATTTAAGTGACAGTGTCAACAA TGCCAA I 1 1 1 1 1 1 1 1 I I I I ACAACAATGCCCACGTTGTTACCGATGCTCGCACGTAGATTCCTTTACTGGCCAAG AACTTGGCGCGAAATGTGATATCGATTGAATCTGATAAAAGAAACAAAAAAAAAAAAAATTTATCCGGTGTA GGGATGTGACTAAACGCCTCGTGTGACAACGTGGGTGGTATCTTTCCTTCGCCACGTGCGCGTGCAACCTATT GTATGGCTAAATTAAAGGGCCATGTCAAAGACCCTTAAACCCTTGATAATAGCAAAGACTGGGGAAGCAGGC CCTGAAAAGACAGAACAATCAGAATTCTCTAATTTCCTCCACCAGAGAGCCGTCCAATGGCATAGATTACCTC GTTAAACGAAATTCGAAAGCTCAATTTCCAAATACCCACTTTCCTTTTCGATCCTTATTGCTGCTGGACCTACTC TCCAAAGTCTTGGCAAGGCCACATGTCTCAA 1 I I 1 1 AATTGAAAACCGTTAGAAAGTGAAGCCGACTTTAGGT ATAAATAGTAGGAACCCCAGCAGGCAGAGCTGATCACTTGTAAACCTTTCTCTGATACACACAAGCATCTATTT GAGTACTCATCTTATAATCATTCACAP63 63 GCATGCAGGAATCTCTGGCACGGTGCTAATGGTAGTTATCCAACGGAGCTGAGGTAGTCGATATATCTGGAT ATGCCGCCTATAGGATAAAAACAGGAGAGGGTGAACCTTGCTTATGGCTACTAGATTGTTCTTGTACTCTGAA TTCTCATTATGGGAAACTAAACTAATCTCATCTGTGTGTTGCAGTACTATTGAATCGTTGTAGTATCTACCTGG AGGGCATTCCATGAATTAGTGAGATAACAGAGTTGGGTAACTAGAGAGAATAATAGACGTATGCATGATTAC TACACAACGGATGTCGCACTCTTTCCTTAGTTAAAACTATCATCCAATCACAAGATGCGGGCTGGAAAGACTT GCTCCCGAAGGATAATCTTCTGCTTCTATCTCCCTTCCTCATATGGTTTCGCAGGGCTCATGCCCCTTCTTCCTT CGAACTGCCCGATGAGGAAGTCCTTAGCCTATCAAAGAATTCGGGACCATCATCGAI 1 1 1 1 AGAGCCTTACCT GATCGCAATCAGGATTTCACTACTCATATAAATACATCGCTCAAAGCTCCAACTTTGCTTGTTCATACAATTCTT GATATTCACAP64 64 TCCCATTACCGACATTTGGGCGCTATACGTGCATATGTTCATGTATGTATCTGTATTTAAAACACTTTTGTATTA H i l l CCTCATATATGTGTATAGGTTTATACGGATGATTTAATTATTACTTCACCACCCTTTATTTCAGGCTGATA TCTTAGCCTTGTTACTAGTTAGAAAAAGACAI 1 1 1 1 GCTGTCAGTCACTGTCAAGAGATTCTTTTGCTGGCATTTCTTCTAGAAGCAAAAAGAGCGATGCGTCTTTTCCGCTGAACCGTTCCAGCAAAAAAGACTACCAACGCAATATAttorney Docket No. 54282-0011WO1Sequence SEQDescription iDNO. Sequence GGATTGTCAGAATCATATAAAAGAGAAGCAAATAACTCCTTGTCTTGTATCAATTGCATTATAATATCTTCTTG TTAGTGCAATATCATATAGAAGTCATCGAAATAGATATTAAGAAAAACAAACTGP65 65 TCCI 1 1 1 1 ACCACCCAAGTGCGAGTGAAACACCCCATGGCTGCTCTCCGATTGCCCCTCTACAGGCATAAGGGT GTGACTTTGTGGGCTTGAATTTTACACCCCCTCCAACTTTTCTCGCATCAATTGATCCTGTTACCAATATTGCAT GCCCGGAGGAGACTTGCCCCCTAATTTCGCGGCGTCGTCCCGGATCGCAGGGTGAGACTGTAGAGACCCCAC ATAGTGACAATGATTATGTAAGAAGAGGGGGGTGATTCGGCCGGCTATCGAACTCTAACAACTAGGGGGGT GAACAATGCCCAGCAGTCCTCCCCACTCTTTGACAAATCAGTATCACCGATTAACACCCCAAATCTTATTCTCA ACGGTCCCTCATCCTTGCACCCCTCTTTGGACAAATGGCAGTTAGCATTGGTGCACTGACTGACTGCCCAACCT TAAACCCAAATTTCTTAGAAGGGGCCCATCTAGTTAGCGAGGGGTGAAAAATTCCTCCATCGGAGATGTATTG ACCGTAAGTTGCTGCTTAAAAAAAATCAGTTCAGATAGCGAGACTTTTTTGATTTCGCAACGGGAGTGCCTGT TCCATTCGATTGCAATTCTCACCCCTTCTGCCCAGTCCTGCCAATTGCCCATGAATCTGCTAATTTCGTTGATTC CCACCCCCCTTTCCAACTCCACAAATTGTCCAATCTCGTTTTCCATTTGGGAGAATCTGCATGTCGACTACATAA AGTTCCGTTCGTCCGAAAAGATCTGTGTAGTTTTCAACATTTTGTGCTCCCCCCGCTGTTTGAAAACGGGGGTG AGCGCTCTCCGGGGTGCGAATTCGTGCCCAATTCCTTTCACCCTGCCTATTGTAGACGTCAACCCGCATCTGGT GCGAATATAGCGCACCCCCAATGATCACACCAACAATTGGTCCACCCCTCCCCAATCTCTAATATTCACAATTC ACCTCACTATAAATACCCCTGTCCTGCTCCCAAATTCTTTTTTCCTTCTTCCATCAGCTACTAGCTTTTATCTTATT TACTTTACGAAA SSI 66 MFNLKTILISTLASIAVASS2 67 MQVKSIVNLLLACSLAVASS3 68 MQFNWNIKTVASILSALTLAQASS4 69 MAATTCFFFLFPFLLLLTLSRASS5 70 MLLQAFLFLLAGFAAKISASS6 71 MVAWWSLFLYGLQVAAPALASS7 72 MSFSSNVPQLFLLLVLLTNIVSGSS8 73 MNLYLITLLFASLCSASS9 74 MKSLILNIISVTLAITSTAASS1O 75 MRFPSIFTAVLFAASSALASS11 76 MFSPILSLEIILALATLQSVFASS12 77 MSFRSLLALSGLVCSGLASS13 78 MSFRSLLALSGLVCSGLANVISKRSS14 79 MKLAYSLLLPLAGVSASS15 80 MTKPTQVLVRSVSILFFITLLHLVVASS16 81 MKLSTNLILAIAAASAVVSASS17 82 MKILSALLLLFTLAFASS18 83 MRPVLSLLLLLASSVLASS19 84 MFKSLCMLIGSCLLSSVLASS2O 85 MSTLTLLAVLLSLQNSALASS21 86 MKLLNFLLSFVTLFGLLSGSVFASS22 87 M KVSTTKF LAVF LLVR LVCASS23 88 MYRNLIIATALTCGAYSSS24 89 MFLKSLLSFASILTLCKAWDLEDVQDAPKSS25 90 MLSILSALTLLGLSCASDLTPPIEVTGNKFFFSS26 91 MINLNSFULTVTLLSPALALPKNVLEEQQASS27 92 MRNHLNDLVVLFLLLTVAAQAHLVTFHSTESS28 93 M KLSATLLLSVFTSI QSAYASS29 94 MRRRAIPLLLLLLLLLLLGSSALAAttorney Docket No. 54282-0011W01Sequence SEQDescription iDNO. SequenceSS3O 95 MRQVWFSWIVGLFLCFFNVSSASS31 96 MQVKSIVNLL LACSLAVARPLEHAHHQHDK RSS32 97 MKLSTNLILAIAAASAVVSAAPVAPAEEAANHLHKRSS33 98 MYRNLHATALTCGAYSAYVPSEPWSTLTPDASLESALKDYSQTFGiAIKSLDADKIKRSS34 99 MFNLKTILISTLASIAVAAPVNTTTEDETAQ. IPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGVS LDKR SS35 100 MQVKSIVNLLLACSLAVAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASiAAKEEGV SLDKR SS36 101 MQFNWNIKTVASILSALTLAQAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAA KEEGVSLDKR SS37 102 MAATTCFFFLFPFLLLLTLSRAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKE EGVSLDKR SS38 103 MLLQAFLFLLAGFAAKISAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEG VSLDKR SS39 104 MVAWWSLFLYGLQVAAPALAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAK EEGVSLDKR SS40 105 MSFSSNVPQLFLLLVLLTNIVSGAPVNTTTEDETAQiPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFiNTTIASIAAK EEGVSLDKR SS41 106 MNLYLITLLFASLCSAAPVNTTTEDETAQ. IPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGVSLD KR SS42 107 MKSLILNIISVTLAITSTAAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGV SLDKR SS43 108 MRFPSIFTAVLFAASSALAAPVNTTTEDETAQIPAEAViGYLDLEGDFDVAVLPFSNSTNNGLLFiNTTIASiAAKEEG VSLDKR SS44 109 MFSPILSLEIILALATLQSVFAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEE GVSLDKR SS45 110 MSFRSLLALSGLVCSGLAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGV SLDKR SS46 111 MSFRSLLALSGLVCSGLANVISKRAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIA AKEEGVSLDKR SS47 112 MKLAYSLLLPLAGVSAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGVSL DKR SS48 113 MTKPTQVLVRSVSILFFITLLHLVVAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASI AAKEEGVSLDKR SS49 114 MKLSTNLILAIAAASAVVSAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEE GVSLDKR SS5O 115 MKILSALLLLFTLAFAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGVSLD KR SS51 116 MRPVLSLLLLLASSVLAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTiASIAAKEEGVSL DKR SS52 117 MFKSLCMLIGSCLLSSVLAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEG VSLDKR SS53 118 MSTLTLLAVLLSLQNSALAAPVNTTTEDETAQJPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEG VSLDKR SS54 119 MKLLNFLLSFVTLFGLLSGSVFAAPVNTTTEDETAQ. IPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGVSLDKRAttorney Docket No. 54282-0011WO1Sequence SEQDescription iDNO. SequenceSS55 120 MKVSTTKFLAVFLLVRLVCAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEE GVSLDKR SS56 121 MYRNLIIATALTCGAYSAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGVS LDKR SS57 122 MFLKSLLSFASILTLCKAWDLEDVQDAPKAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINT TIASIAAKEEGVSLDKR SS58 123 MLSILSALTLLGLSCASDLTPPIEVTGNKFFFAPVNTTTEDETAQJPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFIN TTIASIAAKEEGVSLDKR SS59 124 MINLNSFLILTVTLLSPALALPKNVLEEQQAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFIN TTIASIAAKEEGVSLDKR SS60 125 MRNHLNDLVVLFLLLTVAAQAHLVTFHSTEAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFI NTTIASIAAKEEGVSLDKR SS61 126 MKLSATLLLSVFTSIQSAYAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEG VSLDKR SS62 127 MRRRAIPLLLLLLLLLLLGSSALAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAK EEGVSLDKR SS63 128 MRQVWFSWIVGLFLCFFNVSSAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIA AKEEGVSLDKR SS64 129 MFNLKTILISTLASIAVAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKRSS65 130 MQVKSIVNLLLACSLAVAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS66 131 MQFNWNIKTVASILSALTLAQAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS67 132 MAATTCFFFLFPFLLLLTLSRAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS68 133 MLLQAFLFLLAGFAAKISAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS69 134 MVAWWSLFLYGLQVAAPALAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS7O 135 MSFSSNVPQLFLLLVLLTNIVSGAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS71 136 MNLYLITLLFASLCSAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKRSS72 137 MKSLILNIISVTLAITSTAAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS73 138 MRFPSIFTAVLFAASSALAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS74 139 MFSPILSLEIILALATLQSVFAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS75 140 MSFRSLLALSGLVCSGLAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS76 141 MSFRSLLALSGLVCSGLANVISKRAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS77 142 MKLAYSLLLPLAGVSAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKRSS78 143 MTKPTQVLVRSVSILFFITLLHLVVAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS79 144 MKLSTNLILAIAAASAVVSAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS80 145 MKILSALLLLFTLAFAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKRSS81 146 MRPVLSLLLLLASSVLAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKRSS82 147 MFKSLCMLIGSCLLSSVLAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS83 148 MSTLTLLAVLLSLQNSALAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS84 149 MKLLNFLLSFVTLFGLLSGSVFAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS85 150 MKVSTTKFLAVFLLVRLVCAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS86 151 MYRNLIIATALTCGAYSAPVNTTTEDETAQ. IPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKRSS87 152 MFLKSLLSFASILTLCKAWDLEDVQDAPKAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSL DKR SS88 153 MLSILSALTLLGLSCASDLTPPIEVTGNKFFFAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKRAttorney Docket No. 54282-0011WO1Sequence SEQDescription iDNO. SequenceSS89 154 MINLNSFLILTVTLLSPALALPKNVLEEQQAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVS LDKR SS90 155 MRNHLNDLVVLFLLLTVAAQAHLVTFHSTEAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGV SLDKR SS91 156 MKLSATLLLSVFTSIQSAYAAPVNTTTEDETAQiPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS92 157 MRRRAIPLLLLLLLLLLLGSSALAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS93 158 MRQVWFSWIVGLFLCFFNVSSAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS94 159 MFNLKTiLISTLASIAVAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFiNTTIASiAAKEEGVS LEKR SS95 160 MQVKSiVNLLLACSLAVAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTiASIAAKEEG VSLEKR SS96 161 MQFNWNIKTVASILSALTLAQAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAA KEEGVSLEKR SS97 162 MAATTCFFFLFPFLLLLTLSRAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKE EGVSLEKR SS98 163 MLLQAFLFLLAGFAAKISAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEG VSLEKR SS99 164 MVAWWSLFLYGLQVAAPALAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAK EEGVSLEKR SS1OO 165 MSFSSNVPQLFLLLVLLTNIVSGAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTiASlAA KEEGVSLEKR SS1O1 166 MNLYLITLLFASLCSAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGVSLE KR SS1O2 167 MKSLILNHSVTLAITSTAAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGV SLEKR SS1O3 168 MRFPSIFTAVLFAASSALAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEG VSLEKR SS104 169 MFSPILSLEIILALATLQSVFAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEE GVSLEKR SS1O5 170 MSFRSLLALSGLVCSGLAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGV SLEKR SS106 171 MSFRSLLALSGLVCSGLANVISKRAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIA AKEEGVSLEKR SS1O7 172 MKLAYSLLLPLAGVSAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGVSL EKR SS108 173 MTKPTQVLVRSVSILFFITLLHLVVAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTiASI AAKEEGVSLEKR SS109 174 MKLSTNLILAIAAASAVVSAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEE GVSLEKR SS11O 175 MKILSALLLLFTLAFAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGVSLE KR SS111 176 MRPVLSLLLLLASSVLAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGVSL EKR SS112 177 MFKSLCMLIGSCLLSSVLAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEG VSLEKR SS113 178 MSTLTLLAVLLSLQNSALAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGVSLEKRAttorney Docket No. 54282-0011WO1Sequence SEQDescription iDNO. SequenceSSI 14 179 MKLLNFLLSFVTLFGLLSGSVFAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAK EEGVSLEKR SS115 180 MKVSTFKFLAVFLLVRLVCAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEE GVSLEKR SS116 181 MYRNLIIATALTCGAYSAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGVS LEKR SS117 182 MFLKSLLSFASILTLCKAWDLEDVQDAPKAPVNTTTEDETAQ. IPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINT TIASIAAKEEGVSLEKR SS118 183 MLSILSALTLLGLSCASDLTPPIEVTGNKFFFAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFIN TTIASIAAKEEGVSLEKR SS119 184 MINLNSFLILTVTLLSPALALPKNVLEEQQAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFIN TTIASIAAKEEGVSLEKR SS12O 185 MRNHLNDLVVLFLLLTVAAQAHLVTFHSTEAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFI NTTIASIAAKEEGVSLEKR SS121 186 MKLSATLLLSVFTSIQSAYAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEG VSLEKR SS122 187 MRRRAIPLLLLLLLLLLLGSSALAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAK EEGVSLEKR SS123 188 MRQVWFSWIVGLFLCFFNVSSAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFINTTIASIA AKEEGVSLEKR SS17J.8F 189 MKILSALFLLFTLAFASS17J.8N 190 MKILSALNLLFTLAFASS17_L8T 191 MKILSALTLLFTLAFASS17_L8V 192 MKILSALVLLFTLAFASS17_L9C 193 MKILSALLCLFTLAFASS17.. L9F 194 MKILSALLFLFTLAFASS17__L9I 195 MKILSALLILFTLAFASS17J.9M 196 MKILSALLMLFTLAFASS17_L10F 197 MKILSALLLFFTLAFASS17_L1OI 198 MKILSALLLIFTLAFASS17_L10M 199 MKILSALLLMFTLAFASS17_F15K 200 MKILSALLLLFTLAKASSI 24 201 M KFAISTLLI 1 LQAAAVFAASS125 202 MKSQLIFMALASLVASSS126 203 MKFAISTLLIILQAAAVFAAAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEG VSLDKR SS127 204 MKSQLIFMALASLVASAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGVSL DKR SS128 205 MKFAISTLLIILQAAAVFAAAPVNTTTEDETAQ. IPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKR SS129 206 MKSQLIFMALASLVASAPVNTTTEDETAQIPAEAVIGYLDLEGDFDVAVLPFLASIAAKEEGVSLDKROST1-AMF 207 ATGAGGCAGGTTTGGTTCTCTTGGATTGTGGGATTGTTCCTATG 1 1 1 1 1 1 CAACGTCTCTTCTGCTGCTCCAGTC Coding AACACTACAACAGAAGATGAAACGGCACAAATTCCGGCTGAAGCTGTCATCGGTTACTTAGATTTAGAAGGG Sequence GATTTCGATGTTGCTGTTTTGCCATTTTCCAACAGCACAAATAACGGGTTATTGTTTATAAATACTACTATTGCCAGCATTGCTGCTAAAGAAGAAGGGGTATCTTTGGATAAAAGAAttorney Docket No. 54282-0011WO1Sequence SEQDescription iDNO. SequenceBrazzein 208 GACAAATGCAAGAAAGTCTACGAGAACTACCCCGTATCGAAGTGTCAACTAGCCAATCAGTGTAACTACGATT Coding GTAAGCTCGATAAACATGCTCGCTCCGGAGAATGCTTCTATGACGAGAAGCGGAATCTGCAGTGTATTTGCG sequence ATTATTGCGAATATTGADHAS1 209 ACGGGAAGTCTTTACAGTTTTAGTTAGGAGCCCTTATATATGACAGTAATGCTAGTACGTTTTGTTTTGTTTAA Transcriptio TTAATAACTTAGTTTATGTTAGCCTAGTATAGACTCCATCAATTTTTTTTGTTATTACGTAAGCCGCGATGATAA n TATCTGATGAAAAATTCCTATCAGAAAATAATTTATCAAAAGTTTCATGCGATATGAGACTAAGTAGAATAGG Terminator GACTCCCAAAGTGTCAGTCACAAGGGTCATTCCCGTTCGTAATGTGGTGATAGCGAGGAGAAAACCTGTCAG Sequence AGCAAGTAACACCGACGCAAAGACATGGCTAATGAAAGAAGAGCAGAGAAGAATAAGACAGAAGGAGCAG GAGATGAAACAAAGGCTAGAGGAACTAGAAAGGTTCAAAACAAAAGTACAGAAATCATATATAAGGAAAGA GGATAGGCATTTGGCACAAGAGATAGAAAAGGATCTTGACATAATCACTGATGATTACAATTTGG AOX1 210 TCAAGAGGATGTCAGAATGCCATTTGCCTGAGAGATGCAGGCTTCATTTTTGATAC I I I 1 1 1 ATTTGTAACCTA Transcriptio TATAGTATAGGA I I 1 i 1 i 1 1 G 1 CATTTTGTTTCTTCTCGTACGAGCTTGCTCCTGATCAGCCTATCTCGCAGCAG n ATGAATATCTTGTGGTAGGGGTTTGGGAAAATCATTCGAGTTTGATG I I I I I CTTGGTATTTCCCACTCCTCTTC Terminator AGAGTACAGAAGATTAAGTGAGACCTTCGTTTGTGCSequenceMoneilin 211 GGTGAATGGGAAATAATCGATATAGGGCCGTTCACCCAGAACTTGGGAAAGTTTGCGGTGGACGAAGAGAA coding TAAAATCGGGCAATACGGACGACTGACATTCAATAAAGTAATTCGCCCTTGTATGAAAAAAACGATATATGAA sequence GAGAATGGCTTCCGCGAAATTAAGGGCTACGAGTATCAACTTTACGTCTATGCTTCAGATAAGCTATTTCGTG CAGACATCAGCGAGGACTACAAAACTCGGGGAAGGAAGTTACTCAGATTTAACGGTCCGGTTCCACCCCCCT GAThaumatin 1 212 ATFEIVNRCSYTVWAAASKGDAALDAGGRQLNSGESWTINVEPGTKGGKIWARTDCYFDDSGRGICRTGDCGGL sequence LQCKRFGRPPTTLAEFSLNQYGKDYIDISNiKGFNVPMDFSPTTRGCRGVRCAADIVGQCPAKLKAPGGGCNDACT VFQTSEYCCTTGKCGPTEYSRFFKRLCPDAFSYVLDKPTTVTCPGSSNYRVTFCPTAThaumatin II 213 ATFEIVNRCSYTVWAAASKGDAALDAGGRQLNSGESWTINVEPGTKGGKIWARTDCYFDDSGRGICRTGDCGGL sequence LQCKRFGRPPTTLAEFSLNQYGKDYIDISNIKGFNVPMDFSPTTRGCRGVRCAADIVGQCPAKLKAPGGGCNDACT VFQTSEYCCTTGKCGPTEYSRFFKRLCPDAFSYVLDKPTTVTCPGSSNYRVTFCPTABrazzein-54 214 XDKCKKVYENYPVSKCQLANQCNYDCKLDKHARSGECFYDEKRNLQCICDYCEYBrazzein-53 215 DKCKKVYENYPVSKCQLANQCNYDCKLDKHARSGECFYDEKRNLQCICDYCEYMoneilin 216 FREIKGYEYQLYVYASDKLFRADISEDYKTRGRKLLRFNGPVPPPchain AMoneilin 217 GEWEIIDIGPFTQNLGKFAVDEENKIGQYGRLTFNKVIRPCMKKTiYEENchain BSingle-chain 229 GEWEIIDIGPFTQNLGKFAVDEENKIGQYGRLTFNKVIRPCMKKTIYEENGFREIKGYEYQLYVYASDKLFRADISEDY moneilin KTRGRKLLRFNGPVPPPMiraculin 218 DSAPNPVLDIDGEKLRTGTNYYIVPVLRDHGGGLTVSATTPNGTFVCPPRVVQTRKEVDHDRPLAFFPENPKEDVV RVSTDLNINFSAFMPCRWTSSTVWRLDKYDESTGQYFV TIGGVKGNPGPETISSWFKIEEFCGSGFYKLVFCPTVCGSCKVKCGDVGIYIDQKGRRRLALSDKPFAFEFNKTVYFMabinlin-1 219 EPLCRRQFQQHQHLRACQRYIRRRAQRGGLVDchain AMabinlin-1 220 EQRGPALRLCCNQLRQVNKPCVCPVLRQAAHQQLYQGQIEGPRQVRQLFRAARNLPNICKIPAVGRCQFTRW chain BMabiniin-2 221 QLWRCQRQFLQHQRLRACQRFIHRRAQFGGQPDchain AMabinlin-2 222 QPRRPALRQCCNQLRQVDRPCVCPVLRQAAQQVLQRQliQGPQQLRRLFDAARNLPNICNIPNIGACPFRAW chain BMabiniin-3 223 EPLCRRQFQQHQHLRACQRYLRRRAQRGGLADchain AAttorney Docket No. 54282-0011WO1Sequence SEQDescription iDNO. SequenceMabinlin-3 224 EQRGPALRLCCNQLRQVNKPCVCPVLRQAAHQQ. LYQ. GQIEGPRQVRRLFRAARNLPNICKIPAVGRCQFTRW chain B orMabinlin-4chain BMabinlin-4 225 EPLCRRQ. FQQ. HQHLRACQRYLRRRAQRGchain ACurculin 1 226 DNVLLSGQTLHADHSLQAGAYTLTIQNKCNLVKYQNGRQIWASNTDRRGSGCRLTLLSDGNLVIYDHNNNDVW GSACWGDNGKYALVLQKDGRFVIYGPVLWSLGPNGCRRVNGCurculin 2 227 DSVLLSGQTLYAGHSLTSGSYTLTIQNNCNLVKYQHGRQIWASDTDGQGSQCRLTLRSDGNLIIYDDNNMVVWG SDCWGNNGTYALVLQQDGLFVIYGPVLWPLGLNGCRSLNMycodukei 228 MPDLSSFITIKNNSNHVFTRTAIYSKYAAVQWSPEPQLSISPGKWDLFILKDILSIRGTSGYVQYRVGDGn PGWVRVTFSSLVGADEVAEWSSGDLPDGFVLQKPVRTGSRPLQATFEATKQ.Single-chain 229 GEWEIIDIGPFTQNLGKFAVDEENKIGQYGRLTFNKVIRPCMKKTIYEENGFREIKGYEYQLYVYASDKLFRADISEDYmonellin KTRGRKLLRFNGPVPPPX can be glutamine or pyroglutamate.EXAMPLES

[0105] Various aspects of the disclosure are further illustrated by the following non-limiting examples.Example 1: Promoter Screen for Brazzein Expression

[0106] Several promoters were tested for their abilities to promote brazzein expression.Construct Assembly

[0107] DNA fragments were de novo synthesized (Twist Biosciences) and assembled into cloning vectors by Type IIS restriction enzymes (New England Biolabs). Each vector contained an expression cassette containing: (1) a promoter (selected from those designated in Table 3 and Table 4); (2) the OST1-AMF signal peptide (SEQ ID NO: 207); (3) a brazzein-53 coding sequence (SEQ ID NO: 208); and (4) the DHAS1 transcription terminator sequence (SEQ ID NO: 209).Attorney Docket No. 54282-0011WO1Brazzein Expression under Constitutive Promoter Regulation

[0108] The expression cassette was amplified using Q5 Polymerase (New England Biolabs), transformed into K. phaffii strain BG10 (ATUM Biosciences), and integrated into the genome by homologous recombination.

[0109] Positive transformants each containing a brazzein gene under the control of a promoter from Table 3 were cultured in 96 deep-well plates containing CBMD media (Citrate Buffered Minimal Dextrose) for 48 hours at 300 rpm and 30 °C in a shaking incubator. Supernatants from each culture were assayed for secreted Brazzein protein concentration by HPLC and dot blot. As shown in Table 3, Brazzein secretion was highest in strains in which the brazzein was under the regulation of the promoters designated P1-P34 (SEQ. ID NOS: 1-34). The high production strains from the small-scale 96 well cultures were run in bioreactors to confirm titer improvements.Table 3. Brazzein Expression Under Constitutive Promoter RegulationPromoter SEQ ID NO: Relative Expression Level*Pl 1 +P2 2 +P3 3 ++P4 4 ++P5 5 ++P6 6 +4”P7 7 ++P8 8 ++P9 9 4-4- P10 10 +Pll 11 +P12 12 +P13 13 +P14 14 +P15 15 +P16 16 +P17 17 +P18 18 ++P19 19 +4”P20 20 +P21 21 ++P22 22 4"Attorney Docket No. 54282-0011WO1Promoter SEQID NO: Relative Expression Level*P23 23 +P24 24 +P25 25P26 26 +P27 27 +P28 28 +P29 29 +P30 30 +P31 31 +P32 32 +P33 33 ++P34 34 ++P35 35 L. O. C.P36 36 L. O. C.P37 37 L. O. C.P38 38 L. O. C.P39 39 L. O. C.P40 40 L. O. C.P41 41 L. O. C.P42 42 L. O. C.P43 43 L. O. C.P44 44 L. O. C.P45 45 L. O. C.P46 46 L. O. C.P47 47 L. O. C.P48 48 L. O. C.P49 49 L. O. C.P50 50 L. O. C.P51 51 L. O. C.P52 52 L. O. C.P53 53 L. O. C.P54 54 L. O. C.P55 55 L. O. C.P56 56 L. O. C.P57 57 L. O. C.P58 58 L. O. C.P59 59 L. O. C.P60 60 L. O. C.P61 61 L. O. C.Attorney Docket No. 54282-0011WO1AL. O. C. indicates that the protein secretion was lower than the control.Brazzein Expression and Secretion under Inducible Promoter Regulation

[0110] K. phaffii strains containing Brazzein genes under the control of different inducible promoters (Table 4) were cultured in 96-deep well plates containing BMG media (Buffered Minimal Glycerol) or CBMD media (Citrate Buffered Minimal Dextrose) for 18 hours at 300 rpm and 30°C in a shaking incubator. After 18 hours, protein expression was induced using the inducing agent designated in Table 4

[0111] For ethanol-induced expression, the 18 hr. cultures containing Brazzein genes under control of P22, P61, or P65 were pelleted and resuspended in Buffered Minimal Ethanol (BME) containing 1% ethanol (EtOH) for 96 hours. EtOH was added to a final concentration of 1% every 12 hours during the induction.

[0112] For copper-induced expression, the 18 hr. cultures containing Brazzein genes under control of P64 were pelleted and resuspended in CBMD containing a range of 20-200 mM copper and grown for 72 hours.

[0113] For phosphate limitation-induced expression, the 18 hr. cultures containing Brazzein genes under control of P62 were pelleted and resuspended in CBMD containing a range of 0.5-20 mM phosphate and grown for 72 hours.

[0114] For methanol-induced expression, the 18 hr. cultures containing Brazzein genes under control of P63 were pelleted and resuspended in CBMM (Citrate Buffered Minimal Methanol) containing 1% Methanol. Methanol induction lasted 96 hours during which methanol was added to a final concentration of 1% every 12 hours.

[0115] Supernatants from each culture were assayed for secreted Brazzein protein concentration by HPLC (Table 4).Attorney Docket No. 54282-0011WO1Table 4. Brazzein Expression Under Inducible Promoter RegulationPromoter Inducer SEQ ID NO: Relative Expression Level* P22 ethanol 22 +P62 phosphate limitation 62 L. O. C.P63 methanol 63 LO. C.P64 copper 64 LO. C.P65 ethanol 65 ++ALO. C. indicates that the protein secretion was lower than the control.Example 2: Signal Peptide Screen for Brazzein Secretion

[0116] Approximately 130 signal peptide sequences were tested for their abilities to promote brazzein secretion.Construct Assembly

[0117] DNAfragments were de novo synthesized (Twist Biosciences) and assembled into a library of linear expression cassettes containing (1) the GCW14 Promoter (SEQ ID NO:9); (2) the nucleotide sequence encoding a signal peptide designated in Table 5; (3) a brazzein-53 coding sequence (SEQ ID NO: 208); and (4) the AOX1 transcription terminator sequence (SEQ ID NO: 210) with overlap PCR using Q5 Polymerase (New England Biolabs).Brazzein Expression and Secretion

[0118] The assembled expression cassettes were pooled together and transformed into K. phaffii strain BG10 (ATUM Biosciences) where they were integrated into the genome by homologous recombination. Positive transformants were cultured and assayed for secreted Brazzein protein concentration by HPLC as described in Example 1 and normalized to the concentration of secreted Brazzein with an OST1-AMF signal peptide (SEQ ID NO: 207). Relative Brazzein protein secretion following expression with the various signal peptides is provided in Table 5.Table 5. Brazzein Secretion According to Signal Peptide SequenceSignal peptide SEQ ID NO: Relative Secretion Level*SSI 66 +SS2 67 LO. C.SS3 68 LO. C.Attorney Docket No. 54282-0011WO1Signal peptide SEQID NO: Relative Secretion Level*SS4 69 L. O. C.SS5 70 L. O. C.SS6 71 L. O. C.SS7 72 L. O. C.SS8 73 L. O. C.SS9 74 L. O. C.SS1O 75 L. O. C.SS11 76 L. O. C.SS12 77 L. O. C.SS13 78 L. O. C.SS14 79 L. O. C.SS15 80 L. O. C.SS16 81 ++SS17 82 ++SS18 83 L. O. C.SS19 84 L. O. C.SS20 85 L. O. C.SS21 86 L. O. C.SS22 87 L. O. C.SS23 88 L. O. C.SS24 89 L. O. C.SS25 90 L. O. C.SS26 91 L. O. C.SS27 92 L. O. C.SS28 93 L. O. C.SS29 94 L. O. C.SS30 95 L. O. C.SS31 96 L. O. C.SS32 97 ++SS33 98 L. O. C.SS34 99 L. O. C.SS35 100 L. O. C.SS36 101 L. O. C.SS37 102 L. O. C.SS38 103 L. O. C.SS39 104 L. O. C.SS40 105 L. O. C.SS41 106 L. O. C.SS42 107 L. O. C.Attorney Docket No. 54282-0011WO1Signal peptide SEQID NO: Relative Secretion Level*SS43 108 L. O. C.SS44 109 L. O. C.SS45 110 L. O. C.SS46 111 L. O. C.SS47 112 L. O. C.SS48 113 L. O. C.SS49 114 L. O. C.SS50 115 L. O. C.SS51 116 L. O. C.SS52 117 L. O. C.SS53 118 L. O. C.SS54 119 L. O. C.SS55 120 L. O. C.SS56 121 L. O. C.SS57 122 L. O. C.SS58 123 L. O. C.SS59 124 L. O. C.SS60 125 L. O. C.SS61 126 L. O. C.SS62 127 L. O. C.SS63 128 L. O. C.SS64 129 L. O. C.SS65 130 L. O. C.SS66 131 L. O. C.SS67 132 L. O. C.SS68 133 L. O. C.SS69 134 L. O. C.SS70 135 L. O. C.SS71 136 L. O. C.SS72 137 L. O. C.SS73 138 L. O. C.SS74 139 L. O. C.SS75 140 L. O. C.SS76 141 L. O. C.SS77 142 L. O. C.SS78 143 L. O. C.SS79 144 4-4- SS80 145 +SS81 146 L. O. C.Attorney Docket No. 54282-0011WO1Signal peptide SEQID NO: Relative Secretion Level*SS82 147 L. O. C.SS83 148 L. O. C.SS84 149 +SS85 150 +SS86 151 L. O. C.SS87 152 L. O. C.SS88 153 L. O. C.SS89 154 L. O. C.SS90 155 ++SS91 156 L. O. C.SS92 157 L. O. C.SS93 158 L. O. C.SS94 159 +SS95 160 L. O. C.SS96 161 L. O. C.SS97 162 L. O. C.SS98 163 L. O. C.SS99 164 L. O. C.SS100 165 L. O. C.SS101 166 +SS102 167 L. O. C.SS103 168 L. O. C.SS104 169 L. O. C.SS105 170 L. O. C.SS106 171 L. O. C.SS107 172 L. O. C.SS108 173 L. O. C.SS109 174 +SSI 10 175 L. O. C.SS111 176 L. O. C.SS112 177 L. O. C.SSI 13 178 L. O. C.SSI 14 179 L. O. C.SSI 15 180 L. O. C.SSI 16 181 L. O. C.SSI 17 182 L. O. C.SSI 18 183 L. O. C.SSI 19 184 L. O. C.SS120 185 L. O. C.Attorney Docket No. 54282-0011WO1Signal peptide SEQ ID NO: Relative Secretion Level*SS121 186 L. O. C.SS122 187 L. O. C.SS123 188 L. O. C.AL. O. C. indicates that the protein secretion was lower than the control.

[0119] The high production strains (indicated by ++ expression values in Table 5) from the smallscale 96 well cultures were run in bioreactors to confirm titer improvements.Example 3: Generation and Testing of a Site Saturation Library (SSVL) of SS17

[0120] A Site Saturation Variant Library (SSVL) was generated for the SS17 (SEQ ID NO: 82) signal peptide to identify variants that would further improve Brazzein protein secretion.

[0121] The expression vector generated in Example 2, containing the SS17 signal peptide, was mutated such that each of the amino acids at positions 2-16 of the SS17 signal peptide were mutated to each of the other 19 non-native amino acids, whereby each sequence contained only one amino acid substitution. The pooled variants were transformed into K. phaffii strain BG10 (ATUM Biosciences) and integrated into the genome by homologous recombination. Positive transformants were cultured and assayed for secreted Brazzein protein concentration by HPLC as described in Example 1 and by ELISA. The high production strains (indicated by ++ expression values in Table 6) from the small-scale 96 well cultures were run in bioreactors to confirm titer improvements. Variants of the signal peptide with improved secretion of Brazzein protein, and their relative secretion levels are shown in Table 6.Table 6. Selected signal peptide variants for improved secretionOriginal AA Position Mutation Signal peptide SEQINO: Relative Secretion Level F SS17JL8F 189 +N SS17J.8N 190 ++L 8T SS17_L8T 191 +V SS17_L8V 192 ■b c SS17 L9C 193 +F SS17_L9F 194 +L 91 SS17J.9I 195 +4- M SS17_L9M 196 +L 10 F SS17_L10F197 +Attorney Docket No. 54282-0011WO11 SS17_L10l 198M SS17J.10M 199 +F 15 K SS17_F15K200 +Exampie 4: Signal Peptide Screen for Monellin Secretion

[0122] Signal peptide sequences were tested for their abilities to promote monellin secretion. A library of linear expression cassettes was generated using overlap PCR substantially as described in Example 2, except using the nucleic acid sequence encoding a signal peptide designated in Table 6; and the sequence encoding single chain monellin (SEQ ID NO: 211) in place of the sequence encoding brazzein.

[0123] The assembled expression cassettes were pooled together and transformed into K. phaffii strain BG10 (ATUM Biosciences) where they were integrated into the genome by homologous recombination. Positive transformants were cultured and assayed for monellin protein concentration by HPLC and compared to monellin protein concentration with a monellin construct having an OST1-AMF signaling sequence (SEQ ID NO: 207) as described in Example 1.

[0124] The relative secretion levels of monellin expressed with the various signal peptides is provided in Table 7. The high production strains from the small-scale 96 well cultures were run in bioreactors to confirm titer improvements.Table 7. Monellin Signal peptidesSignal peptide SEQ ID NO: Relative Secretion Level*SSI 66 L. O. C.SS2 67 L. O. C.SS3 68 L. O. C.SS4 69 L. O. C.SS5 70 L. O. C.SS6 71 L. O. C.SS7 72 L. O. C.SS8 73 L. O. C.SS9 74 L. O. C.SS10 75 L. O. C.SS11 76 L. O. C.SS12 77 L. O. C.SS13 78 L. O. C.SS14 79 L. O. C.Attorney Docket No. 54282-0011WO1Signa! peptide SEQID NO: Relative Secretion Level*SS15 80 L. O. C.SS16 81 L. O. C.SS17 82 L. O. C.SS18 83 L. O. C.SS19 84 L. O. C.SS20 85 L. O. C.SS21 86 L. O. C.SS22 87 L. O. C.SS23 88 L. O. C.SS24 89 L. O. C.SS25 90 L. O. C.SS26 91 L. O. C.SS27 92 L. O. C.SS28 93 L. O. C.SS29 94 L...

Claims

Attorney Docket No. 54282-0011WO1WHAT IS CLAIMED IS:

1. An expression cassette comprising a promoter operably linked to a coding sequence of a heterologous protein, wherein the promoter comprises a first nucleotide sequence selected from any one of SEQ ID NOs: 3-8, 10-13, 18, 26-32, 34, 56, 58, or 65.

2. The expression cassette of claim 1, wherein the heterologous protein is selected from the group consisting of brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, or mycodulcein protein or a functional fragment thereof.

3. The expression cassette of claim 1 or claim 2, wherein the coding sequence of the heterologous protein is operably linked to a second nucleotide sequence encoding a signal peptide operably linked to the coding sequence of the heterologous protein.

4. The expression cassette of claim 3, wherein the signal peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 66-71, 79, 81, 82, 85, 97, 100, 106, 107, 109, 113-116, 119, 120, 122, 125, 127, 134, 144, 145, 149, 150, 155, 158, 159, 166, 174, and 203.

5. A cell comprising the expression cassette of any one of claims 1-4.

6. The cell of claim 5, wherein the cell is a yeast cell or a filamentous fungal cell, optionally wherein the cell is a Komagataella sp., optionally Komagataella phaffii.

7. A promoter comprising a first nucleotide sequence comprising a first nucleotide sequence set forth in any one of SEQ ID NOs:3-8, 10-13, 18, 26-32, 34, 56, 58, or 65.

8. An expression cassette comprising a promoter operably linked to a coding sequence of a heterologous protein that is a sweet protein selected from the group consisting of brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, mycodulcein or a functional fragment thereof, wherein the promoter comprises a first nucleotide sequence selected from any one of SEQ ID NOs: 1-34 or 65.Attorney Docket No. 54282-0011WO19. The expression cassette of claim 8, further comprising a second nucleotide sequence encoding a signal peptide linked to the coding sequence of the sweet protein.

10. The expression cassette of claim 8 or 9, wherein the first nucleotide sequence is selected from the group consisting of SEQ ID NOs: 3, 4, 5, 6, 7, 8, 9, 18, 19, 21, 25, 33, 34, and 65.

11. The expression cassette of any one of claims 3, 4, 9, and 10, wherein the second nucleotide sequence encodes an amino acid sequence selected from the group consisting of SEQ ID NOs: 66, 81, 82, 97, 144, 145, 149, 150, 155, 159, 166, 174, and 189-200.

12. The expression cassette of claim 11, wherein the amino acid sequence is selected from the group consisting of SEQ ID NOs: 81, 82, 97, 144, 155, 190, and 195.

13. The expression cassette of claim 11 or claim 12, wherein the heterologous protein comprises brazzein, brazzein 53, brazzein-54 or a functional fragment thereof.

14. The expression cassette of any one of claims 9-13, wherein the second nucleotide sequence encodes an amino acid sequence selected from the group consisting of SEQ ID NOs: 100, 106, 107, 109, 113-116, 119, 120, 122, 125, 127, 149, 155, 158, and 203.

15. The expression cassette of claim 14, wherein the amino acid sequence is selected from the group consisting of SEQ ID NOs: 100, 109, 115, 119, 120, 149, and 158.

16. The expression cassette of claim 14 or claim 15, wherein the heterologous protein comprises monellin or a functional fragment thereof.

17. The expression cassette of any one of claims 9, 10, and 12, wherein the second nucleotide sequence encodes an amino acid sequence selected from the group consisting of SEQ ID NOs: 67-71, 79, 81, 85, 116, 134, and 150.Attorney Docket No. 54282-0011WO118. The expression cassette of claim 17, wherein the amino acid sequence is selected from the group consisting of SEQ ID NOs: 69, 79, 81, and 85.

19. The expression cassette of claim 17 or claim 18, wherein the heterologous protein comprises thaumatin, thaumatin I, thaumatin II or a functional fragment thereof.

20. A signal peptide, comprising the amino acid sequence set forth in any one of SEQ ID NOs: 99- 107, 109-158, or 203-206.

21. A protein coding sequence comprising a first nucleic acid encoding (a) the signal peptide of claim 20 or (b) a signal peptide with an amino acid sequence set forth in any one of SEQ ID NOS: 67, 75, 77, 81, or 88, wherein the first nucleic acid sequence is fused in frame to a second nucleic acid sequence encoding a heterologous protein.

22. The protein coding sequence of claim 21, wherein the signal peptide is 5' to the heterologous protein.

23. The protein coding sequence of claim 21, wherein the signal peptide is 3' to the heterologous protein.

24. The protein coding sequence of any one of claims 21-23, wherein the heterologous protein is a sweet protein selected from the group consisting of brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, mycodulcein or a functional fragment thereof.

25. A protein coding sequence comprising a nucleic acid encoding a signal peptide comprising the amino acid sequence set forth in any one of SEQ ID NOS: 66-206 fused in frame to a coding sequence for a heterologous protein that is a sweet protein selected from the group consisting of a brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, or mycodulcein protein or a functional fragment thereof.Attorney Docket No. 54282-0011WO126. A fusion protein comprising a signal peptide having an amino acid sequence set forth in any one of SEQ ID NOS: 66-206 operatively linked to a heterologous protein.

27. An expression cassette comprising the protein coding sequence of any one of claims 21-25.

28. The expression cassette of claim 27, further comprising a promoter, wherein the promoter comprises a first nucleotide sequence set forth in any one of SEQ ID NOS: 1-34 or 65.

29. A vector comprising the promoter of claim 7, the expression cassette of any one of claims 1-4, 8- 19, 27, or 28, the signal peptide of claim 20, or the protein coding sequence of any one of claims 21-25.

30. A cell comprising the promoter of claim 7, the expression cassette of any one of claims 1-4, 8-19, 27, or 28, the signal peptide of claim 20, or the protein coding sequence of any one of claims 21- 25.

31. The cell of claim 30, wherein the cell is a eukaryotic cell.

32. The cell of claim 30, wherein the cell is a yeast cell or a filamentous fungal cell.

33. The cell of claim 30, wherein the cell is Komagataella sp., optionally Komagataella phaffii.

34. A method of producing a heterologous protein, the method comprising inserting the expression cassette of any one of claims 1-4, 8-19, 27, or 28 into an expression system whereby the heterologous protein is produced.

35. The method of claim 34, wherein the expression system is a cell.

36. The method of claim 34, wherein the expression system is a eukaryotic cell.

37. The method of claim 35, wherein the cell is a yeast cell or a filamentous fungal cell.Attorney Docket No. 54282-0011WO138. The method of claim 35, wherein the cell is Komagataella sp., optionally Komagataella phaffii.

39. The method of any of claims 34-38, wherein the heterologous protein is secreted into a culture medium.

40. The method of claim 39, further comprising collecting the culture medium.

41. The method of claim 40, further comprising isolating the heterologous protein from the culture medium.

42. The method of any one of claims 34-41, wherein the heterologous protein is a sweet protein selected from the group consisting of a brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, or mycodulcein protein or a functional fragment thereof.

43. An expression vector comprising any one of the promoter-signal sequence combinations set forth in Table 9, optionally, wherein the expression vector comprises a heterologous protein, optionally wherein the heterologous protein is selected from the group consisting of a brazzein, monellin, miraculin, mabinlin, curculin, thaumatin, or mycodulcein protein or a functional fragment thereof.

Images